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ABSTRACT 
Multiple sclerosis (MS) is the most common demyelinating disease. It is 
characterised by a great variety of neurological deficits, which most commonly 
present initially in a relapsing remitting fashion and then take on a gradually 
progressive course.  MS is incurable, since present medications do not counteract 
progression of the disease. Therefore, an additional strategy aims to focus on 
prevention of the neuronal loss in an attempt to stop or slow down the progression 
of the disease.  
In this thesis the neuroprotective potential of modafinil is tested in MS in a 
retrospective study. The ability of modafinil to reduce neurological dysfunction in the 
MS animal model is also investigated.  
In retrospective study the expanded disability status scale (EDSS) progression of 
thirty patients with MS who received modafinil for the treatment of MS-related 
fatigue for an uninterrupted period of 3 years or more was compared with ninety 
matched patients not treated with modafinil, followed up for a matching period of 
time. We found that the EDSS increase in patients not treated with modafinil was 
greater than in those treated with modafinil in both relapsing/remitting and 
progressive MS.  
In another experiment, we evaluated the effect of two treatment doses (low dose 
and high dose) of modafinil on the level of disability in experimental autoimmune 
encephalomyelitis (EAE) in a placebo controlled study. Modafinil decreased the 
severity of EAE at both treatment doses and the effect was greater in high dose. 
The study in chapter 4 was aimed to explore the anti-fatigue and alerting effects of 
modafinil in MS in an attempt to link these with the potential neuroprotective effects 
of modafinil. This was a detailed reanalysis of a prospective placebo controlled 
study (based on prospectively collected data), in which we examined whether there 
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is any difference between MS patients with fatigue, MS patients without fatigue, and 
healthy controls on measures of alertness and autonomic function. We found that 
MS patients with fatigue, compared with healthy controls, had reduced level of 
alertness on all the tests used, MS patients with fatigue had a reduced level of 
autonomic function compared to the other two groups. Furthermore, we found that 
Modafinil displayed alerting and sympathomimetic effects in all three groups of 
subjects. 
In Chapter 5, we assessed a problem relevant to the progression of MS. We take 
advantage of the methods and data used in the chapter 2 to apply the same 
retrospective study methodology and statistical retrospective modeling of EDSS 
progression using the linear regression model to look at the role of oligoclonal band 
(OCB) positivity or negativity in EDSS progression. Unlike previous studies in 
smaller cohorts, we did not find that OCB negative patients have a more benign 
course of disease.  
The meta-analysis study in chapter 6 was designed to generate some knowledge 
regarding the central mechanism of fatigue in general and fatigue related to MS, 
using a novel functional magnetic resonance imaging (fMRI) meta-analysis method 
developed by CR Tench in our group. The study has also aimed to explore the brain 
areas which could be activated by modafinil treatment. The conclusion of this study 
was that the thalamus and striate are central and relevant nodes for the 
pathogenesis of fatigue in MS. The study has not detected the specific brain area to 
be activated by modafinil and showed multiple brain activations.  
With regard to the promising findings in our previous experiments, the protocol of a 
prospective phase II clinical trial was designed and detailed in appendix 10 using 
radiological primary and clinical secondary outcome measures. 
In conclusion, modafinil may slow down the progression of disability in patients with 
MS and decrease disease severity in EAE. Modafinil can display alerting and 
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sympathomimetic effects in MS patients as well as in healthy subjects. The 
thalamus and striate are central and relevant nodes for the pathogenesis of fatigue 
in MS. These are also areas affected by the MS gray matter pathology and may be 
targets for neuroprotection by modafinil in MS. Finally, we have not reported a 
significant difference in disease progression measured by EDSS and MSSS 
between OCB negative and OCB positive in our patients with MS.  
This seemingly heterogeneous group of experiments, primarily centred on 
PRGDILQLO¶VSRWHQWLDODVPHFKDQLVWLFWKHUDS\LQ06EULQJ,KRSHQHZNQRZOHGJHRI
aspects of disease progression and pharmacological neuroprotection in a stage of 
the disease where therapeutic options are currently limited and the need for new 
treatments is great.  
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LIST OF ABBERVIATION 
 
AD   autonomic dysfunction 
ABM   autologous bone marrow 
ACTH   adrenocorticotrophic hormone 
ADHD   attention deficit-hyperactivity disorder 
ALE   activation likelihood method 
AMPA 2-amino-3-(3-hydroxy-5-methyl-soxazol-4-yl) propanoic acid  
ANS   autonomic nervous system 
APC   antigen-presenting cells 
ATP   adenosine triphosphate 
BA   brodmann area 
BBB   blood brain barrier 
BDI   Beck Depression Inventory 
BOLD   blood oxygen level-dependent 
BP   blood pressure 
CBT   cognitive behaviour therapy 
CC   corpus callosum 
CD   cluster of differentiation 
CDMS   clinically definite multiple sclerosis 
CFA   FRPSOHWH)UHXQG¶VDGMXYDQW 
CFFF   critical flicker fusion frequency 
CFS   chronic fatigue syndrome 
CHMP Committee for Medicinal Products for Human Use 
CIS   clinically isolated syndrome 
CNS   central nervous system 
CNTF   cilliary neurotrophic factor 
CPAP   continuous positive airway pressure 
CRT   choice reaction time 
CSF   cerebro spinal fluid 
DA   dopamine 
DAT   dopamine transporters 
DMSO   dimethylsulfoxide 
DMTs   disease modifying therapies 
DPCC   dorsal posterior cingulate cortex 
DR   dopamine receptor 
EAE   experimental autoimmune encephalomyelitis 
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EDS   excessive daytime sleepiness 
EDSS   expanded disability status scale 
ESS   Epworth sleepiness scale 
FAI   fatigue assessment instrument 
FCDR   false cluster discovery rate 
FDA   food and drug administration 
FDS   fatigue descriptive scale 
FWER   family wise error rate 
FIS   fatigue impact scale 
FMRI   functional magnetic resonance imaging 
FODOS  fields of dead oligodendrocytes 
FOSQ   functional outcomes of sleep questionnaire 
FSS   fatigue severity scale 
GA   glatiramer acetate 
GABA   gamma-amino butyric acid 
GM   gray matter 
GNDS   Guy's Neurological Disability Scale 
HLA   human leukocyte antigen 
IEF   isoelectric focusing 
IGF   insulin like growth factor 
IgG   immunoglobulin G 
IL   interleukin 
IM   intramuscular 
INF   interferon 
IV   intravenous 
LH/PF   lateral hypothalamic/prefronatal 
LIF   leukaemia-inhibitory factor 
LP   lumbar puncture 
MBP   myelin basic protein 
MFG   medial frontal gyrus 
MFIS   modified fatigue impact scale 
MHC   major histocompatibility complex 
MHRA Medicines and Healthcare Products Regulatory Agency 
MNI   Montreal Neurological Institute 
MOG   myelin oligodendrocyte glycoprotein 
MPTP   1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine 
MRI   magnetic resonance imaging 
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MRS   magnetic resonance spectroscopy 
MRT   motor reaction time 
MS   multiple sclerosis 
MSC   mesenchymal stem cell 
MSFC   multiple sclerosis functional composite 
MSLT   multiple sleep latency test 
MSSS   multiple sclerosis severity scale 
MWT   maintenance of wakefulness test 
NAA   N-acetylaspartate 
NAA/Cr  N-acetylaspartate/creatinine 
NAT   noradrenalin transporters 
NE   norepinephrine 
NET   norepinephrine transporters  
NFI-MS  neurological fatigue index 
NMO   neuromyelitis opica 
NO   nitric oxide 
OCB   oligo clonal band 
OSA   obstructive sleep apnoea 
PASAT  paced auditory serial addition test 
PBS   phosphate-buffered saline  
PD   3DUNLQVRQ¶VGLVHDVH 
PET   positron emission tomography 
PLP   proteolipid protein 
PPAR   peroxisome proliferators-activated receptor 
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CHAPTER 1 INTRODUCTION 
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Overview of the chapter 
This chapter begins with a general review of multiple sclerosis (MS), regarding its 
history and background, epidemiology, immunopathology, clinical courses, clinical 
features, diagnosis, current therapies for MS and the future treatment strategies. As 
experimental autoimmune encephalomyelitis (EAE) is a useful model for predicting 
success with clinical trials in MS, and it is considered a valuable model for aiding the 
development of new treatments for MS, a section of this chapter is an overview of 
EAE, focusing on: history, EAE induction, pathophysiology and its contribution to the 
development, validation, and testing of MS drugs. This is followed by a review of 
modafinil, the wakefulness-promoting drug, which focuses on general description of 
the drug, mode of the action, the effect of modafinil in MS and other neurodegerative 
diseases, and the possible neuroprotective properties of modafinil.  
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1.1     MULTIPLE SCLEROSIS 
MS is the most common demyelinating disease. It is characterised clinically by a 
great variety of neurological deficits, which most commonly present initially in a 
relapsing remitting fashion and then take on a gradually progressive course.  
Pathologically, MS is characterised by inflammation, demyelination, axonal loss, and 
gliosis. 
1.1.1     History and background of Multiple Sclerosis 
In the United Kingdom the case of Elizabeth Foster, dating to 1757, likely, 
represents the first reasonably convincing case of MS in the medical literature. She 
was presented with paralytic disorders in the left side of the body. She was treated 
by electrical stimulations. This case was reported by Dr Patrick Brydone, and the 
report was published in the leading scientific journal of the day (Philosophical 
Transactions) (Lincoln and Ebers, 2012).  
Two cases have been reported from the late 13th century, a woman in Iceland 
(Poser, 1994), and a Dutch woman (Medaer, 1979) both with chronic, multifocal, 
and partially remitting neurologic illnesses that might have been MS. 
In 1868 MS was pathologically described by Jean-Martin Charcot (Figure 1.1) a 
French neurologist at the University of Paris, who examined a young woman with a 
tremor and some other neurological features including slurred speech and abnormal 
eye movements, which were different from neurological features in other reported 
neurological conditions. Post-mortem, he examined her brain and found the 
characteristic plaques of MS (Murray, 2009). In the USA MS was recognized by Dr. 
Edward Seguin in 1878. In 1916 Dr James Dawson at the University of Edinburgh 
SHUIRUPHGPLFURVFRSLFH[DPLQDWLRQVRIWKH06SDWLHQW¶VEUDLQSRVW-mortem. 
 
 4 
 
Figure 1.1 Dr Martin Charcot (1825-1893). Source:  (Paciaroni et al., 2008). 
MS is a chronic progressive inflammatory and degenerative disease of the central 
nervous system (CNS). It is characterised by the presence of areas of multifocal 
demyelination (plaques) that result from damage the protective coat (myelin) of 
nerve fibres. Also there is destruction of oligodendroglia, perivascular inflammation, 
and chemical changes in lipid and protein constituents of myelin in and around the 
plaques. 
In the mid-1990s the understanding of MS changed. The results of clinical trials and 
findings from neuropathology of MS demonstrated a neurodegenerative process 
with axonal injuries that follows demyelination, which are responsible for progressive 
neurological impairment. 
Spinal cord lesions in MS are common, particularly in the cervical spine, and usually 
occur early in the disease. The first description of cervical spinal cord MS by MRI 
was performed in 1988 (Honig and Sheremata, 1989). Spinal MS is often associated 
with concomitant brain lesions; however, as many as 20% of patients with spinal 
lesions do not have intracranial plaques (Noseworthy et al., 2000). 
An increasing amount of evidence suggests that MS is heterogeneous (Compston, 
2007). Genetic, immunological and unknown environmental factors are known to 
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contribute to the development of MS, but a specific cause for this disease is not 
identified (Compston and Coles, 2002). Potentially, it is the most common cause of 
non-traumatic neurological disability in young adults and is a tremendous burden for 
years to come (Compston and Coles, 2002). Any age group can be affected but its 
peak is in the most economically productive years of life. 
MS is more common in temperate climates in people of Northern European descent 
and it is infrequent in equatorial areas.  
 Currently, the four major clinical types of MS include relapsing-remitting (RRMS), 
primary progressive (PPMS), secondary progressive (SPMS) and progressive 
relapsing (PRMS) (Lublin and Reingold, 1996). 
Benign MS is a variant of RRMS where patients remain fully functional in all 
neurologic systems 10-15 years after disease onset. Clinically isolated syndrome 
(CIS) is described as the first neurological episode and may or may not progress to 
clinically definite MS (CDMS).  
1HXURP\HOLWLV RSWLFD 102 'HYLF¶V GLVHDVH LV DQ 06-like inflammatory 
demyelinating disease, extensively affecting the spinal cord and optic nerves 
(Compston and Coles, 2008; Weinshenker et al., 2006; Wingerchuk et al., 2006). 
Despite many similarities, current data strongly suggest NMO is an entity distinct 
from MS. 
Although progressive neurological disability might be present from the onset of MS, 
the initial attack of MS is generally mild and self-limiting, but relapsing is common 
after a variable duration (Crayton et al., 2004). 
Diagnosis of MS is based on evidence of the dissemination in space, dissemination 
in time. History and neurological assessment are the cornerstone for the diagnosis 
of MS. MRI is the most sensitive method for showing white matter (WM) lesions in 
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patients suspected of having MS. Lumbar puncture (LP) and clinical 
neurophysiological tests may be necessary to establish the diagnosis of MS. 
So far, there is no curable treatment for MS. Currently approved MS therapeutics 
have a mainly anti-inflammatory mode of action. The aim of treatment in MS is to 
reduce the frequency, and limit the lasting effects, of relapses, relieve symptoms, 
prevent disability arising from disease progression, and promote tissue repair.  
The expected future course of the disease mainly depends on subtype. Individuals 
with progressive subtype, particularly the primary progressive subtype, have a more 
rapid decline in neurological and cognitive functions. The prognosis in females 
generally is better than in males. Initial MS symptoms of visual loss or sensory 
problems are thought to be markers for a relatively better prognosis. In general, one 
third of patients will still be able to work after 15±20 years of the onset of the disease 
(Ebers, 2005). 
MS is not lethal by itself but death is the result of remarkable disability and disease 
complications such as repeated respiratory and urinary tract infections. 
1.1.2     Epidemiology of Multiple Sclerosis 
MS is recognised throughout the world with high prevalence in the Northern 
Europeans, the North of America and Southern Australia. It is seen less frequently in 
Asians and is very rare among indigenous people of Africa and Australia (Figure 
1.2) Although genetic susceptibility and ethnic group pattern are likely involved, no 
concrete data have been shown as to why certain regions have a higher incidence 
of MS (Wallin et al., 2000). 
The disease has an incidence of about seven per 100000 every year, prevalence of 
around 120 per 100000, and lifetime risk of one in 400 (Compston and Coles, 2008). 
It has been estimated that within 15 years more than 50% of non-treated MS 
patients need assistance with their daily household and employment responsibilities 
 7 
 
Figure 1.2 Geography of multiple sclerosis and migration. 
The five continents are depicted to show medium prevalence of multiple sclerosis 
(orange), areas of exceptionally high frequency (red), and those with low rates 
(grey-blue). Some regions are fairly uncharted and these colours are only intended 
to provide an impression of the geographical trends. Major routes of migration from 
the high-risk zone of northern Europe, especially including small but informative 
studies, are shown as dotted arrows. Studies involving migrants from low-risk to 
high-risk zones are shown as solid arrows. Source: (Compston and Coles, 2008). 
 
(Pugliatti et al., 2006). Most of the people with MS usually die of complications such 
as pneumonia and repeated urinary tract infection rather than of MS itself (especially 
in bedridden patients) (Ebers, 2005). MS is more common in females, according to 
Pugliatti's review article the women-to-men ratio for MS in Europe varies from 1.1 to 
3.4 (Pugliatti et al., 2006). However recent reports have stated an increase in 
incidence of MS in women. The basis for this difference is unknown, but hormonal 
components may be responsible (Debouverie et al., 2007). 
1.1.3     Pathogenesis of Multiple Sclerosis 
1.1.3.1     Plaque formation 
The mechanisms of the initial pathogenic events leading to plaque formation are 
controversial (Lucchinetti et al., 2000). The most commonly held view is that the 
peripherally activated T-cells migrate into the CNS and attack myelin and 
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oligodendrocytes resulting in production of focal inflammatory lesions (Lassmann et 
al., 2007). Barnett and Prineas  (2004) had an alternative view: they suggested that 
in some cases the earliest lesions comprise large areas of apoptotic 
oligodendrocytes, termed fields of dead oligodendrocytes (FoDOs). The 
pathogenesis of FoDOs is tentative, but could involve humoral factors or 
oligodendrocyte degeneration in response to viral infection. In any case, the 
evolution of active lesions involves widespread, focal loss of myelin, the presence of 
large numbers of activated macrophages digesting myelin degradation products, 
and a T-cell infiltrate, with CD8+ T-cells predominating (Figure 1.3). 
 
 
Figure 1.3 Characteristic brain pathology in multiple sclerosis. 
A / Low-power image of active demyelinating white matter lesion, showing 
macrophages with myelin degradation products (arrows) and reactive gliosis 
(arrowheads). B/ Higher-magnification image of the active lesions shown in (A) 
reveals demyelinated axons (arrows), macrophages with myelin debris (arrowheads) 
and dystrophic axons (asterisk) within the myelin sheath. Source: (Lassmann et al., 
2012). 
 
Although the pathogenesis of MS is not fully understood involvement of cell-
mediated immune and humoral immune response to undetermined antigen(s) is 
doubtless. Pathologically MS is characterized by perivenular and parenchymal 
infiltration of lymphocytes and macrophages in the parenchyma of the brain, brain 
stem, optic nerves, and spinal cord. In general the accepted view of MS 
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pathogenesis has linked the disease course to sensitisation a myelin-specific, CD4+ 
T lymphocyte in the peripheral in response to macrophage presentation of a foreign 
antigen in association with major histocompatibility complex (MHC) class I and class 
II (Höftberger et al., 2004; Wucherpfennig and Strominger, 1995). This results in 
peripherally activated T cells expressing, and recognising, vascular adhesion 
molecules facilitating their entry through blood brain barrier (BBB). Inside the CNS 
activated T cells release pro-inflammatory cytokines resulting in up regulation of 
local antigen-presenting cells (APC) with the capacity to present self-myelin proteins 
(Lassmann et al., 2007).  
In addition to T cells the autoimmune B cells and humoral immune mechanisms are 
now believed also to play key roles in the pathogenesis of MS and plaque initiation 
(Gay and Esiri, 1991; Owens et al., 2006), and  demyelination in patients with 
established MS (Wucherpfennig and Strominger, 1995). This component has been 
recognised previously in MS diagnosis through the presence of oligoclonal bands 
(OCB) in the cerebrospinal fluid (CSF) and increased intrathecal Immunoglobulin G 
(IgG) synthesis (Link and Huang, 2006). Variable degrees of   clonally expanded 
populations of memory B cells and plasma cells are found in lesions and CSF from 
patients with MS %DUWRãHWDO0DJOLR]]LHWDO2ZHQVHWDO. It 
has been shown that depletion of B-cells in MS lesions results in a reduction in 
gadolinium enhanced lesions on MRI and reduced relapse frequency  (Bar-Or et al., 
2008). 
1.1.3.2     Neurodegeneration in Multiple Sclerosis 
Besides the inflammatory activity in the CNS the degenerative process in MS 
appears to start early in the disease (Figure 1.4). Significant brain atrophy has been 
found in early diagnosed MS patients with little disability (Chard et al., 2002). 
Atrophy of CNS is most pronounced in the progressive phase of MS, and correlates 
with the rate of decline in neurological function (Losseff et al., 1996). A study 
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showed low level of N-acetylaspartic acid (NAA), a marker for axonal damage 
shown by magnetic resonance spectroscopy (MRS) in MS patients (De Stefano et 
al., 2002).Pathologically, in these stages, the lesions are characterised by  
 
 
 
Figure 1.4 Immune-mediated demyelination and axonal transaction. 
Axonal ovoids are hallmark of transacted axons. Abundant axonal ovoids were 
detected in MS tissue (a) when stained for myelin protein (red) and axons (green). 
There are areas of demyelination (arrowheads), mediated by microglia and 
haematogenous monocytes. One of the axons ends in a large swelling (arrow) or 
axonal retraction bulb (arrow). (b and c) Schematic of axonal response during and 
following transaction. Demyelination is an immune-mediated or immune cell assisted 
process leading to axonal transaction. When transacted, the distal end of the axon 
rapidly degenerates while the proximal end connected to the neuronal cell body 
survives and transported organelles accumulate at the transaction site and form an 
ovoid (arrows). Source: (Trapp and Nave, 2008). 
 
demyelination, activated microglia, apoptotic death of neurons, interlaced with 
macrophages and myelin debris, making up the glial scar tissue. The lesions have 
less leukocyte infiltrations and there is marked depletion of oligodendrocytes 
(Lucchinetti et al., 2003). 
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1.1.3.2.1     Axonal Degeneration in Multiple Sclerosis 
Although the MS lesion includes both inflammatory and demyelinating components 
their relative influence on axonal loss is unclear. Axonal pathology was mentioned in 
early reports that included description of axonal swelling, axonal transaction and 
Wallerian degeneration (Kornek and Lassmann, 1999). Some studies have 
demonstrated a high incidence of acute axonal injury within both early and chronic 
MS lesions (Ferguson et al., 1997; Kornek and Lassmann, 1999; Trapp et al., 1998). 
Axonal degeneration is occurs  in the setting of acute inflammatory demyelination 
(Trapp et al., 1998) and/or as a consequence of chronic demyelination (Bjartmar et 
al., 2000; Dutta et al., 2006) (Figure 1.4). 
1.1.3.2.1.1     Mechanism of Axonal Degeneration 
1.1.3.3.1.1.1     Axonal degeneration in acute inflammatory process 
The most accepted contributing causal factors for axonal damage in the acute 
lesions are: 
Immune-cell mediated injury: There is a close link between axonal injury and 
cytotoxic effect of T-cell in human which initiated through direct T cell mediated 
cytotoxicity with the target axon (Neumann et al., 2002). Axonal transection has 
been reported in  vitro in an antigen dependent immunological reaction with  Class I 
MHC restricted T lymphocytes (Medana et al., 2001). Also the interaction of 
activated macrophages or microglia cells with axons in the course of axonal injury 
has been suggested in EAE, such cells are consistently found in close contact with 
degenerating axons in EAE (Brunn et al., 2008). 
Glutamate in acute axonal injury: Increased levels of glutamate after inflammatory 
injury leads to excess excitatory activation of inotropic subtypes of glutamate 
receptors such as Į-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) 
receptors.  This results in toxic accumulation of intracellular sodium and calcium 
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during normal electrical activation (Ouardouz et al., 2009). Evidence of increased 
oligodendrocyte and axonal survival, after treatment with a glutamate antagonist in 
animal and cellular models, further supports a role for glutamate in acute axonal 
injury (Pitt et al., 2000). 
Nitric oxide and acute axonal injury: Evidence suggests that nitric oxide (NO), which 
is released from inflammatory cells, at higher concentrations may lead to irreversible 
destruction of axons (Smith et al., 2001). Also it has been reported that NO may 
even directly damage nerve cell bodies and dendrites and  can play a role in 
demyelination and oligodendroglia damage (Bolanos et al., 1997). 
1.1.3.3.1.1.2     Progressive axonal damage in chronic plaques 
The most accepted contributing causal factors for axonal damage in the chronic 
plaques are: 
Remyelination failure: In vitro, trophic factors such as insulin-like growth factor-type 
1 (IGF-1) which is a polypeptide growth factor similar in structure to insulin and 
neuregulin provided by oligodendrocyte promote normal axon function and survival 
to axons. Lack of these factors in chronic lesion result in neurodegeneration and 
death of the axons (Compston, 1996; Wilkins and Compston, 2005). 
Conduction defects: Axonal conduction is a continuous energy dependent process 
that is essential for maintaining cell function. Demyelination disrupts axonal 
conduction. Studies have shown that conduction defects along chronically 
demyelinated axons contribute to the progression of neurological disability (Kornek 
et al., 2001; Waxman, 2001). 
Toxic level of intracellular calcium: Studies have shown that stimulation of glutamate 
receptors results in Ca2+ influx from both the extracellular space, and from 
ryanodine-dependent intracellular stores. The processes result in abnormally 
increased intracellular levels of Ca2+ that culminates in the activation of degradation 
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enzymes, inhibition of mitochondrial function and cellular death (Ouardouz et al., 
2009; Trapp and Stys, 2009). 
1.1.3.3     Gray Matter lesions in Multiple Sclerosis 
MS is generally believed to be a WM disease but conclusions from advanced MRI 
techniques and histopathological findings have indicated prominent gray matter 
(GM) changes suggestive of both demyelination and axonal damage. These have 
been detected in MS cortical lesions (Chard et al., 2002). Generally, GM lesions are 
a more prominent feature of PPMS and SPMS, where they can be extensive, 
suggesting it is a predominantly late phenomenon in MS pathology (Kutzelnigg et 
al., 2005). However, it is also documented that cortical lesions are present from the 
earliest stages of MS, accumulate over time, and exceed WM lesions in progressive 
MS (Brownell and Hughes, 1962; Lassmann and Lucchinetti, 2008). Pathologically 
the lesions are characterised by demyelination, activated microglia, apoptotic death 
of neurons, and have less leukocyte infiltrations. Furthermore it is believed that 
cortical plaques have important role in contributing to the disease burden in patients 
with MS (Peterson et al., 2001). 
1.1.4     Clinical courses of Multiple Sclerosis 
MS is divided into four clinical subtypes (Lublin and Reingold, 1996) (Figure 1.5). 
Relapsing-remitting MS: It is defined as more than one clinical attack of 
demyelination, that is an initial episode followed by at least one (relapse), separated 
by period(s) of complete or partial recovery (remission). Approximately 80-85% of 
patient with MS have RRMS at the onset.  
Secondary progressive MS: It is the stage that follows RRMS; symptoms are 
continuous and gradually worsen, without remission. Relapses may occur, but less 
frequent than in the RR phase. After several years about 50% of patients with 
RRMS progress into SPMS (Rovaris et al., 2006). 
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Primary progressive MS: less than 20% people with MS experience continuous 
worsening from disease onset with no preceding relapses, although relapses may 
subsequently occur, but at low frequency. 
Progressive relapsing MS: It is an uncommon form of MS characterised by acute 
relapses superimposed on progressive course. 
 
 
Figure 1.5 Clinical courses of multiple sclerosis. 
A/ Relapsing/remitting multiple sclerosis: Clearly-defined disease relapses with full 
recovery or with squeal and residual deficit upon recovery; periods between disease 
relapses characterised by a lack of disease progression. B/ Secondary progressive 
multiple sclerosis: Initial relapsing/remitting disease course followed by progression 
with or without occasional relapses, minor remissions or plateaux. C/ Primary 
progressive multiple sclerosis: Disease progression from onset, with occasional 
plateaux and temporary minor improvements. D/ Progressive-relapsing multiple 
sclerosis: Progressive disease from onset, with clear acute relapses, with or without 
full recovery. 
 
1.1.5     Clinical Features of Multiple Sclerosis 
Clinical features of MS are varied and capricious, depending on location and degree 
of the lesions affecting the CNS (Table 1.1). Symptoms start with beginning of 
interruption of myelinated tracts in the CNS. Insidious or abrupt weakness in one or 
more limbs, a sensory disturbance, monocular visual loss (optic neuritis), double 
vision (diplopia), gait instability, and ataxia are the possible initial symptoms of MS.  
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Early symptoms may be severe or trivial.  With progression of the disease bladder 
dysfunction, heat intolerance and fatigue occur in most patients. Additional  
 
Table 1.1 Clinical features of multiple sclerosis. Source: (Compston and Coles, 
2008) 
Cerebrum Cognitive impairment Deficits in attention, 
reasoning, and executive 
function (early); dementia 
(late) 
Hemisensory and motor Upper motor neuron signs 
Affective (mainly 
depression) 
 
Epilepsy (rare)  
Focal cortical deficits (rare)  
Optic nerve Unilateral painful loss of 
vision 
Scotoma, reduced visual 
acuity, colour vision, and 
relative afferent pupillary 
defect 
Cerebellum and cerebellar 
pathways 
Tremor Postural and action tremor, 
dysarthria 
Clumsiness and poor 
balance 
Limb incoordination and 
gait ataxia 
Brainstem Diplopia, oscillopsia Nystagmus, internuclear 
and other complex 
ophthalmoplegias 
Vertigo  
Impaired swallowing Dysarthria 
Impaired speech and 
emotional lability 
Pseudobulbar palsy 
Paroxysmal symptoms  
Spinal cord Weakness Upper motor neuron signs 
Stiffness and painful 
spasms 
Spasticity 
Bladder dysfunction  
Erectile impotence  
Constipation  
Other Pain  
Fatigue  
Temperature sensitivity 
and exercise intolerance 
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 symptoms include Lhermitte's symptom, hemifacial weakness, vertigo, and tonic 
spasms and other paroxysmal symptoms. Cognitive deficits commonly occur in late 
onset. Depression and suicide ideation are more common than in age-matched 
controls (Compston and Coles, 2008). 
1.1.6     Disabilities in Multiple Sclerosis 
MS is associated with physical and cognitive disabilities. They have clear impact on 
quality of life (QoL) (Janardhan and Bakshi, 2000). Several scales are used to 
measure disability in MS such as  expanded disability status scale (EDSS), The 
Guy's Neurological Disability Scale (GNDS), Multiple sclerosis severity score 
(MSSS), paced auditory serial addition test (PASAT), symbol digit substitution test 
(SDT), multiple sclerosis functional composite (MSFC), etc.  
1.1.6.1     Physical Disabilities 
MS Patients vary in the severity of their illness from no obvious physical disability to 
being severely disabled. It has become increasingly important both in the clinical 
setting and in therapeutic trials to measure disability levels repeatedly in order to 
assess progression of disability. The  EDSS is a gold-standard measure for 
assessing level of disability (Kurtzke, 1983). It is an ordinal scale with 19 disease 
steps between 0 and 10 (Appendix 3) The scale measures activity limitation based 
on the examination of eight functional systems (pyramidal, cerebellar, brainstem, 
sensory, bowel and bladder, visual, cerebral, other) plus ambulation. It does have 
some well documented limitations, the most important of which are:  it is biased 
towards locomotor function, not a sensitive measure to define irreversible 
progression of disease and has only moderate inter- and intra-rater reliability (Ebers 
et al., 2005; Sharrack et al., 1999). To address this limitations Sharrack and Hughes 
estaEOLVKHG D QHZ GLVDELOLW\ VFDOH *X\¶V 1HXURORJLFDO 'LVDELOLW\ 6FDOH  *1'6
which is a simple clinical disability scale capable of embracing the whole range of 
disabilities which could be encountered in the course of MS (Sharrack and Hughes, 
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1999). Identification of sustained disability progression is an important outcome 
measure in therapeutic trials in MS. An increase of 1 point on the EDSS above 
baseline (or 1.5 EDSS points if the baseline EDSS is 0), subsequently confirmed at 
repeat assessment either 3 or 6 months later are the most commonly used 
measures (Kappos et al., 2006b). Clinically important change in the EDSS was 
deemed to be 1 point change in the range 0±5.0 and 0.5 point change in the range 
5.5±8.5. There are some difficulties with these definitions; relapses may produce 
neurological changes persisting for many months still followed by full recovery and 
people with RRMS exhibit day-to-day fluctuation in neurological signs and 
symptoms unrelated to relapses (Leary et al., 2005). EDSS does not take into 
account the important aspect of disease duration, which is a major factor in 
accumulation of CNS damage over time and the accumulation of functional 
disability. To address this deficiency, Roxburgh with his colleagues based on 
databases from 11 countries have introduced the MSSS as a method for comparing 
disease progression in MS using single assessment at a single point in time 
(Roxburgh et al., 2005). 
1.1.6.2     Cognitive Disabilities 
Cognitive dysfunction is common in MS. It does not strongly correlate with the 
physical disability and EDSS score (Miller et al., 1998). Cognitive impairments are 
evident in tests measuring attention, vigilance, processing speed, working memory 
and executive function. Tests such as PASAT, SDT and MSFC are useful tools to 
detect cognitive disability progression in MS and they are sensitive to change over 
time. 
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1.1.7     Fatigue in Multiple Sclerosis 
1.1.7.1     Definition and overview  
As fatigue is a subjective feeling, there is no unique definition for fatigue. Initially, 
fatigue in MS has been  defined as "an abnormal sense of tiredness or lack of 
energy, out of proportion to the degree of effort or level of disability, that significantly 
interferes with routine physical or intellectual functioning" (Weinshenker et al., 
1992). The 8.0XOWLSOH6FOHURVLV6RFLHW\GHILQHV06IDWLJXHDV³DQRYHUZKHOPLQJ
VHQVHRIWLUHGQHVVIRUQRDSSDUHQWUHDVRQ´.UXSSKDVGHVFULEHGIDWLJXHDVDQ
RYHUZKHOPLQJVHQVHRIWLUHGQHVVWKDWLVRXWRISURSRUWLRQWR³QRUPDO´WLUHGQHVV
(Krupp, 2006)0HGLFDOO\IDWLJXHLQ06KDVEHHQGHILQHGDVD³UHYHUVLEOHPRWRUDQG
cognitive impairment with reduced motivation and desire to rest, either appearing 
spontaneously or brought on by mental or physical activity, humidity, acute infection 
and food ingestion. It can occur at any time but is usually worse in the afternoon. In 
MS, fatigue can be daily, has usually been present for years and has greater 
VHYHULW\WKDQDQ\SUHPRUELGIDWLJXH´(Mills and Young, 2008). Fatigue is one of the 
most common symptoms in patients with MS. It is reported that 50% to 92% of 
patients with MS experience significant fatigue (Kaynak et al., 2006; Lerdal et al., 
2007; Zajicek et al., 2010). It has been described as chronic and the most 
debilitating feature of the disease by 15% to 40% of MS patients (Fisk et al., 1994b; 
Giovannoni, 2006; Krupp, 2003). 
Fatigue has a significant negative impact on daily work, family life, and social 
activities of persons with MS and is associated with the perception of an impaired 
general health, mental state (Janardhan and Bakshi, 2002; Ritvo et al., 1996).  The 
majority of patients with MS experience worse fatigue when temperature is higher, 
especially those with severe fatigue (Leavitt et al., 2012; Lerdal et al., 2007), and 
clearly carries a major physical and psychological burden, especially when 
completing everyday tasks (Leocani et al., 2008; Mills and Young, 2008). MS 
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patients often report specific triggers for fatigue, such as heat (Krupp and 
Christodoulou, 2001). 
The common fatigue symptoms are: reduced energy, malaise, motor weakness 
during sustained activity, and difficulty maintaining concentration. Fatigue is 
diagnosed when the presence of fatigue symptoms lasts for at least 50% of days for 
more than 6 weeks (Multiple Sclerosis Clinical Practice Guideline, 1999). Self-report 
questionnaires such as the fatigue severity scale (FSS) may be useful in the 
diagnosis of MS fatigue and as a surrogate outcome measure. 
Fatigue in MS may manifest itself in a variety of forms, including acute fatigue 
localized to specific muscle groups and persistent, global fatigue. Fatigue affects 
both motor and cognitive ability. 
1.1.7.2     Types of Fatigue 
1.1.7.2.1     Motor Fatigue 
Motor fatigue is defined as a decline in motor performance during sustained muscle 
activity (Bigland-Ritchie et al., 1998). Motor fatigue worsens during MS 
exacerbations involving the motor system and improves during remission, but does 
not change during exacerbations in which the motor system is unaffected (Djaldetti 
et al., 1996). Studies have found that motor fatigue during intermittent voluntary 
submaximal contractions of the tibialis anterior muscle was associated neither with 
self-reported fatigue in MS patients nor with overall neurologic impairment/disability, 
but it was associated with pyramidal signs on examination (Djaldetti et al., 1996; 
Sharma et al., 1995). The pathophysiologic basis for motor fatigue in MS patients 
remains unclear. Both peripheral and central mechanisms have been suggested. 
Studies using transcranial magnetic stimulation have suggested that there may be 
decreased central activation as fatigue occurs in MS patients (Brasil-Neto et al., 
1994; Sheean et al., 1997). On the other hand studies focusing on exercise-induced 
 20 
biochemical changes in muscle have suggested that peripheral mechanisms are 
involved, producing alterations in muscle metabolism (Hainut and Duchateau, 1989; 
Kent-Braun et al., 1994; Miller et al., 1990). 
1.1.7.2.2     Cognitive fatigue 
Cognitive fatigue can be defined as a decrease in, or inability to sustain, task 
performance throughout the duration of a continuous information processing speed 
task (Schwid et al., 2002). Cognitive fatigue can occur in all stages of the disease 
and usually does not correlate with demographic or disease characteristics such as 
age, gender, depression, disability or disease severity, or disease duration 
(Parmenter et al., 2003). 
Comparing with healthy control, during continuous information processing speed 
task patients with MS become cognitively fatigued sooner, reflected by a breakdown 
in task performance (Bryant et al., 2004). 
1.1.7.3     Measurement of Fatigue 
Available measurements for fatigue so far are; FSS, Fatigue Descriptive Scale 
(FDS), Modified Fatigue Impact Scale (MFIS), Neurological Fatigue Index (NFI-MS) 
and Visual Analogue Scale for Fatigue (VAS-F) (Johnson, 2008). These measures 
are mainly self-report questionnaires, and they are not specific to MS. One of the 
most commonly used self-report scales is FSS, which is a self-report questionnaire 
designed to assess fatigue in general (Krupp et al., 1989). It has shown that FSS 
has ability to highlight the approach towards appropriate and individualised 
treatments (Valko et al., 2008). 
1.1.7.4     Pathogenesis of MS fatigue 
The exact aetiology and pathophysiology of fatigue in MS patients are not well 
understood, it appears to be complex and multifactorial.  Both peripheral and central 
mechanisms have been suggested but no satisfactory conclusion has been 
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achieved so far (Kos et al., 2008). Fatigue may be directly related to the underlying 
MS disease process and the disease mechanisms such as proinflammatory 
cytokines, CNS lesion load, cerebral quantitative imaging abnormalities and patterns 
of cerebral activation, endocrine influences and axonal injury (primary fatigue), 
[reviewed in (Induruwa et al., 2012)] or may be secondary to non-disease-specific 
factors such as secondary effects of inflammation on neuromodulation, disruption of 
neural pathways necessary for brain activity, and daytime somnolence due to 
nocturnal sleep disturbances such as sleep problems, urinary problems, spasms, 
pain, anxiety or depression (secondary fatigue) (Bakshi, 2003; Krupp, 2003; Schwid 
et al., 2002). MS fatigue has not been shown to be correlated with disease duration, 
gender, psychosomatic mechanisms, physical disability, or sleep dysfunction. A 
study has showed that obvious fatigue has been observed in patients with benign 
MS with no disability and it was also showed that MS fatigue is not related to some 
markers of systemic inflammation (Giovannoni et al., 2001). 
A study by Bakshi et al. showed a significant relationship between fatigue and 
depression in MS independent of physical disability (Bakshi et al., 2000). Kaminska 
et al (2011) have found that sleep disturbances in MS may also result in or 
exacerbate fatigue in MS. 
Using conventional MRI, only a weak correlation between MRI lesion load and 
fatigue has been reported (Bakshi et al., 1999; Colombo et al., 2000). In contrast, by 
using more advanced MRI techniques other studies have found that GM pathology 
(Cantor, 2010) and the basal ganglia (Téllez et al., 2008) may be a contributing 
factor to the development of MS related fatigue. The results of the Niepel et al study 
had supported the role of the GM in the pathogenesis of fatigue in MS (Niepel et al., 
2006).  The relationship between MS fatigue and brain atrophy has been suggested 
by several studies. Yaldizli et al (2011) have found that corpus callosum (CC) 
atrophy was present in subjects with MS and may play a role in the evolution of MS-
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related fatigue. Other studies have suggested that patients with higher levels of 
fatigue have higher WM and GM atrophy (Marrie et al., 2005; Pellicano et al., 2010; 
Tedeschi et al., 2007). In a comparative study with healthy control a strongest 
correlation between cortical atrophy and fatigue in the MS patient has reported 
(Pellicano et al., 2010). 
It has been found that the fatigued MS patients have significantly increased 
adrenocorticotropic hormone (ACTH) levels in the combined dexamethasone-
corticotrophin releasing hormone (Dex-CRH) test, compared to those without fatigue 
(Gottschalk et al., 2005). In a similar study with 73 progressive MS patients, Téllez 
et al. proposed that fatigue could be related to low serum levels of 
dehydroepiandrosterone (Tellez et al., 2006). There is also evidence suggest that 
increased activation of central neural circuits is associated with MS fatigue. Several 
studies have suggested that performing motor function increases loss of strength 
and increased cortex excitability in a wider cerebral area than in control subjects and 
led to early fatigue (Benwell et al., 2007; Leocani et al., 2001; Thickbroom et al., 
2008). 
Axonal damage is also suggested as being a factor for fatigue in MS. A study by 
Tartaglia et al used MRS, found that the N-acetyl aspartate (NAA): Creatinine 
(NAA/Cr) ratio used as marker of CNS axonal damage was significantly lower in a 
high-fatigue than in a low-fatigue group of MS patients. There was also a significant 
inverse linear correlation between the FSS scores and the NAA/ Cr ratio (Tartaglia 
et al., 2004). 
1.1.7.5     Management of fatigue 
Fatigue in MS is different from fatigue in healthy subjects and it is one of the most 
challenging symptoms to treat (Krupp et al., 2010). Despite various non-
pharmacological and pharmacological treatments or combinations trials definitive 
evidence of their relative efficacy and tolerability is unavailable. 
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1.1.7.5.1     Non-pharmacologic therapies 
Non-pharmacological approaches include aerobic exercise programmes, energy 
conservation strategies and cognitive behavioural therapy (CBT). The benefit of 
cooling therapies has been tested which been reported to be effective in reduction of 
fatigue and improvements in physical, cognitive, and psychosocial function 
(Flensner and Lindencrona, 2002). Improvement of sleep has been evaluated to 
treat fatigue in MS (Heesen et al., 2006) . Aerobic exercise program found to be 
effective in reduction of MS fatigue and improvement of health (Mostert and 
Kesselring, 2002). 
The use of CBT to treat fatigue in MS is still under investigation. A randomised 
control trial of patients with MS related fatigue receiving either CBT or relaxation 
therapy showed that at 6 months after treatment, both groups described clinically 
significant decreases in fatigue levels equivalent to those of the healthy comparison 
group (van Kessel et al., 2008). 
1.1.7.5.2     Pharmacologic Drug therapy 
Several medications have been tried for treatment of fatigue in MS. Amantadine is a 
dopaminergic agent that has been evaluated for fatigue. A significant efficacy on 
some of the studies, but not all, has been found (Cohen and Fisher, 1989; Krupp et 
al., 1995; Murray, 1985; Rosenberg and Appenzeller, 1988). Modafinil is a wake-
promoting agent has been studied in patients with MS, and was effective on several 
measures of fatigue (Rammohan et al., 2002; Zifko et al., 2002). Aminopyridines are 
potassium channel-blocking agent exert their effect through enhancing conduction in 
demyelinated nerve fibres. Its effects on MS fatigue have been suggested but not 
definitively demonstrated (Rossini et al., 2001; Schwid et al., 1997). 
Improvement of fatigue score in MS patients by Prokarin, which is a proprietary 
blend of histamine and caffeine, has been found in a placebo controlled study 
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(Gillson et al., 2002). Metz et al. have provided evidence that MS fatigue may be 
improved with immune modulating treatment with either glatiramer acetate  (GA) or  
interferon beta (IFN-ȕVKRZQE\ LPSURYHG WRWDO fatigue impact scale (FIS) scores 
(Metz et al., 2004). 
1.1.8     Autonomic dysfunction in multiple sclerosis 
Autonomic dysfunction (AD) in people with MS is well documented, but, the 
significance of these abnormalities and the relationship to clinical characteristics is 
not yet established (Flachenecker et al., 2003; Merkelbach et al., 2001). 
AD particularly affects the bladder, bowel, cardiovascular function, sleep, sexual and 
sweat glands. This may be clinically evident  such as bladder disturbances or may 
be subclinical, when abnormal sympathetic skin response (SSR) or decreased heart 
rate variation is estimated (Linden et al., 1995; Linden et al., 1997). 
AD has an important impact on the disability in MS patients and is considered as 
one of the crucial components that have an impact on the QoL outcomes in these 
patients. 
The pathophysiology behind AD remains unclear but plaques located adjacent to the 
pathways significant for autonomic function in the hypothalamus involving fornix, 
anterior commissure, internal capsule, optic system and spinal cord might be the 
basis for autonomic disturbances in MS patients (Huitinga et al., 2001). It has been 
suggested that demyelination may disrupt the central autonomic network in the 
insular, anterior cingulate and ventromedial prefrontal cortices, central nucleus of 
the amygdala, paraventricular hypothalamus and the medulla or interfere with the 
descending autonomic nervous system (ANS) pathways during their course in the 
brainstem or spinal cord (Vita et al., 1993). 
The autonomic nerve activity is not assessed directly, but the response of the 
effector organs can be measured. Electrophysiological evaluations for assessing AD 
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in MS patients has been established as a diagnostic tool for AD, some studies have 
suggested the use of some self-completed questionnaires on the symptoms of 
patients with AD (Flachenecker et al., 2001; Nasseri et al., 1999). 
AD may not only be a consequence of the disease but may also in itself play a 
pathogenetic role; evidence from animal and clinical studies suggest  interactions 
between the immune system and the ANS (Chelmicka-Schorr and Arnason, 1994; 
Zoukos et al., 1994). 
1.1.9     Diagnosis of Multiple Sclerosis 
Diagnosing MS is complex and sometimes lengthy process.  Clinical findings and 
supporting evidence from supplementary tests, such as MRI of the brain, CSF 
examination, and clinical neurophysiology are the bases for diagnosis of MS. 
Clinical ground is a cornerstone for diagnosis of MS.  MRI has become a valuable 
test for confirming the probable cases of MS. The diagnosis depends on detection of 
lesions which are disseminated in time and space.  CSF examination is used for 
detection of OCBs and IgG level in the CSF. Finally the clinical neurophysiology has 
a role in supporting the diagnosis especially the visual and somatosensory evoked 
potentials, which are helpful in identifying additional, silent lesions (Polman et al., 
2005b). 
1.1.9.1     Diagnostic Criteria for Multiple Sclerosis 
1.1.9.1.1     The Poser criteria 
In 1983 Poser with his colleagues established a new diagnostic criteria for MS 
(Poser et al., 1983): 
Clinically definite MS  
2 attacks and clinical evidence of 2 separate lesions  
2 attacks, clinical evidence of one and paraclinical evidence of another separate 
lesion  
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Laboratory supported Definite MS  
2 attacks, either clinical or paraclinical evidence of 1 lesion, and CSF immunologic 
abnormalities  
1 attack, clinical evidence of 2 separate lesions & CSF abnormalities  
1 attack, clinical evidence of 1 and paraclinical evidence of another separate lesion, 
and CSF abnormalities  
Clinically probable MS  
2 attacks and clinical evidence of 1 lesion  
1 attack and clinical evidence of 2 separate lesions  
1 attack, clinical evidence of 1 lesion, and paraclinical evidence of another separate 
lesion  
Laboratory supported probable MS  
2 attacks and CSF abnormalities 
1.1.9.1.2     The McDonald criteria 
In 2001 an international panel in association with the National Multiple Sclerosis 
Society of America recommended revised Diagnostic criteria of MS. They make use 
of advances in MRI imaging techniques in order to facilitate in diagnosis of MS and 
using MS, possible MS or not MS (McDonald et al., 2001). Currently, McDonald 
criteria are regarded as the gold standard for MS diagnosis (Appendix 2). 
1.1.9.1.2.1     Revised 2005 
The McDonald criteria were revised in 2005 to clarify some terms such as exactly 
what is meant by an "attack," "dissemination," a "positive MRI," etc. (Polman et al., 
2005b) (Appendix 4). 
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1.1.9.1.2.2     Revised 2010 
In 2010, the International Panel on Diagnosis of MS revised the McDonald 
diagnostic criteria. This  revision had simplified  the demonstration of CNS lesions in 
space and time by MRI techniques and made the criteria for all people  including  
the non-Western Caucasian populations (Polman et al., 2011) (Appendix 5). 
1.1.10     Treatment of Multiple Sclerosis 
MS is a progressive disease that has no cure. Treatment categories are:  
¾ Acute treatment  
¾ Disease-modifying therapies  
¾ Combination therapies 
¾ Investigational Therapies 
¾ Symptomatic therapy,  
¾ Neuroprotective agents 
1.1.10.1     Acute Treatment 
Treatment of acute attacks will shorten the duration and possibly decrease the 
severity of the attack. 
Corticosteroids: Corticosteroids are a mainstay of treatment for acute exacerbations 
associated with MS. The most commonly used corticosteroids are 
methylprednisolone and prednisone. There are several potential modes of action, 
which include reducing oedema, stabilising the BBB, decreasing pro-inflammatory 
cytokines, and T cell apoptosis (Gold et al., 2001).  
Plasmapheresis: Patients have been treated with plasmapheresis for acute, severe 
attacks, were reported to exhibit moderate or marked functional improvement after 
the initial treatment. In cases steroids are contraindicated or not effective, plasma 
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exchange can be an alternative for short term use in severe attacks (Meca-Lallana 
et al., 2003; Weinshenker, 2001).  
The 2011 American Academy of Neurology (AAN) guideline confirms that 
plasmapheresis is probably effective in relapsing forms of MS as second-line 
treatment for exacerbations that resist steroid treatment. 
1.1.10.2     Approved disease modifying therapies  
The disease modifying therapies (DMT) for MS currently approved for use in 
relapsing forms of MS include the following:  
Interferons (INF): INFs are natural proteins that are produced by the body in 
response to infectious stimuli. They were first described in 1957.  Based on the type 
of receptor through which they signal, human INFs have been classified into three 
major types: INF type I; bind to a specific cell surface receptor complex known as 
the INF- ĮUHFHSWRU7KHW\SH,,1)VSUHVHQWLQKXPDQVDUH,)1-Į,1)-ȕDQG,)1-Ȧ
INF type II: Binds to interferon-gamma receptor. In humans this is IFN-Ȗ ,1)W\SH
III: Signal through interleukin 28 receptor, alpha subunit (Papatriantafyllou, 2013). 
7KH,1)FXUUHQWO\DSSURYHGIRUWUHDWPHQWRI06DUH,1)ȕ-1b (Betaseron, Extavia) 
DQG,1)ȕ-D5HELI$YRQH[,1)ȕ has been shown to inhibit T-cell activation and 
reduce BBB permeability to inflammatory cells, Pivotal phase III studies of ,1) ȕ 
have all demonstrated a significant reduction in relapse rate and improvement in 
MRI measures of disease activity in RRMS (Ebers, 1998; Jacobs et al., 1996; The 
Ifnb Multiple Sclerosis Study Group, 1993). 
Glatiramer Acetate (GA) : In experimental models, the immunomodulatory 
mechanism of action for GA involves binding to MHC molecules and consequent 
competition with various myelin antigens for their presentation to T cells (Arnon and 
Aharoni, 2004). In addition, GA is a potent inducer of specific T helper 2 type 
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suppressor cells that migrate to the brain and lead to bystander suppression; these 
cells also express anti-inflammatory cytokines. 
The benefit of GA was first established in patients with RRMS. Two placebo-
controlled studies have shown that GA significantly lowered relapse rate (Johnson et 
al., 1995), and significantly reduced disability progression (Johnson et al., 1998) as 
compared to the placebo. Another trial found that GA treatment led to a significant 
reduction in the number of new T2 lesions on brain MRI (Comi et al., 2001a). A 
recent head-to-KHDGFRPSDULVRQ WULDO %HWDIHURQ »%HWDVHURQYV*$ (O'Connor et 
al., 2009) KDVVKRZQODUJHO\VLPLODUHIILFDF\EHWZHHQWKH,1)ȕWUHDWPHQWVDQG*$ 
Mitoxantrone (Novantrone): Mitoxantrone is an antineoplastic drug. USA food and 
drug administration (FDA) has approved this drug for patients suffering from 
secondary-progressive, progressive-relapsing, or worsening RRMS. Mitoxantrone 
decreases proinflammatory cytokines, augments suppressor cell function and 
decreases the migration of T cells into the CNS by suppressing the activity of T 
cells, B cells, and macrophages. In Progressive MS mitoxantrone can alter the 
disease course and also suggested benefit in the treatment in RRMS (Mahdavian et 
al., 2010). 
Natalizumab (Tysabri): Natalizumab is a monoclonal antibody against the cell 
adhesion molecule Į-integrin. It inhibits the migration of T and B cells into the CNS, 
resulting in a reduction of inflammatory demyelinating lesions. Natalizumab  can 
slow the disease progression and decreases the number of relapses (Mahdavian et 
al., 2010). An uncommon, but potentially deadly, side effect of treatment of MS 
patients with natalizumab is the development of progressive multifocal 
leukoencephalopathy (PML). Clinically, PML manifests with subacute progressive 
cognitive decline and focal neurological deficits, and it is usually fatal (Sahraian et 
al., 2012). 
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Fingolimod: In 2010, fingolimod became the first oral DMT approved for treatment of 
MS and categorized in a new class called sphingosine 1-phosphate receptor (S1P-
R) modulators. This S1P-R modulator deprives T cells of the signal they need to 
leave lymph nodes, thus inhibiting them from circulating and entering the brain. 
Studies have found that fingolimod reduces the number of lesions detected on MRI 
and clinical disease activity in patients with MS (Kappos et al., 2006a; Mahdavian et 
al., 2010). 
Teriflunomid: Teriflunomide is an oral reversible inhibitor of dihydroorotate 
dehydrogenase (DHODH), a mitochondrial membrane protein essential for 
pyrimidine synthesis (Palmer, 2010). DHODH blocks de-novo pyrimidine synthesis 
leading to an inhibition of the proliferation of autoreactive B and T cells. In the 
presence of teriflunomide, replication of hematopoietic and memory cells is 
preserved through metabolism of the existing pyrimidine pool. Teriflunomide has 
been shown to have modulation of immunoglobulin class switching, IL-2 production, 
and IL-2 receptor expression (Siemasko et al., 1996) 
Teriflunomide was compared with placebo in a phase II trial in patients with RRMS 
and SPMS still experiencing relapses. Patients who received teriflunomide had 
significantly fewer T1-enhancing lesions or new or enlarging T2 lesions than those 
treated with placebo. Patients receiving teriflunomide had significantly reduced T2 
disease burden. The proportion of patients with increased disability by EDSS at 36 
weeks was significantly lower with teriflunomide compared with placebo (O'Connor 
et al., 2006) 
Two phase II studies evaluated teriflunomide as adjunctive therapy in persons with 
MS  (Freedman et al., 2010; Freedman et al., 2009). In these studies, patients 
UHFHLYLQJ JODWLUDPHU DFHWDWH RU D ȕ-IFN were randomised to add placebo or 
teriflunomide their current therapy. In both studies, teriflunomide had good safety 
and tolerability and was associated with improved disease control manifested as 
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reduced number and volume of T1 gadolinium-enhancing lesions, compared with 
placebo. 
Results from the phase III, TEMSO study demonstrated significant reduction in 
annualized relapse rate (ARR) and disability progression with teriflunomide 
compared with placebo (Miller et al., 2012). The numbers of gadolinium-enhancing 
T1 lesions and unique active lesions per scan were also reduced with teriflunomide 
vs. placebo (Nelson et al., 2011).  
Teriflunomide is also being evaluated as an adjunctive therapy in combination with 
IFN-ȕ LQ WKHSKDVH ,,,7(5$&/(6VWXG\ZLWKHVWLPDWHGFRPSOHWLRQ LQ7ZR
additional studies are underway; TOWER and TENERE are monotherapy studies 
comparing teriflunomide with placebo and IFN-ȕ-1a subcutaneous, respectively    
(ClinicalTrials.gov., 2011a). TOPIC is an ongoing phase 3 trial evaluating the 
efficacy and safety of once daily teriflunomide vs. placebo in patients with clinically 
isolated syndrome (ClinicalTrials.gov., 2011b). 
BG-12 (Dimethyl Fumarate): BG-12 is a fumaric acid ester with immunomodulatory 
properties. BG-12 has demonstrated benefits in animal models of EAE. Fumaric 
acid esters may decrease leukocyte passage through the BBB and exert 
neuroprotective properties by the activation of antioxidative pathways(Lee et al., 
2008). 
DEFINE was a phase III, placebo-controlled, comparative study of BG-12 in RRMS 
patients (Gold et al., 2012). Patients with were randomised to BG-12 at two different 
doses dose or to placebo. Both BG-12 doses were associated with a significant 
decrease in the proportion of patients who relapsed at 2 years compared with 
placebo. Both BG-12 doses were significantly superior to placebo in reducing ARR, 
the number of new or newly enlarging T2 hyperintense lesions, and the number of 
new gadolinium-enhancing lesions. BG-12 was also superior to placebo in slowing 
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the rate of disability progression as measured by EDSS scores at 2 years (Gold et 
al., 2012).  
CONFIRM was a phase III, study, investigated the efficacy and safety of oral BG-12, 
at two different doses, as compared with placebo in patients with RRS. An active 
agent, glatiramer acetate, was also included as a reference comparator. In patients 
with RRMS, BG-12 (at both doses) and glatiramer acetate significantly reduced 
relapse rates and improved neuroradiologic outcomes relative to placebo (Fox et al., 
2012). 
1.1.10.3     Combination therapies 
The combinations of intravenous (IV) methylprednisolone and methotrexate with 
LQWUDPXVFXODU ,0 ,1)ȕ-1a have been tested in clinical trials (Cohen et al., 2008; 
Cohen et al., 2009). The results have revealed a non-significant trends favouring IV 
methylprednisolone for new or enlarging T2-hyperintense lesions, gadolinium-
enhancing lesions, relapse rate, EDSS change, MSFC score change, and a 
combined measure of clinical and MRI disease activity. The benefit of methotrexate 
has not been suggested.  
The results of another clinical trial of oral methylprednisolone as add-on therapy to 
,1)ȕ-1a for the treatment of RRMS (Sorensen et al., 2009) have suggested that the 
mean yearly relapse rate was less in the methylprednisolone group compared to the 
placebo group while EDSS progression was not significantly different between the 
two groups.  
Calabresi et al (2002) in a pilot study have investigated the effect of adding 
PHWKRWUH[DWH WR ,1) ȕ-1a in MS patients. They found a significant reduction in 
gadolinium-enhancing lesion number and mean relapse number. A similar open-
ODEHO WULDOKDGLQYHVWLJDWHGWKHFRPELQDWLRQRID]DWKLRSULQHZLWK,1)ȕ-1a (Pulicken 
et al., 2005) found a reduction in gadolinium-enhancing MRI lesions. 
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&RPELQDWLRQRI,0,1)ȕ-1a with IV natalizumab has been studied in a clinical trial 
where it was found that the risks of relapse, number of new or enlarging T2-
hyperintense lesions, and mean number of gadolinium-enhancing lesions were 
significantly lower in the natalizumab group than in the placebo group. This was a 
largest combination trial so far and data from this trial indicated a clear advantage of 
QDWDOL]XPDE SOXV LQWUDPXVFXODU ,1) ȕ-D   RYHU LQWUDPXVFXODU ,1) ȕ-1a alone on 
clinical and imaging endpoints (Rudick et al., 2006). 
A monthly infusion of IV natalizumab along with GA has been evaluated in a clinical 
trial. The results have indicated that combination group had superiority compared to 
placebo group for the primary and most secondary imaging outcomes (Goodman et 
al., 2009). 
In some pilot studies a short course of mitoxantrone is used to induce 
immunosuppression, followed by immunomodulation with first-line drugs such as 
INF-ȕ RU *$ 7KHVH WULDOV KDYH VXJJHVWHG D SURPLVLQJ ILQGLQJV ZLWK ERWK GUXJV
[reviewed in (Boggild, 2009)]. 
Despite evidence from many preliminary studies that lends support to the safety, 
tolerability, and efficacy of several combination regimens, many of larger trials of 
these combinations have yielded negative or conflicting results. Combination 
therapy remains an attractive option in MS treatment, however, the neuroprotection 
strategy in MS was rarely studied. The future efforts should focus on combining anti-
inflammatory and neuroprotective or reparative strategies. 
Investigation therapies in multiple sclerosis 
Research into additional treatment options continues to advance. Multiple 
approaches are being investigated based on the increasing knowledge about 
immune system abnormalities and CNS lesion formation in MS. These include 
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approaches to counteract or reduce immune system activation, BBB disruption, 
neuronal loss and myelin loss.  
The development of new pharmacologic agents for the treatment of MS has led to 
changes in the treatment of MS. To date, six drugs have entered or completed 
phases II and III clinical trials. These include laquinimod, alemtuzumab, daclizumab, 
rituximab, ocrelizumab and ofatumumab. 
MS requires lifelong DMTs, and all of the currently available first-line DMTs are 
parenteral formulations only. As the advent of new oral drugs will lead to increased 
patient compliance and contribute to longer sustain symptom-free periods and less 
marked disability. 
Recent approval of fingolimod, teriflunomide and dimethyl fumarate, as the oral 
drugs to treat MS has marked a new frontier in the treatment of MS. Their entry onto 
the market will provide additional treatment options.  
Laquinimod: Laquinimod is an immunomodulator has been shown to promote anti-
inflammatory cytokine profiles in human peripheral blood mononuclear cells. In EAE 
models, laquinimod had effectively reduced inflammation, demyelination, and axonal 
damage (Bruck and Wegner, 2011). 
Laquinimod has been evaluated in phase III trials, in patients with RRMS who were 
randomised to receive laquinimod or placebo. Laquinimod treatment resulted in 
reduction in ARR vs. placebo and decrease in the risk for disability progression, as 
measured by EDSS. Treatment with laquinimod was also associated with reduction 
in progression of brain atrophy vs. placebo (Comi, 2013). 
In the second phase III study, laquinimod was compared with placebo in patients 
with RRMS. Laquinimod was associated with a statistically significant reduction of 
ARR , risk of disability progression and of brain volume loss compared with placebo 
(Consortium of Multiple Sclerosis Centers, 2011)..  
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Alemtuzumab: Alemtuzumab is a humanised monoclonal antibody against CD52, a 
glycoprotein antigen found on the surface of mature lymphocytes and monocytes. 
The exact biological function of CD52 remains unclear but some evidence suggests 
that it may be involved in T-cell migration (Watanabe et al., 2006).  Alemtuzumab 
has also been shown to induce production of neurotrophic factors in reconstituted 
autoreactive T cells (Jones et al., 2010).  
Efficacy of alemtuzumab for the treatment of MS has been assessed through a 
number of clinical trials. In a Phase II study (CAMMS223), Treatment with 
alemtuzumab was associated with a significant reduction of annualized relapse rate 
compared to IFN-ȕ-1a as well as significantly decreased T2-weighted lesion burden 
than IFN-ȕ-1a Patients who were treated with alemtuzumab experienced a 
significantly lower rate of sustained disability accumulation versus IFN-ȕ-1a as 
evidenced by improvements of the EDSS score (Coles, 2008). 
Two Phase III studies [CARE-MS I and CARE-MS II (Cohen et al., 2012; Coles et 
al., 2012) evaluated the safety and efficacy of alemtuzumab compared with INF-ȕLQ
patients with RRMS. In both studies, a significant reduction in relapse rate 
compared with interferon-beta 1a was observed. In one of the trials, a significant 
reduction in disease progression compared with interferon-beta 1a was also seen.  
Daclizumab: Daclizumab is a humanised monoclonal antibody directed against the 
high-affinity IL-2 receptor. This receptor is present on activated, but not resting, T 
cells. Binding of IL-2 to this receptor is necessary for clonal expansion and 
continued viability of activated T cells (Vincenti et al., 1998) . 
Daclizumab was evaluated for the treatment of RRMS in the phase II CHOICE trial. 
It was a placebo-controlled study in patients with active disease despite IFN-ȕ
treatment. Patients were randomised to receive two different subcutaneous doses of 
daclizumab or placebo as an adjunct to their current IFN-ȕ WKHUDS\ 7KH PHDQ
number of new or enlarged gadolinium-enhancing lesions was 4.75 in the IFN-ȕ±
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placebo group vs. 1.32 for patients who received IFN-ȕZLWKKLJK-dose daclizumab 
and 3.58 for those treated with IFN-ȕZLWKORZ-dose daclizumab) (Wynn et al., 2010).  
SELECT is a phase II clinical trial that evaluated two doses of daclizumab in patients 
with RRMS (Business Wire., 2011). At 1 year, daclizumab was associated with 
significant reductions in ARR for both dose groups,  
Daclizumab is also being compared with i.m. IFN-ȕ-1a in a phase III study in 
patients with RRMS (ClinicalTrials. gov., 2011). 
Rituximab: Rituximab is a chimeric monoclonal antibody that depletes CD20-positive 
B cells through cell-mediated and complement-dependent cytotoxic effects and 
promotion of apoptosis. A phase II clinical trial assessed efficacy of rituximab in 
patient with RRMS, rituximab treatment resulted in significantly decreased numbers 
of gadolinium-enhancing lesions vs. placebo as well as a significantly decreased risk 
for relapse (Hauser et al., 2008). The results of a phase II/III placebo±controlled trial 
in PPMS revealed no significant difference in the time to confirmed disease 
progression between the placebo and rituximab groups (Hawker et al., 2009). 
Ocrelizumab: Ocrelizumab is a humanised anti-CD20 monoclonal antibody that 
results in B cell depletion. It has been evaluated in patients with RRMS who were 
randomised to treatment with i.v. ocrelizumab and i.m. IFN-ȕ-1a or placebo. The 
mean number of gadolinium-enhancing lesions was reduced in the treated group 
compared to placebo (Kappos et al., 2011). 
Ocrelizumab is also being evaluated in phase III, placebo-controlled trial in patients 
with PPMS  (Montalban et al., 2011). The primary outcome measure of this trial is 
time to onset of sustained disability progression (Hauser et al., 2008). Two large 
global studies will compare ocrelizumab with IFN-ȕ-1a subcutaneous (OPERA I and 
II) in patients with RRMS (Clinical Trials. gov., 2012).  
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Ofatumumab: Ofatumumab is a third anti-CD20 antibody being developed for the 
treatment of MS. A phase II safety and pharmacokinetics study in with RRMS 
indicated no dose-limiting toxicities and no unexpected safety findings. Active 
treatment also resulted in significant reductions in the number of gadolinium-
enhancing T1 lesions and new/enlarging T2 lesions in patients treated with 
ofatumumab vs. placebo (Genmab., 2011). 
1.1.10.4     Symptomatic Treatment 
Symptomatic treatment is an essential component of the management of MS. The 
aims of symptomatic treatment are ; elimination or reduction of symptoms impairing 
the functional abilities and QoL of the affected patients  and avoiding development 
of a secondary physical impairment due to an existing disease effects. Many 
therapeutic techniques as well as different pharmacological agents have tried for the 
treatment of MS symptoms (Table1.2). 
 
Table1.2 Symptomatic treatments for multiple sclerosis. Source:  (Compston 
and Coles, 2008)  
Symptoms Signs Treatment 
Established 
efficacy 
Equivocal 
efficacy 
Speculative 
Cognitive 
impairment 
Deficits in 
attention, 
reasoning, and 
executive function 
(early); dementia 
(late) 
  Cognitive 
training 
Hemisensory 
and motor 
Upper motor 
neuron signs 
   
Affective 
(mainly 
depression) 
 Antidepressant 
drugs 
  
Epilepsy (rare)  Anticonvulsants   
Focal cortical 
deficits (rare) 
    
Unilateral 
painful loss of 
Scotoma, reduced 
visual acuity, 
Low vision aids   
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vision colour vision, and 
relative afferent 
pupillary defect 
Tremor Postural and 
action tremor, 
dysarthria 
  Carbamazepine
, B.blockers, 
clonazepam, 
thalamomectom
y,and thalamic 
stimulation 
Clumsiness 
and poor 
balance 
Limb 
incoordination 
and gait ataxia 
   
Diplopia, 
oscillopsia 
Nystagmus, 
internuclear 
ophthalmoplegias 
  Baclofen, 
gabapentin 
Vertigo   Prochloperazine
, cinnarazine 
 
Impaired 
swallowing 
Dysarthria Anticholinergic 
drugs 
 Speech therapy 
Impaired 
speech  
Pseudobulbar 
palsy 
Tricyclic 
antidepressants  
 Speech therapy 
Paroxysmal 
symptoms 
 Carbamazepine, 
gabapentin 
  
Weakness Upper motor 
neuron signs 
   
Stiffness and 
painful 
spasms 
Spasticity Tizanidine, 
baclofen,dantrol
-ene, 
benzodiazepine, 
intrathecal 
baclofen 
Botulinum toxin, 
corticosteroids  
Cannabinoids 
Bladder 
dysfunction 
 Anticholinergic 
drugs and/or 
intermittent self-
catheterisation,  
Decompressing, 
intrvesical 
botulinum toxin 
Abdominal 
vibration, 
cranberry juice 
Erectile 
impotence 
 Sildenafil   
Constipation  Bulk laxatives, 
enema 
  
Pain  Carbamazepine, 
gabapentin 
Tricyclic 
antidepressant 
drugs, 
transcutaneous 
electrical nerve 
stimulation 
 
Fatigue  Amantadine Modafinil Pemoline, 
fluoxetine 
Temperature 
sensitivity and 
exercise 
intolerance 
   Cooling suit, 4-
aminopyridine 
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1.1.10.5     Neuroprotective agents 
There is increasing evidence that degenerative mechanisms are present in all the 
progressive forms of MS. Therefore restorative therapies that improve function of 
damaged neural pathways, as well as neuroprotective and repair strategies, will be 
necessary.  
There are several agents which may show promise as potential neuroprotective 
therapies that could prevent axonal and neuronal damage either directly or indirectly 
after CNS insults. These include: 
Disease modifying therapies: Results from several studies have suggested 
improvement disability outcomes in DMTs treated patients but the actual benefit of 
long term treatment in the later stages of the disease is unclear (Van der Walt et al., 
2010). Importantly, the available DMTs are only partially effective in preventing the 
onset of permanent disability in MS patient (Trojano et al., 2007). The current 
existing DMTs predominantly target the recruitment of systemic immune responses 
and, as such, they would not be expected to modulate significantly the pathogenesis 
of axonal degeneration once it is established.  
Growth Factors:  
x Insulin-like growth factor-1 (IGF-1): IGF-1 promotes  oligodendrocytes 
growth and maturation (McMorris and McKinnon, 1996) and also enhances 
neuronal development (Ozdinler and Macklis, 2006). The results of studies of 
IGF-1 in EAE models are conflicting, initial studies showed an improvement 
in disability in acute and chronic demyelinating EAE (Li et al., 1998; Yao et 
al., 1996). Subsequent studies showed a transient effect only (Cannella et 
al., 2000), or failed to show a sustained benefit of IGF-1 in EAE (Genoud et 
al., 2005). In a pilot study  IGF-1 had administered to  few patients with 
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SPMS showed  no improvement in the primary MRI endpoints, including new 
enhancing lesions, WM lesion load (Frank et al., 2002). 
x Erythropoietin: Erythropoietin is a haematopoietic growth factor.  Its anti-
inflammatory and neuroprotection effects has been established in 
experiments in different models of EAE (Agnello et al., 2002). Both Li et al 
and Diem et al have found that Erythropoietin decrease in axonal loss in 
EAE compared to controls (Diem et al., 2005; Li et al., 1998). In an open-
label pilot study Erythropoietin has been tested in humans suffering from 
chronic progressive MS. Clinical and neurophysiological improvement of 
motor function and cognitive performance was reported (Ehrenreich et al., 
2007) 
x The neuropoietic cytokines (leukaemia-inhibitory factor (LIF) and ciliary 
neurotrophic factor (CNTF): There is a large amount of evidence to suggest 
that LIF and CNTF enhance neuronal survival in the context of axonal injury 
(Hagg et al., 1993). It has been found that survival after axotomy (transaction 
of the axon from the nerve cell body) can be improved in new born rats by 
the administration of either LIF (Hughes et al., 1993) or CNTF (Sendtner et 
al., 1992). Recent work highlights the fact that CNTF exerts more robust 
effects on neuronal survival and growth when applied in combination with its 
soluble form of CNTF-receptor- Į(Ozog et al., 2008). 
Sodium Channel Blockers: Evidence from EAE studies has shown a beneficial effect 
of sodium-blocking agents,  such as flecainide and lamotrigine to improve axonal 
survival and decrease disability (Bechtold et al., 2004; Bechtold et al., 2006). In 
contrast, in a phase II placebo-controlled clinical trial Kapoor et al have not found  
neuroprotective effects  of treatment with lamotrigine in SPMS (Kapoor et al., 2008). 
Calcium Channel Blockers: A study suggested that calcium channel blockers 
prevent axonal loss and disability in treated EAE animals (Brand-Schieber and 
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Werner, 2004). Another study has suggested a possible neuroprotective effect of 
some of the calcium channel blockers such as nimodipine, nifedipine and ryanodine 
(Ouardouz et al., 2009).  
Mesenchymal Stem Cells: Autologous bone marrow (ABM) derived mesenchymal 
stem cell (MSC) can promote neuroprotection by inhibiting gliosis, apoptosis, and  
stimulate  local progenitor cells (Yang et al., 2009).  Evidence shows a specific 
immunomodulatory effect  of MSCs through inhibition of T and B cells and  
maturation of antigen presenting cells (Uccelli et al., 2006). On the other hand 
several EAE experiments have shown that treatment with ABM derived MSC 
significantly improved clinical outcomes (Bai et al., 2009; Gordon et al., 2008; Kassis 
et al., 2008; Zappia et al., 2005; Zhang et al., 2005).  
Glutamate Antagonists: Treatment with glutamate antagonist in EAE result in 
substantial amelioration of disease, increased oligodendrocyte survival and reduced 
neurofilament H, an indicator of axonal damage (Pitt et al., 2000). Memantine, a  N-
methyl-D-aspartate antagonist has shown amelioration of disability in EAE 
(Wallstrom et al., 1996). Kalkers et al. has assessed the effect of riluzole in a small 
cohort of PPMS patients in an open-label study. The study revealed a nonsignificant 
reduction in the rate of cervical cord atrophy and decrease in the development of T1 
hypointense lesions (Kalkers et al., 2002).  
HMG-CoA Reductase Inhibitors (Statins): Evidence of neuroprotection due to statin 
therapy in preclinical studies has been demonstrated in several studies through a 
possible reduction in axonal loss (Neuhaus and Hartung, 2007; Paintlia et al., 2009; 
Sena et al., 2003; Youssef et al., 2002). Available clinical data regarding statins in 
the treatment of MS are not entirely consistent. Most of the studies have showed no 
benefit (Rudick et al., 2009; Sorensen et al., 2011; Wang et al., 2011). In contrast, a 
study enrolled 30 patients with active RRMS (Vollmer et al., 2004)  has showed a 
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significant decrease in the number of gadolinium-enhancing lesions in brain MRI 
scans compared with pre-treatment brain MRI scans.  
Cannabinoids: Cannabis is used by MS patients for relief from a variety of 
symptoms (Clark et al., 2004). In vitro studies have suggested effect of 
cannabinoids on several potential mechanisms of axonal injury, including glutamate 
release (Fujiwara and Egashira, 2004),  oxidative free radicals as well as damaging 
calcium flux (Kreitzer and Regehr, 2001). Which, in excess, can cause neuronal 
death in neuroinflammatory disease (Kapoor et al., 2003; Pitt et al., 2000). 
Furthermore, exogenous agonists of the cannabinoid CB1-receptor have possible 
neuroprotective effects in EAE animal models (Pryce et al., 2003). Subsequent 
clinical studies on cannabinoids for symptomatic treatment of MS (Rog et al., 2005; 
Zajicek et al., 2003; Zajicek et al., 2012) , and  understanding of the biology of 
cannabis shows that cannabis signals to an endogenous cannabinoid system via 
cannabinoid receptors which can regulate neurotransmission and cell death 
pathways (Howlett et al., 2002). Despite these promising results, neuroprotective 
effects in MS by cannabinoids and the modulation of the endocannabinoid system 
must still be established. 
Modafinil: Modafinil is a wakefulness-promoting agent. Besides the already FDA 
approved uses, modafinil also has potential non-approved clinical uses which some 
of them increasingly believed to be neuroprotection. Modafinil prevents glutamate 
toxicity in cultured cortical cells (Antonelli et al., 1998). Another study conducted on 
rat had suggested that modafinil can decrease toxic aspartate and glutamate levels 
after striatal ischemic injury caused by endothelin-1 (Ueki et al., 1993a). 
Furthermore, it was found that modafinil can  prevents development of lesions in the 
hippocampus induced by the neurotoxic nerve gas soman (Lallement et al., 1997). 
Clinically, in a recent retrospective study, we suggest that modafinil significantly 
reduces the disease severity in MS measured by EDSS score (Bibani et al., 2012). 
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The neuroprotective potential of modafinil has been tested in other 
QHXURGHJHQHUDWLYH GLVHDVHV LQ SDUWLFXODU 3DUNLQVRQ¶V GLVHDVH 3' 7KH UHVXOW RI
some studies found that modafinil could prevent degeneration of the nigrostriatal 
pathway in1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) induced PD models 
and mechanical injury of the nigrostriatal pathway (Fuxe et al., 1992; Jenner et al., 
2000; van Vliet et al., 2006; Xiao et al., 2004). Modafinil will be discussed further in 
this thesis. 
1.1.11     Prognosis and complications of Multiple Sclerosis 
The clinical subtype of the disease; the individual's sex, race, age, and initial 
symptoms; and the degree of disability the person experiences were shown to have 
contribution with the expected future course of MS. Individuals with progressive 
subtypes of MS, particularly the primary progressive subtype, have a more rapid 
decline in physical and mental functions. Older individuals when diagnosed are 
more likely to experience a chronic progressive course, with more rapid progression 
of disability. Females generally have a better prognosis than males. Initial MS 
symptoms of sensory problems or visual symptoms, are predictors for a relatively 
good prognosis, whereas motor problems are markers for a relatively poor 
prognosis. Better outcomes are also associated with the presence of only a single 
symptom at onset. 
The degree of disability varies among individuals with MS. In general, one of three 
individuals will still be able to work after 15±20 years. 15% of people diagnosed with 
MS never have a second relapse, and these people have minimal or no disability 
after ten years (Pittock et al., 2004). 
The life expectancy of people with MS is 5 to 10 years lower than that of unaffected 
people and two-thirds of the deaths in people with MS are directly related to the 
consequences of the disease (Compston and Coles, 2008). Despite improvement in 
management of MS, along with some successful treatment infection such as 
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pneumonia and urinary tract infection are common complications of MS. The risk of 
suicide is common in MS patients. Young patients are the most likely victim 
(Sadovnick et al., 1992). 
Interestingly, it has been found that deaths from malignancy are less common than 
in age-matched controls (Sadovnick et al., 1991).  
Higher EDSS scores are associated with increased mortality. Median time from 
disease onset to reaching a disability level when one needs a walking-aid is about 
20 years (Confavreux et al., 2003; Myhr et al., 2001; Phadke, 1987). MS has heavy 
economic and personal burden. The costs are highly correlated with disease 
severity (Kobelt et al., 2006; Parkin et al., 2000).  
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1.2     EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS AND MULTIPLE 
SCLEROSIS  
In the second decade of 20th century, Experimental autoimmune encephalomyelitis 
(EAE) was first described by Koritschoner and Schweinburg (Koritschoner and 
Schweinburg, 1925),They induced spinal cord inflammation in rabbits by inoculation 
with human spinal cord. Subsequently, researchers have attempted to reproduce 
the encephalitic complications associated with rabies vaccination by repetitive 
immunisation of rhesus monkeys with CNS tissue (Rivers et al., 1933). Moreover, 
studies have showed that EAE can be elicited in many different species, including 
rodents and primates, and from these studies it became clear that EAE can 
reproduce many of the clinical, neuropathological and immunological aspects of the 
neurodegenerative disease including MS (Hohlfeld and Wekerle, 2001). At the 
present time, EAE studies have provided an insight into general neuroscience and 
immunology concepts, and developing general therapeutic strategies.  
1.2.1     EAE induction 
EAE can be induced in susceptible strains of different species by sensitisation with 
CNS myelin antigens (Active EAE) (Williams et al., 1994), or by the adoptive transfer 
of CNS myelin antigen-specific CD4+ T cells into naive syngeneic recipients 
(Passive EAE)  (Pender, 1995; Pettinelli and McFarlin, 1981).  
1.2.2     Pathogenesis of EAE 
There is substantial evidence that the initiating effector lymphocyte in EAE 
pathogenesis is the autoreactive CNS specific CD4+ T cell; however, it has been 
found that myelin specific CD8+ T cells also play a role in EAE pathogenesis 
[reviewed in (Goverman et al., 2005)].  
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Besides T cells the role of B cells in EAE pathogenesis has been demonstrated 
(Wolf et al., 1996). However, the role of B cell and its contributions to EAE 
pathogenesis appears to be contradictory and may reflect the involvement of 
multiple roles for B cells or different B cell subsets during disease pathogenesis 
(Bouaziz et al., 2008).  
1.2.3     Clinical scores of EAE 
In the classic EAE model, animals develop an ascending flaccid paralysis, which ± 
depending on disease severity ± The clinical scoring scale is as follows; 0²healthy, 
1²flaccid tail, 2²impaired righting reflex and/or impaired gait, 3²partial hind-leg 
paralysis, 4²total hind-leg paralysis, 5²any sign of front-leg paralysis, and 6²
moribund/ dead (O'Brien et al., 2010).  
1.2.4     EAE and multiple sclerosis 
EAE is primarily used as an animal model of autoimmune inflammatory diseases of 
the CNS. It has become a well characterised model for organ-specific autoimmune 
disease in general. EAE contributed enormously to our understanding of 
autoimmunity, neuroinflammation, cytokine biology and immunogenetics, and the 
development of MS therapeutics.  
Mice and rats have been used commonly for EAE. In addition certain monkey 
species like marmosets are used for specific questions that cannot be easily 
assessed in rodents (t Hart et al., 2011). Most studies are presently done using 
C57BL/6 mice, where disease is induced by immunisation with myelin 
oligodendrocyte glycoprotein (MOG) peptide, representing residues 35±55, 
emulsified in Freund's adjuvant that is supplemented with Mycobacterium 
tuberculosis extract. This protocol is used because it works reproducibly and 
because it allows one to take advantage of the wealth of genetic resources on the 
C57BL/6 background. There are some limitations of this protocol when translated to 
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the MS:  In most cases, the C57BL/6 model of EAE is monophasic, without 
relapses; the T cell component is predominantly CD4+; and spinal cord is affected 
out of proportion to brain.  
1.2.5     EAE and multiple sclerosis treatments 
EAE has contributed to the development, validation, and testing of MS drugs.  One 
major MS treatment (Natalizumb) came directly, in a mechanism-based fashion, 
from EAE research (Polman et al., 2006). EAE has  also played a successful role in 
assurance of the currently licensed and used DMT: IFN-beta (Abreu, 1982) GA 
(Johnson et al., 1995; Teitelbaum et al., 1971) and the anti-VLA-4 antibody (Polman 
et al., 2006). A substantial number of other studies have shown treatment success 
with concordant results in EAE and MS, using a variety of compounds. Some of 
these agents, like azathioprine, mitoxantrone and fingolimod are licenced or well-
established therapies for specific groups of patients with MS. Others, like laquinimod 
have reached late phase clinical trials [reviewed in (Constantinescu et al., 2011a)].  
However, numerous other therapeutics that showed promise in EAE were found to 
be ineffective or detrimental in MS (Denic et al., 2011). 
1.2.6     Major differences between EAE and multiple sclerosis 
Beside all promising achievement from EAE studies in relation to MS, there are 
differences in aetiopathogenesis, immunohistopathology, and genetic components 
between EAE and MS. To reduce the gap between EAE and MS creating new and 
refined EAE models in humanized mice or perhaps by switching to species more 
closely related to humans, such as the common marmoset (Callithrix jacchus). The 
MS-like disease phenotype of marmoset EAE is particularly useful to investigate 
treatment approaches in relapsing-remitting and chronic forms of MS (t Hart et al., 
2011).  
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1.3     MODAFINIL (PROVIGIL) 
1.3.1     Introduction 
In the late 1970s scientists working with the French pharmaceutical company Lafon 
have generated a novel wake-promoting agent known as Adrafinil. In the early 
1990s the primary metabolite of Adranifil, Modafinil, was derived which had similar 
activity. Modafinil has been prescribed in France since 1994 under the name 
Modiodal, and in the US since 1998 as Provigil. Its approval for use in the UK was in 
December 2002. In 1998 modafinil was approved by the United State food and drug 
administration (USFDA) for excessive daytime sleepiness (EDS) associated with 
narcolepsy. Almost a decade later evidence emerged showing its effectiveness in 
treating several sleep disorders (Ballon and Feife, 2006). Modafinil was approved by 
USFDA  in 2004 for the treatment of obstructive sleep apnoea/hypopnoea (OSA) 
syndrome, and shift work sleep disorder (SWSD) (Minzenberg and Carter, 2007).  
Modafinil that is chemically and pharmacologically different from other central 
nervous system (CNS) stimulants (Saper and Scammell, 2004) has a large potential 
for many uses in psychiatry, neurology and general medicine. Because of its ability 
to improve several clinical symptoms in different diseases modafinil seems to be 
one of the important drugs. The pharmacologic effects of modafinil are complex and 
it is thought to alter various neurotransmitters in the brain (Minzenberg and Carter, 
2007). A clear mode of action of modafinil has not been established so far but 
interaction of modafinil with dopaminergic, noradrenergic, glutamatergic, gamma-
aminobutyric acid (GABA)ergic, serotoninergic, orexinergic, and histaminergic 
pathways have been suggested in several animal studies (Ballon and Feife, 2006; 
Ferraro et al., 1999; Ferraro et al., 1998; Ferraro et al., 2002; Madras et al., 2006; 
Minzenberg and Carter, 2007). 
Modafinil has been investigated in healthy volunteers, and in individuals with clinical 
disorders. Its beneficial effect has been shown in many clinical disorders associated 
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with excessive sleepiness, fatigue, impaired cognition and other symptoms such as 
myotonic dystrophy (MacDonald et al., 2002), attention deficit hyperactivity disorder 
(ADHD) in children and adolescents (Lindsay et al., 2006), depression (DeBattista et 
al., 2004) 3DUNLQVRQ¶V GLVHDVH 3' PXOWLSOH VFOHURVis (MS) (Bibani et al., 2012; 
Littleton et al., 2010; Rammohan et al., 2002), and hastening recovery from general 
anaesthesia (Larijani et al., 2004). In sleep-deprived healthy volunteers, modafinil 
improves mood, fatigue, sleepiness and cognition (Wesensten et al., 2005). 
Modafinil improves the ability of the on call physicians to attend lectures after a full 
night shift in emergency departments (Gill et al., 2006). 
The potential interactions of modafinil with a variety of drugs through induction and 
inhibition several cytochrome P450 isoenzymes has been reported (Robertson et 
al., 2000). Reduction of the modafinil dose in old age groups and in patients with 
hepatic and renal impairment is mandatory. Insomnia, headache, nausea, 
nervousness and hypertension are commonly reported adverse effects of modafinil 
(Robertson and Hellriegel, 2003). Other less common side effects of modafinil are 
decrease of appetite, weight loss and dermatological problems. Children and 
adolescents have greater risk to get these side effects. Modafinil may theoretically 
have some abuse/addictive potential. The results seen in two trials on cocaine 
addiction treated with modafinil were inconclusive (Dackis et al., 2005; Umanoff, 
2005).  
1.3.2     Pharmacodynamic Properties of Modafinil 
Modafinil is (2-[(diphenylmethyl) sulfinyl] acetamide. The molecular formula is 
C15H15NO2S and the molecular weight is 273.35. The chemical structure is shown in 
(Figure 1.6). 
Modafinil has two enantiomers (R-modafinil and S-modafinil). The R-modafinil also 
known as armodafinil has longer half-life than S-modafinil while the S-modafinil has 
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Figure 1.6 Chemical structure of modafinil. 
 
a faster rate of clearance. The wake-promoting activity is likely due primarily to the 
R-modafinil (Robertson and Hellriegel, 2003). Modafinil is used in a once-daily 
dosing. It is readily absorbed from gastrointestinal tract and maximum plasma 
concentrations occur at 2±4 hours (Robertson and Hellriegel, 2003). Metabolism 
occurs primarily through the liver, with renal elimination of metabolites (Robertson 
and Hellriegel, 2003). Less than 10% of the administered dose is excreted in urine 
as unchanged drug (Robertson and Hellriegel, 2003; Wong et al., 1999). Modafinil 
induces the cytochrome P450 enzymes CYP1A2, and CYP3A4 and has potential to 
inhibit CYP2C19 (Robertson et al., 2000), thus it may prolong elimination and 
increase circulating levels of drugs that are primarily metabolized via this enzyme 
(e.g., diazepam, phenytoin, and propranolol). Modafinil suppressed CYP2C9 activity 
in cultures of human hepatocytes, suggesting a potential for drug interactions 
between modafinil and enzyme substrates such as warfarin and phenytoin 
(Robertson Jr et al., 2002). Modafinil also enhances the effects of antidepressants 
(Menza et al. 2000, Ninan et al. 2004). 
1.3.3     Clinical Efficacy and Tolerability of Modafinil 
The efficacy and tolerability of modafinil were recognised in several studies with 
different designs. These studies have been conducted in patients with OSA (Black 
and Hirshkowitz, 2005; Pack et al., 2001), SWSD (Czeisler et al., 2005), and 
 51 
narcolepsy (Mitler et al., 2000). However, a significant greater frequency of adverse 
effects has been reported with modafinil in placebo-controlled clinical trials, and 
these were more frequent with fixed dose studies than the in flexible dose study 
(Swanson et al., 2006). Increase in both systolic and diastolic blood pressure (BP) 
with modafinil has been  reported (Muller et al., 2004; Turner et al., 2003). In 
contrast, several studies have reported no significant changes in BP (systolic and 
diastolic), pulse rate and/or electrocardiography (ECG) (Biederman et al., 2005; 
Black and Hirshkowitz, 2005; Broughton et al., 1997; Greenhill et al., 2006; Saletu et 
al., 1989) .  A significantly higher rating for somatic anxiety and several physical 
symptoms such as tremor, palpitations, dizziness, muscular tension, physical 
tiredness and irritability have been reported with modafinil compared with placebo 
(Randall et al., 2003). Decreased appetite and weight loss with modafinil was 
reported in studies of ADHD (Biederman et al., 2005; Greenhill et al., 2006). 
Different types of skin lesions related to modafinil taking have been reported inform 
of maculopapular/morbiliform rash and a case of possible erythema 
multiforme/Stevens-Johnson Syndrome (Biederman et al., 2005). Two patients with 
major depressive disorder developed suicidal ideation in the second week of a trial 
of combined modafinil and serotonin reuptake inhibitors (SRI) therapy (Dunlop et al., 
2007). Psychosis has been reported with modafinil in schizophrenia, post-polio 
fatigue patients and in SWSD patient without any history of psychiatric disorder 
(Mariani and Hart, 2005; Spence et al., 2005; Vasconcelos et al., 2007). Withdrawal 
symptoms of modafinil have not been observed in subjects with ADHD (Greenhill et 
al., 2006). There is no conclusive evidence for abuse potential  of modafinil so far, 
as the psychomotor effects of modafinil do not appear to be mediated via a 
catecholamine mechanism (Ferraro et al., 1996), which might account for modafinil's 
reduced side-effect profile and low abuse potential (Deroche-Gamonet et al., 2002). 
A single fatal case of multi-organ hypersensitivity reaction has been described 
(Sabatine et al., 2007).   
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1.3.4     Mechanism of Action of Modafinil 
0RGDILQLO KDV EHHQ QDPHG ³D GUXJ LQ VHDUFK RI D PHFKDQLVP´ (Saper and 
Scammell, 2004). Despite several years of studies a well-defined biochemical 
mechanism of action of modafinil has not yet been elucidated. The pharmacologic 
effects of modafinil are complex and it is thought to alter various neurotransmitters in 
the brain (Minzenberg and Carter, 2007). Briefly, in animal studies, modafinil has 
been shown to interact with dopaminergic, noradrenergic, glutamatergic, 
GABAergic, serotoninergic, orexinergic, and histaminergic pathways (Ballon and 
Feife, 2006; Madras et al., 2006; Minzenberg and Carter, 2007). It has been 
demonstrated that modafinil activates the hippocampus, which receives afferent 
innervation from the sleep-wake centre of the hypothalamus (Becker et al., 2004; 
Kim et al., 2007).  
1.3.4.1     Effects of Modafinil on the Dopaminergic Pathways 
The evidence regarding the interaction of dopaminergic pathway in modafinil's mode 
of action has changed over time. The initial animal studies showed modafinil had 
only a weak affinity for dopamine receptors (Mignot et al., 1994), and had not 
stimulated release of dopamine in the mouse caudate nucleus (De Sereville et al., 
1994). Furthermore,  it has no effect on  the firing rate of the dopaminergic neurons 
in the rat midbrain (Akaoka et al., 1991). In other studies it was also found that 
various dopamine D1 and D2 receptor antagonists and inhibition of dopamine 
synthesis does not affect on the modafinil-induced hyperactivity in mice (Duteil et al., 
1990; Simon et al., 1995), importantly, a slight reduction of the arousal with 
modafinil has been reported in cats (Lin et al., 1992). In contrast subsequent animal 
studies showed that modafinil administration in different doses and routes leads to 
increased extracellular levels of dopamine in the prefrontal cortex (Hilaire et al., 
2001), caudate nucleus (Wisor et al., 2001), nucleus accumbens (Murillo-Rodriguez 
et al., 2007), and striatal slices preloaded with [3H]dopamine (Dopheide et al., 2007). 
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Also it has been found that modafinil inhibits the dopaminergic neurons in the ventral 
tegmental area and the substantia nigra (Korotkova et al., 2006). Evidence from 
preclinical studies suggests that Modafinil increases dopamine in brain by targeting 
the dopamine transporters (DAT) (Greenhill, 2006). On the other hand  the role of 
dopamine receptors (D1 and D2) in the mode of action of modafinil have been 
evaluated and it was found that  D1 and D2 receptors are involved in alerting effects 
of modafinil (Qu et al., 2008).   
By using recent MRI techniques (positron emission tomography (PET)) the idea 
about interaction of dopamine in the mode of action of modafinil was further 
expanded. Madras et al (2006) used this technique and documented the significant 
occupancy of striatal  DAT by modafinil in monkeys and in vitro modafinil inhibits 
DATs . Furthermore, in a supporting study it was found that mice lacking DAT do not 
respond to the wake-promoting effects of modafinil (Wisor et al., 2001). Findings 
from a human study documented the crucial role of dopamine in the wake-promoting 
effects of modafinil, and the blockage of DATs and increased dopamine in the 
human brain (including the nucleus accumbens) (Volkow et al., 2009). 
1.3.4.2     Effects of Modafinil on Noradrenergic Pathways 
There is considerable pharmacological evidence that modafinil, acts through 
adrenergic mechanisms to promote waking.  Animal studies found that modafinil 
increases levels of noradrenaline in the rat prefrontal cortex and medial 
hypothalamus (de Saint Hilaire et al., 2001). In rat brain slices, modafinil potentiates 
noradrenergic inhibition of the sleep active neurons of the ventrolateral preoptic area 
of the hypothalamus (Gallopin et al., 2004) 9DULRXV Į-adrenoceptor antagonists 
attenuate the modafinil-induced arousal in cats (Lin et al., 1992), and locomotor 
activity in mice (Stone et al., 2002) and monkeys (Duteil et al., 1990). Evidence has 
VWURQJO\ VXJJHVWHG WKDW PRGDILQLO SURPRWHV ZDNLQJ E\ DFWLYDWLQJ Į-adrenergic 
receptors. Response to modafinil was significantly reduced in genetically Į1-
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adrenoceptor-deficient mice (Stone et al., 2002). Furthermore, modafinil occupies 
noradrenaline transporter (NAT) sites in the thalamus of rhesus monkeys in vivo and 
blocks noradrenaline transport via NAT in vitro (Madras et al., 2006). On the other 
hand, it has been found that Modafinil does not bind to adrenergic receptors at 
physiological doses (Mignot et al., 1994), and it does not affect the firing rate of the 
rat pontine noradrenergic neurons (Akaoka et al., 1991) and it does little to reduce 
cataplexy that normally responds to Į1-receptor agonists or to agents that block the 
reuptake of noradrenaline by NAT (Mignot et al., 1993; Nishino et al., 1993). 
1.3.4.3    Effects of Modafinil on Glutamate  
Ferraro et al in series of studies found that modafinil increases levels of the 
glutamate in the thalamus and hippocampus (Ferraro et al., 1997), striatum (Ferraro 
et al., 1998) and medial pre-optic area and the posterior hypothalamus (Ferraro et 
al., 1999) of the rat brain. 
1.3.4.4     Effect of Modafinil on gama amino butyric acid (GABA) 
Animal studies have reported the effect of modafinil in reducing GABA levels in the 
cortex (Tanganelli et al., 1994),  medial pre-optic area and posterior hypothalamus 
(Ferraro et al., 1999), hippocampus (Ferraro et al., 1997), nucleus accumbens, 
striatum, globus pallidus and substantia nigra (Ferraro et al., 1998). This might lead 
to the conclusion that via GABA reductions, modafinil is able to improve motor 
activity and cortical functions (Della Marca et al., 2004). 
1.3.4.5     Effect of Modafinil on serotonin 
There is an inverse effect of modafinil on the level of serotonin and GABA in 
different brain areas. Studies have found that modafinil decreases levels of GABA, 
but increases levels of serotonin (Ferraro et al., 2000; Ferraro et al., 2002).  Also, it 
has found that SRIs and serotonin selective neurotoxins abolish the effect of 
modafinil on GABA release (Tanganelli et al., 1992; Tanganelli et al., 1995). SRIs 
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enhance the effect of modafinil on serotonin levels (Ferraro et al., 2005; Ferraro et 
al., 2002). 
1.3.4.6     Effects of Modafinil on Histaminergic Pathways 
Ishizuka et al (2008) found that modafinil increases histamine levels in the anterior 
hypothalamus in rats . They also found that enhancement of the locomotor activity in 
treated rats with modafinil is reversible with depletion of neuronal histamine. 
1.3.4.7     Effects of Modafinil on Orexinergic Pathways 
The interaction of modafinil with orexin neurons in the brain is complicated and not 
clear yet. Although modafinil activates the orexin neurons (Scammell et al., 2000), it 
is also useful for  narcolepsy deficient in orexin neurons (Nishino, 2003). It has also 
been found that modafinil is more effective in producing wakefulness in orexin 
knockout mice than in wild-type litter mates (Willie et al., 2005). 
1.3.5     Approved Indications of Modafinil 
The use of modafinil has been approved for ameliorating the excessive sleepiness 
associated with narcolepsy, SWSD and residual sleepiness in OSA. 
1.3.5.1     Narcolepsy 
The main symptoms of narcolepsy are EDS, cataplexy (an abrupt loss of muscle 
tone triggered by emotion), hypnagogic hallucinations and sleep paralysis.  Four 
randomised, double-blind, placebo-controlled trials have assessed the usefulness of 
modafinil in treatment of EDS in narcolepsy (Billiard et al., 1994; Broughton et al., 
1997; Fry, 1998; US Modafinil in Narcolepsy Multicenter Study, 1998). Improvement 
of EDS by the objective measures in all four studies have demonstrated and 
improvement by the subjective Epworth Sleepiness Scale (ESS) was also seen 
except the Billiard et al study.  
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1.3.5.2     Obstructive Sleep Apnoea (OSA) 
EDS is one of the main symptoms of OSA and continuous positive airway pressure 
(CPAP) is the gold-standard treatment for OSA.  Modafinil is approved by the FDA 
for treating residual sleepiness despite optimal treatment of OSA (in November 2010 
The $JHQF\¶V &RPPLWWHH IRU 0HGLFLQDO 3URGXFWV IRU +XPDQ 8VH &+03
recommended that this indication should remove from the product information). 
Several studies have carried out for evaluation the role of Modafinil in OSA. The 
largest of these studies was a double-blind, randomised, placebo-controlled study 
(Pack et al., 2001) The primary efficacy measures were ESS, multiple sleep latency 
test (MSLT) results, and CPAP use. The positive effects of modafinil have 
demonstrated in both the ESS and MSLT results, while there was no difference 
noted in CPAP use between groups.  In another relatively similar size study Black 
and Hirshkowitz, have confirmed  the  effectiveness of modafinil in the clinical 
situation which showed that the efficacy of modafinil, as measured subjectively by 
the ESS and objectively by the maintenance of wakefulness test (MWT), does not 
change over an extended period of the study which was 12 weeks (Black and 
Hirshkowitz, 2005). Although reduction in the CPAP usage was not decreased in 
both mentioned studies this was noted in the smaller randomised study of modafinil 
(Kingshott et al., 2001)  and in an open-label extension trial (Schwartz et al., 2003). 
Moreover, modafinil improved symptoms of depression, anxiety, and irritability in 
patients with OSA (Kumar, 2008).  
1.3.5.3    Shift-Work Sleep Disorder (SWSD) 
Three randomised, double-blind, placebo-controlled, parallel group, multicentre trials 
have evaluated the usefulness of modafinil in SWSD with different measures of 
efficacy. In the first trial (Czeisler et al., 2005), The modafinil group had a statistically 
significant increase in mean sleep latency compared with the placebo group,  
Patients taking modafinil also had a significant improvement in performance on a 
 57 
vigilance test. In the second trial (Erman and Rosenberg, 2007),  a statistically 
significant greater increase in the mean Functional Outcomes of Sleep 
Questionnaire score in patients received modafinil compared with placebo was 
seen, also a significant improvements in the activity and in the vigilance and 
productivity domain scores with modafinil were reported. Furthermore Modafinil 
significantly improved the mental and emotional scores compared with placebo.  In 
the third study (Walsh et al., 2004) a significant improvement on vigilance testing 
and the Maintenance of Wakefulness Test (MWT) have been reported. 
1.3.6     Investigational Uses of Modafinil 
1.3.6.1     Neurological Disorders 
1.3.6.1.1     Parkinson's disease 
EDS is one of the main symptom of PD (Ondo et al., 2005). Significant improvement 
in ESS scores were seen in two small, randomised, double-blind, placebo-controlled 
studies (Adler et al., 2003; Happe et al., 2001). In contrast this achievement was not 
found in another study with similar design (Ondo et al., 2005). Also striatal activation 
in PD by modafinil has been shown (Scammell et al., 2000).  
Two studies were conducted by Ferraro et al indicating that modafinil could have 
anti-parkinsonian effects on the motor symptoms of PD (Ferraro et al., 1997; Ferraro 
et al., 1998).  
1.3.6.1.2     Myotonic Dystrophy 
EDS is common symptom in  myotonic dystrophy (Laberge et al., 2004). Three 
randomised, double-blind, placebo-controlled, crossover trials suggested positive 
effects of modafinil in improving EDS in patients with myotonic dystrophy 
(MacDonald et al., 2002; Talbot et al., 2003; Wintzen et al., 2007).  
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1.3.6.2     Psychiatric Disorders 
1.3.6.2.1     Attention Deficit Hyperactivity Disorder (ADHD) 
Three placebo-controlled, open-label trials have assessed modafinil for treatment of 
ADHD in children. A beneficial effect of modafinil in ADHD symptoms in children in 
terms of increasing attention and decreasing hyperactive and impulsive behaviour 
was observed (Amiri et al., 2008; Boellner et al., 2006; Rugino and Copley, 2001). 
Two other studies also  found that modafinil progressively decreases the ADHD 
symptoms (Biederman et al., 2006; Swanson et al., 2006). A small comparative 
study had conducted to explore the efficacy of modafinil with dexamphetamine and 
placebo in adults with ADHD (Taylor and Russo, 2000). They found that both 
dexamphetamine and modafinil significantly reduced the ADHD symptoms.  Another 
study suggested a beneficial effects of a single dose of modafinil  on working 
memory, visual memory, planning, response inhibition and sustained attention in 
adults with ADHD (Turner et al., 2004a). 
1.3.6.2.2     Depression 
Three studies have assessed the efficacy of modafinil in major depression by using 
different combinations of instruments (DeBattista et al., 2004; Dunlop et al., 2007; 
Fava et al., 2005). Two of these studies have shown considerable placebo effect, 
with reductions in ESS and FSS scores with both modafinil and placebo (DeBattista 
et al., 2004; Fava et al., 2005). However in a small study the efficacy of modafinil as 
adjunctive treatment for bipolar depression has been assessed (Frye et al., 2007). 
The result has suggested that modafinil may be helpful in bipolar depression.  
1.3.6.2.3     Schizophrenia 
Several studies have assessed the effect of modafinil on clinical measures in 
schizophrenia. Modafinil showed no greater effect on fatigue than placebo (Pierre et 
al., 2007; Sevy et al., 2005) and no effect (Sevy et al., 2005) or only limited effect 
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(Hunter et al., 2006; Spence et al., 2005; Turner et al., 2004b) on cognition 
performance.   
1.3.6.2.4     Alzheimer's disease 
$OLQNEHWZHHQV\VWHPLFLQIODPPDWLRQDQG$O]KHLPHU¶VGLVHDVHKDVEHHQVXJJHVWHG
(Rogers et al., 1988). A recent study has found that the modafinil derivatives exhibit 
anti-inflammatory activity as evidenced by lowering of lipopolysaccharide-induced 
nitric oxide (NO) generation and of inflammation-related enzymes in BV2 microglial 
cells. They have also reported that the anti-inflammatory activity of modafinil 
derivatives is better than that of aspirin in the cultured cells used. These results 
suggest that modafinil derivatives can be developed as potential anti-inflammatory 
DJHQWVDQGDWUHDWPHQWVWUDWHJ\IRU$O]KHLPHU¶VGLVHDVHUHODWHGGHPHQWLD (Jung et 
al., 2012). In contrast, Frakey et, al., (2012) have reported that the addition of 
modafinil to the standard of care treatment (cholinesterase inhibitor medication) in 
individuals with Alzheimer's disease has not resulted in significant additional 
reductions in apathy or improvements in performance of activities of daily living. 
1.3.6.2.5     Effect of modafinil on addiction and substances dependency 
1.3.6.2.5.1     Cocaine 
Modafinil has been assessed for potential treatment of cocaine addiction. Modafinil 
could induce a decline in cocaine use (Dackis et al., 2005; Hart et al., 2008) and this 
more specifically in a subset of cocaine without alcohol dependence (Anderson et 
al., 2009). Another supporting study found that the decrease of use also was 
associated with longer periods of abstinence (Dackis et al., 2005). 
In contrast to the previous positive results Dakis et al in a recent study had 
concluded that modafinil has no significant differences compared to placebo on the 
cocaine abstinence, cocaine craving, cocaine withdrawal, retention, and tolerability 
(Dackis et al., 2010, 2012). 
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1.3.6.2.5.2     Methamphetamine 
Two studies have suggested that modafinil can increases in the number drug-free 
days in amphetamine dependence and it can decrease the withdrawal syndrome 
(McGregor et al., 2008; Shearer et al., 2009). However Shearer et al found no effect 
of modafinil on craving for methamphetamine (Shearer et al., 2009). 
1.3.6.2.5.3     Nicotine 
A positive role of modafinil in abstinent smokers has not been confirmed in two 
clinical trials; in contrast, they have reported an increase of negative effects and 
depressive symptoms after ingestion of modafinil (Schnoll et al., 2008; Sofuoglu et 
al., 2008). Furthermore, one of the trials reported that nicotine-abstinent participants 
smoked more with modafinil and had more withdrawal symptoms reported than non-
abstinent participants with placebo, which resulted in the trial being discontinued 
(Schnoll et al., 2008). 
1.3.6.3     Effect of modafinil on Disorders Associated with Fatigue 
1.3.6.3.1     Chronic Fatigue Syndrome 
In a single randomised, double-blind, placebo-controlled, crossover study in patients 
with chronic fatigue syndrome (CFS) modafinil had inconsistent effects on the 
primary efficacy measure of cognition (Randall et al., 2005a), and no improvement 
was seen in the secondary efficacy measures of fatigue, quality of life (QoL) or 
mood. 
1.3.6.3.2     Fatigue in Post-Polio Syndrome 
A placebo-controlled study, conducted by Chan et al revealed no significant 
difference between the two treatments in the terms of the ESS scores and other 
secondary efficacy measures (Chan et al., 2006). Another study with relatively 
similar design revealed improvements in primary efficacy measures of ESS,visual 
analogue scale for fatigue (VAS-F) and fatigue impact scale (FIS) with both placebo 
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and modafinil without significant differences between the two treatments 
(Vasconcelos et al., 2007).  
1.3.6.3.3     Fatigue in Multiple Sclerosis 
Fatigue is the most troublesome symptom in MS (Fisk et al., 1994a). Modafinil has 
been reported to improve fatigue in patients with MS (Lange et al., 2009; Littleton et 
al., 2010; Rammohan et al., 2002; Zifko et al., 2002). The benefits of modafinil on 
the FSS were more pronounced than those previously reported with other commonly 
used medications, including amantadine. In patients with RR or progressive forms of 
MS, modafinil was associated with significant improvements on several measures of 
fatigue, including the fatigue severity scale (FSS), the modified fatigue impact scale 
(MFIS), and the VAS-F (Rammohan et al., 2002). In a supporting study Zifko et al 
found that a low-dose regimen of modafinil is significantly improves fatigue and 
sleepiness and is well tolerated by patients with MS (Zifko et al., 2002). Littleton et al 
(2010) have suggested that modafinil may be useful for treatment of fatigue in MS, 
particularly when the fatigue is associated with sleepiness. In contrast Stankoff et al 
found no improvement of fatigue in patients with multiple sclerosis treated with 
modafinil vs. placebo according to the MFIS (Stankoff et al., 2005). 
1.3.6.3.4     Fatigue in Parkinson¶s disease 
Lou (2009) had conducted a study to evaluate the subjective mental and physical 
fatigue in PD patients by using self-report questionnaires. The findings revealed that 
Levodopa and modafinil could improve physical fatigability in PD subjects. In 
another study Lou et al demonstrated that although modafinil may be effective in 
reducing physical fatigability in PD, it did not  improve fatigue symptoms (Lou et al., 
2009). 
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1.3.6.3.5     Cancer-related Fatigue 
Morrow et al (2005) found that using modafinil was associated with significant 
improvement in fatigue severity and other measures of QoL in women who reported 
persistent fatigue after completion of breast cancer treatment . Kaleita et al (2006) 
found that modafinil significantly improves fatigue scores in people with malignant 
and benign brain tumours who were treated with surgery, radiotherapy, and/or 
chemotherapy. Spathis et al (2009) found  a statistically and clinically significant 
reduction in fatigue and improvement of daytime sleepiness and depression/anxiety 
in cancer patients whom treated with Modafinil. This finding has further supported by 
other studies (Cooper et al., 2009; Rabkin et al., 2009). 
1.3.6.4     Recovery from General Anaesthesia 
A study found that patients who receive modafinil have significantly less exhaustion 
and they will be more alert and energetic during the stage of recovery from general 
anaesthesia compared with the control (Larijani et al., 2004). On the other hand 
studies found that the sedative effects of anti-psychotics and opiates after general 
anaesthesia can be reduced by modafinil (Larijani et al., 2004; Makela et al., 2003; 
Webster et al., 2003). 
1.3.6.5     Sleep-Deprived Emergency Room Physicians 
It has found that modafinil  improves  mood, fatigue, sleepiness and cognition in 
sleep-deprived healthy volunteers, and in full night shift duty physicians in 
emergency department (Gill et al., 2006). 
1.3.6.6     Effects of modafinil on quality of life (QoL) 
A study found that modafinil significantly improves the QoL (Black and Hirshkowitz, 
2005), but this effect was not found in the another study (Kingshott et al., 2001). 
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1.3.6.7     Effects of modafinil on Cognitive Performance 
A positive effect of modafinil on cognition has been found in healthy young and 
elderly volunteers (Makris et al., 2007; Turner et al., 2003). A significant 
improvement in the level of alertness has been found with modafinil (Niepel et al., 
2012), while a significant effectiveness on cognitive performance was not shown in 
the small crossover trial by using the Steer Clear (a computerised driving simulator 
with road obstacles which can be avoided by pressing a key) (Dinges and Weaver, 
2003).  
1.3.6.8     Effects of Modafinil in Healthy Volunteers 
1.3.6.8.1     Non-sleep deprived volunteers 
Effects of modafinil have been studied in healthy volunteers under differing 
conditions. Studies have found improvement of cognition with modafinil in non-
sleep-deprived, healthy young and elderly volunteers (Makris et al., 2007; Turner et 
al., 2003). In contrast, results from three studies conducted by Randall et al suggest 
that the benefits of modafinil are insufficient to be considered as a cognitive 
enhancer in non-sleep-deprived individuals (Randall et al., 2004; Randall et al., 
2005b; Randall et al., 2003). 
1.3.6.8.2     Sleep-deprived volunteers 
The effect of modafinil in healthy sleep-deprived subjects has been evaluated in 
several studies.  Modafinil led to improved subjective measures such as mood, 
fatigue, sleepiness, vigilance and improved objective measures such as reaction 
times, logical reasoning and short-term memory, and the Maintenance of 
Wakefulness Test (MWT) (Pigeau et al., 1995; Wesensten et al., 2002; Wesensten 
et al., 2005).  
 64 
1.3.7     Neuroprotective aspects of modafinil 
Evidence from preclinical studies suggests neuroprotective effects of modafinil. The 
neuroprotective mechanisms of modafinil are unknown. Generally two groups of 
theories exist: the protective effect could be via modulation of neurotransmitters or 
could be via interference with cell death processes. The ability of modafinil to protect 
against degeneration of nigrostriatal dopamine neurons induced by 1-methyl-4-
phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP) has been suggested to be related to 
actions on GABAergic mechanisms of modafinil (Fuxe et al., 1992; Ueki et al., 
1993a). It has also been suggested that modafinil has the ability to restore the 
locomotor activity in neurons already injured by MPTP, but not during the initial 
phase (Jenner et al., 2000). Findings from another study suggest that administration 
of a high dose modafinil with MPTP can selectively alter GABA binding density in 
the internal globus pallidus and prevents the MPTP toxicity (Zeng et al., 2004). 
Another supporting study suggested that modafinil prevents the decline in motor 
activity induced by  MPTP treatment (Xiao et al., 2004). This potential 
neuroprotective role for modafinil in rodents was found to be mediated by anti-
oxidant effects and modulation of nigrostriatal GABA and striatal nor-adrenaline and 
oxitriptan release, decreasing the GABA release and increasing the glutathione 
through an antioxidative process which may be independent of its wake-promoting 
effects (Xiao et al., 2004). These findings were supported by another study, which 
showed that modafinil significantly prevented the MPTP-induced change in 
locomotor activity, hand-eye coordination and small fast movements (van Vliet et al., 
2006).  
In two studies Ferraro et al have found that modafinil could normalise the disturbed 
balance of neurotransmitters by affecting glutamate and GABA release in specific 
areas of the basal ganglia through a maximal increase in glutamate release in these 
brain regions, associated with a lack of effect on GABA release. Furthermore, they 
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found that modafinil inhibits dose-dependently the activity of GABA neurons in the 
cerebral cortex and in the nucleus accumbens, sleep-related brain areas such as 
the medial preoptic area and the posterior hypothalamus (Ferraro et al., 1997; 
Ferraro et al., 1998). 
The second group of theories addresses the interference of modafinil with cellular 
processes. The explanation for the mechanism of action of modafinil in the neuronal 
cellular processes has been argued in several studies. Taking together, the 
modulation of neurotransmitters by modafinil may be related to improvement of 
energy metabolism, synthesis and release of neurotrophic factors, recovery of 
calcium homeostasis, improvement in metabolic activity, free radical scavenging or 
stimulation of repair processes such as axonal regeneration from the surviving cell 
bodies (Antonelli et al., 1998; Fuxe et al., 1992; Jenner et al., 2000; Lallement et al., 
1997; Ueki et al., 1993b). Modafinil stimulates the enzymatic breakdown of 
glutamate resulting in an increase in glutamine and a reduction in the cytotoxic 
effects of glutamate (Touret et al., 1994). Modafinil inhibits the cytochrome P450 
enzymes particularly CYP2C9 (Robertson et al., 2000). Inhibition of cytochrome 
P450 enzymes reduces damage in arterial ischemia and reperfusion (Fleming et al., 
2001; Granville et al., 2004) 0RGDILQLO¶V VXSSUHVVLRQ RI EUDLQ F\WRFKURPH 3
could occur through a direct intracellular site of action to suppress CYP2C9 or 
through enhancement of serotonin release (Ferraro et al., 2005; Tanganelli et al., 
1995). These effects of modafinil could explain its ability to reduce the production of 
reactive oxygen species and to promote better mitochondrial function.  
Piérard et al (1995) suggested that the neuroprotective effect of modafinil is due to 
its ability to increase the cortical pool of creatine-phosphocreatine. 
Furthermore, modafinil also protects noradrenergic and serotonergic neurons 
against mechanical trauma induced by partial hemitransection as well as neostriatal 
neurons against ischemic lesions associated with local endothelin-1 microinjection 
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and  prevent increases in toxic aspartate and glutamate levels after striatal ischemic 
injury (Ueki et al., 1993a).  
Modafinil prevents development of lesions in the hippocampus induced by the 
neurotoxic nerve gas soman (Lallement et al., 1997). A MRS study has shown the 
neuroprotective ability of modafinil to prevent neuronal death and prevent glutamate 
toxicity in cultured cortical cells (Antonelli et al., 1998). Modafinil inhibits GABA 
release in areas involved in the direct and indirect pathways of the basal ganglia-
thalamus-cortex loop (Ferraro et al., 1997). The direct or indirect protective effects 
or the sustained administration of modafinil could have increased the activity of the 
remaining serotonergic neurons in the striatum, as modafinil does affect 5-HT levels 
in the brain (Ferraro et al., 2002). 
Modafinil activates the histaminergic system and increases hypothalamic histamine 
release and c-Fos expression provided there are intact orexinergic neurons 
(Ishizuka et al., 2010). It has been shown that histamine, via its H3 receptors 
has wakefulness-promoting effects, improves cognition and is neuroprotective 
against brain ischemia and neurodegenerative disorders (Fan et al., 2011; Stocking 
and Letavic, 2008). The presence of the central H3 receptor is CNS-protective 
against experimental autoimmune encephalomyelitis (EAE), an experimental model 
of MS. H3 receptor activation reduce the susceptibility to autoimmune inflammatory 
disease of the CNS (Parmentier et al., 2007; Teuscher et al., 2007).  
Evidence suggests that modafinil may also act via a mechanism similar to the 
neuropeptides orexin-A and -B to promote histamine release (Chemelli et al., 1999; 
Ishizuka et al., 2003; Scammell et al., 2000). 
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1.1.4     Summary and conclusions  
The primary aim of this thesis is to gain greater insight into the potential 
neuroprotective effects of modafinil in MS. In order to investigate this, we have 
reviewed MS in general and the literature related to the principal aim of this thesis. 
MS is a debilitating CNS disease in which neurodegeneration is the major 
determinant of the accumulation of irreversible (progressive) disability. MS has 
many physical and mental health consequences that limit the independence and 
QoL of those living with the disease. MS is a challenging disease to treat. 
Successful early on, DMTs eventually become partially ineffective in reducing 
relapses and slowing disease progression, resulting in long term disability 
accumulation.  However, DMT may not or may only partially confer neuroprotection. 
Neuroprotective agents that impact directly on neuronal survival would be desirable, 
particularly since axonal loss and neuronal injury have been shown to be the 
histological correlates of neurological disability.  
Evidence from preclinical studies suggests a potential neuroprotective effect of 
modafinil. The symptomatic benefits of modafinil have been studied in neurological, 
psychiatric, general medicine and even in healthy volunteers. However, its potential 
neuroprotection has not been extensively evaluated in persons with MS.   
Part of this chapter was a review of EAE. From the pathogenesis point of view, EAE 
is a good model for studying MS mechanisms (Farooqi et al., 2010). The possible 
role of EAE in exploring the neuroprotection strategy for MS was also reviewed in 
this chapter and in chapter three.  
Taken together, understanding the defects in the current MS treatment strategies, 
and the potential neuroprotective effect of modafinil encouraged us to look for 
developing and evaluating a new therapeutic strategy for MS. The following 
chapters in this thesis will attempt to shed light on this topic. 
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CHAPTER 2 EXPLORING THE POTENTIAL 
NEUROPROTECTIVE EFFECTS OF MODAFINIL IN MULTIPLE 
SCLEROSIS (RETROSPECTIVE STUDY). 
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2.1     Introduction 
Modafinil is a wakefulness-promoting agent. It has been used for treatment of 
narcolepsy, obstructive sleep apnoea, and shift-work sleep disorder (Robertson and 
Hellriegel, 2003). Modafinil has been used with varying success for symptomatic 
treatment in MS. The majority of these studies focused on the effects of modafinil on 
fatigue (Brioschi et al., 2009; Lange et al., 2009). A recent study supports a 
beneficial effect of modafinil in MS fatigue, particularly in the considerable proportion 
MS patients whose fatigue was associated with excessive daytime sleepiness 
(Littleton et al., 2010). 
Evidence from preclinical studies suggests neuroprotective effects of modafinil. The 
neuroprotective potential of modafinil has been studied in animal models of 
neurodegenerative diseases (Antonelli et al., 1998; Jenner et al., 2000; Piérard et 
al., 1995; van Vliet et al., 2006; Xiao et al., 2004) (see chapter1). 
These findings led us to explore, in a retrospective study, the potential 
neuroprotective potential of modafinil, as inferred through the impairment/disability 
progression, in MS, as it has been used widely in the treatment of MS related 
fatigue. The neuroprotective potential of modafinil, if confirmed clinically, may lead to 
new modalities for treating neurodegenerative diseases. 
2.2     Methods  
2.2.1     Patients 
The MS clinic database at the Nottingham University Hospital was interrogated for 
selection of patients who had received or were receiving modafinil.  
Of these, we selected patients who had been on modafinil for 3 years or more, on 
the assumption that a subtle neuroprotective effect may require this length of time to 
be recognised clinically in terms of expanded disability status scale (EDSS) change. 
The demographic and clinical characteristics (age, sex, type of MS, disease  
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duration, follow up period and concomitant disease modifying therapies (DMT)) of 
these patients were obtained. For each modafinil subject three best matched MS 
control subjects, who had no exposure to modafinil at all, were selected based on 
the clinical characteristics of the patients mentioned above. 
EDSS scores were recorded before the start of the modafinil treatment and at a 
follow-up point, at least 3 years later, in the modafinil group; and at matching time 
points in the non-modafinil group. 
The primary parameter investigateG ZDV FKDQJH LQ ('66 DIWHU   \HDUV RI
PRGDILQLOWUHDWPHQWRU\HDUVRIIROORZXSLQWKHQRQ-modafinil group.  
2.2.2     Data Analysis and Statistics 
Descriptive statistics were used to describe the sample characteristics.  R (a 
language and environment for statistical computing) (http://CRAN.R-project.org/) 
was used to assess differences between treated and untreated groups when other 
relevant covariates were considered. These covariates were age, gender, disease 
duration, MS type (relapsing or progressive), duration of follow up, baseline EDSS, 
and any history of treatment with DMTs. Covariates that did not contribute 
significantly to the model were removed one at a time and least significant first.  
The number of patients who had an increase in EDSS of 1 step or more for EDSS 
DQGRIRUPRUHIRU('66ZDVFRPSDUHGEHWZHHQWUHDWPHQWJURXSV For 
this I used )LVKHU¶VHxact test using SPSS version 18 (www.ibm.com/uk/SPSS). 
2.3     Results  
2.3.1     Demographic and Clinical Characteristics 
2.3.1.1     Patient demographics 
Of 65 patients with clinically definite MS, according to Poser and/or MacDonald 
criteria, (Poser et al. 1983; McDonald et al. 2001) who had exposure to modafinil, 
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thirty had received modafinil for the treatment of MS-related fatigue for an 
uninterrupted period of 3 years or more. Modafinil dose ranged between 100mg and 
400mg. Ninety matched non-modafinil treated patients were also included in this 
study. Patient demographics are provided in (Table 2.1) and (Table 2.2).  
 
Table 2.1 Demographic characteristics and clinical epidemiology of the 
patients. 
 Modafinil-treated patients 
(n=30) 
Non-modafinil 
patients (n=90) 
 
P value 
Median(range)  
   Age in years 
   DD in years 
   Follow-up  
   EDSS (baseline) 
   EDSS (follow up)  
44.5 (27-61) 45(28-61) 0.995* 
9 (4-30) 9 (3-32) 0.870** 
4 (3-7) 4 (3-8) 0.607* 
3 (1-6.5) 3 (0-7.5) 0.751* 
3 (0-7.0) 4 (0-8.5)  
Gender n(%) 
Female 
 
19 (63.3%) 
 
60 (66.6%) 
 
 
MS 
clinical 
types 
n(%) 
RRMS 20 (23%) 67 (77%)  
 
0.409*** 
 
PMS 10 (30%) 23 (70%) 
DMTs n(%) 
Yes 
 
18 (60%) 
 
42 (47%) 
 
0.206*** 
*t test; **Mann-Whitney test; ***Chi-square test 
Results are given in medians (ranges).  DD; Disease duration,  pre-treatment EDSS 
(baseline), EDSS at point of 3 years or more  of modafinil treatment or follow up, RR; 
relapsing-remitting, SP; secondary progressive, PP; primary progressive, DMTs; disease 
modifying therapies. 
 
2.3.2     Effect of modafinil on EDSS progression  
We used general linear regression to model the EDSS change. A complete model of 
EDSS change included group (treatment with modafinil or not) and all potential 
covariates (age, sex, MS type, disease duration, follow-up period, baseline EDSS 
and concomitant DMTs). After stepwise elimination of non-significant covariates, the 
treatment group remained a significant predictor of EDSS change, as did MS type, 
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follow-up period, and there was a trend for baseline EDSS. We checked the model 
residuals for outliers and violation of the normal distribution assumptions. We further 
checked that the heteroscedasticity assumption of the model was not violated; in  
 
Table 2.2 Patient's Characteristics according to the multiple sclerosis clinical 
types. 
 Modafinil-
treated 
patients 
(RRMS) 
(n=20) 
Modafinil-treated 
patients 
(PMS) (Primary 
and Secondary) 
(n=10) 
Non-modafinil 
patients 
(RRMS) 
(n=67) 
Non-modafinil 
patients 
(PMS) (Primary 
and Secondary) 
(n=23) 
Median(range) 
Age 41.5(27-60) 51.5(39-61) 45(28-61) 47(32-61) 
DD 8.5(4-30) 14.5(7-29) 9(3-32) 10(4-28) 
Follow-Up 4(3-7) 4(3-5) 4(3-6) 4(3-8) 
EDSS  
(baseline)  2.5(1.0-6.0) 4.5 (3.0-6.5) 2.5(0.0-6.5) 5.5(3.0-7.5) 
EDSS  
(follow-up)   2(0.0-6.0) 6(3.0-7.0) 3.5(0.0-8.5) 6.5(4.0-8.0) 
Gender n(%) 
Female 
 
14(70%) 
 
5(50%) 
 
51(76.1%) 
 
9(39.1%) 
DMTs n(%) 
Yes 
 
13(65%) 
 
5(50%) 
 
33(49.3%) 
 
9(39.1%) 
Results are given in medians (ranges). RRMS; relapsing-remitting MS, PMS; progressive 
MS. DD; Disease duration, pre-treatment EDSS (baseline), EDSS at point of 3 years or more  
of modafinil treatment or follow-up period. 
 
this case that the residual variance at low EDSS was similar to that at higher EDSS. 
The model R squared value was 0.2; p<0.00001. 
For RRMS patients treated with modafinil, there was no significant change in EDSS 
(mean change ±standard error -0.22±0.23; p=0.34) over the follow-up period. For  
RRMS patients not treated with modafinil, there was a significant increase in EDSS 
(0.94±0.24; p=0.0001) over the follow-up period. Independent of modafinil treatment 
status, our model indicated an additional mean EDSS increase of 1.1±0.29 points 
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(p=0.0002) for progressive patients over the follow-up period i.e. mean EDSS 
increase was 1.1 point for modafinil treated, and 1.1+0.94=2.04 points for modafinil-
untreated patients (Figure 2.1). There was a significant effect of follow-up period on 
the EDSS change, increasing it by 0.2 (p=0.026) for every year of follow-up. The 
model also indicated a reduction in mean EDSS change of -0.15±0.075 (p=0.053) 
points, for each one point increase in baseline EDSS. 
 
 
Figure 2.1 Mean ±SEM EDSS changes at baseline EDSS and EDSS after 3 or 
more years treatment or follow-up in Modafinil-treated group and non-mdafinil 
group with progressive and RRMS. 
(A) Mean±SEM EDSS changes at E1 (baseline EDSS) and E2 (EDSS after 3 or 
more years treatment or follow-up) in Modafinil-treated group and non-modafinil 
group with progressive MS. (B) Mean±SEM EDSS changes at E1 (baseline EDSS) 
and E2 (EDSS after 3 or more years treatment or follow-up) in Modafinil-treated 
group and non-modafinil group with relapsing-remitting MS. 
 
 
7KH )LVKHU¶V H[DFW WHVWV XVHG WR DVVHVV GLIIHUHQFHV LQ SURSRUWLRQ RI VXEMHFWV ZLWK
increased EDSS over the study period. There was a significantly lower proportion of 
patients with baseline EDSS of 0-5 score who had an EDSS increase of 1 point or 
PRUHDQGSDWLHQWVZLWKEDVHOLQH VFRUHZKRKDGDQ('66 LQFUHDVHRI RU
more point in the modafinil-treated group vs. non-modafinil group (p=0.017) (Table 
2.3). 
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Table 2.3 Fisher's exact test analysis in the modafinil-treated and untreated 
groups have baseline EDSS 0-ZLWK('66LQFUHDVHE\SRLQWDQGWKH
SDWLHQWVKDYHEDVHOLQH('66VFRUHZLWK('66LQFUHDVHE\SRLQW 
Baseline 
EDSS 
EDSS changes Modafinil-treated 
patients 
Non-modafinil 
patients 
p-
value 
 n(%) n(%) n n(%)  

score 
EDSS changed by 
<1.0 point 
15(68.2)       18(60)       
  
 
28   30(33.3)       0.017 

score 
EDSS changed by 
<0.5 point 
3(37.5)         2 

score 
EDSS changed by 
SRLQW 
7(31.8)       12(40)       43        
 
60(66.7) 

score 
EDSS changed by 
SRLQW 
5(62.5) 
          
17 
Total  30   90 
 
2.3.3     Evaluation the role of DMTs concomitantly received with modafinil on 
EDSS changes 
To evaluate the possible effect of concomitant use of DMTs on the EDSS 
progression in modafinil treated patients. The EDSS changes in 30 modafinil-treated 
patients were analysed to compare the EDSS progression in those receiving DMTs 
vs. non- received subjects. 17 patients (56.6%) were concomitantly treated with 
 
Table 2.4 Mean±SD of the EDSS1 (baseline) and EDSS2 (post treatment) in 
modafinil-treated patients received or not received DMTs. 
Subjects Mean± SEM  
EDSS before 
treatment (E1) 
(baseline) 
EDSS after 3 or 
more years of 
treatment (E2) 
Modafinil-treated 
group n=30 
Modafinil with DMTs 
n=17 
3.47±0.41 3.79±0.56 
 Modafinil without DMTs 
n=13 
3.5±0.44 3.8±0.64 
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Figure 2.2 Mean ±SEM EDSS changes at baseline EDSS and EDSS after 3 or 
more years treatment in modafinil-treated group concomitantly received or not 
received DMTs. 
(A) Mean±SEM EDSS changes at E1 (baseline EDSS) and E2 (EDSS after 3 or 
more years treatment in Modafinil-treated patients concomitantly received DMTs. (B) 
Mean±SEM EDSS changes at E1 (baseline EDSS) and E2 (EDSS after 3 or more in 
Modafinil-treated patients not received DMTs. 
 
 
DMTs and 13 patients (43.4%) were not received DMTs. The effects of DMTs were 
considered as the covariate was entered into the model. After backwards 
elimination, within the general linear model using EDSS change as the dependent 
variable treatment with DMTs was not significant explanatory variables in the linear 
model used (Figure 2.2) and (Table 2.4). 
2.4     Discussion 
The aim of this study was to explore the neuroprotective effect of modafinil in MS. 
This effect was suggested in studies of experimental model of neurodegenerative 
diseases (Antonelli et al., 1998; Jenner et al., 2000; Piérard et al., 1995; van Vliet et 
al., 2006; Xiao et al., 2004), and in vitro studies (Ferraro et al., 2005; Tanganelli et 
al., 1995; Ueki et al., 1993a).  
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In this relatively large, matched-groups retrospective study the most notable finding 
was that the ninety MS patients who had no exposure to modafinil experienced 
significantly greater increases in EDSS compared to thirty patients with MS who 
received modafinil for three and more years without interruption. This was seen in 
both relapsing-remitting and progressive types of MS. The EDSS increase in 
patients not treated with modafinil was, approximately one score point greater than 
in those treated with modafinil. 
There was no EDSS increase in RRMS in the treated group but there was an 
average increase in non-modafinil RRMS group of approximately 1 point. In 
progressive MS, the increase in EDSS in the treated group was approximately 1 
point while it was twice this figure in non-treated group. These results suggest that 
treating with modafinil may slow down the EDSS progression and severity of the 
disease. 
The effect appeared more prominent in patients initiating treatment at a lower EDSS 
level, although the fewer patients in each treatment group with a baseline EDSS of 5 
or more may explain why the differences in favour of modafinil fell short of statistical 
significance (Table 2.3). It is nevertheless possible that the effects of modafinil on 
disability/impairment progression are more beneficial if it is initiated at lower starting 
levels of disability. 
Due to the retrospective nature of the study and the small number of well-
documented relapses altogether, we cannot assess whether the effect of modafinil 
on progression in the less disabled group was related to any effect of relapses. 
However, we think it is a primary effect on the neurodegenerative component of MS 
(thus neuroprotective) in view of the fact that DMT, despite their proven effect on 
reducing relapses, did not appear to affect the progression in this cohort. 
A few studies have suggested that modafinil may have neuroprotective effects in 
neurodegenerative diseases. Pierard et al. (1995) showed that modafinil can 
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increase creatinine- phosphocreatine in a rat cortical pool. Phosphocreatine can 
compensate for the lack of adenosine triphosphate (ATP) synthesis that is caused in 
the brain by deficiency of oxygen due to anoxia or ischemia. Antonilli et al. (1998) 
showed the ability of modafinil to reduce GABA release in the cortical neurons, 
which may help cell recovery after glutamate exposure. van Vliet et al. (2006) in 
their study in a marmoset MPTP-induced PD model suggested the role of modafinil 
in restoring the locomotor activity. Jenner et al. (2000) showed the ability of 
modafinil to attenuate or prevent the oxidative damage in neurons by neurotoxic 
agents. 
Limitations of the study 
There are limitations of retrospective studies such as the one presented in this 
chapter. Therefore, caution needs to be exercised in retrospective cohort studies 
because errors due to confounding and bias are common in such studies. On the 
other hand, such a study may provide a proof of concept and a basis for a 
prospective study, and can be achieved, in a relatively inexpensive and quick 
manner.  Also, the fact that the retrospective study was obtained on prospectively 
collected data (with the initial intent of studying the effect of co-morbidity in MS), 
makes the data more uniform and mitigates to some extent the disadvantages of the 
retrospective study. 
The sample size of modafinil-treated patients was based on the inclusion criteria 
which was patients received modafinil for three and more years without interruption. 
A total of 30 patients were found to fulfil these inclusion criteria.  
To select a non-modafinil group among those patients who have no exposure to 
modafinil we matched the patients one to one for all variables (age, sex, MS clinical 
type, disease duration, and baseline EDSS). For matching on age and disease 
duration controls were allowed to be in range of ±5 and ±3, respectively, while exact 
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matching was done for other variables (Sex, MST, baseline EDSS). Eventually, we 
found three controls from the non-modafinil treated group for each case in the 
modafinil-treated patients who fulfill the inclusion criteria. Total of 90 patients were 
selected to be included as controls.. Increasing the number of controls up to a ratio 
of about 4/1 improves the power of the study. This rise is not linear, however. 
Beyond a ratio of about 4/1 little power improvement results from increasing the 
number of controls (Kearney et al., 2003). 
Among other biases which can negatively impact the veracity of this type of study is 
selection bias (a statistical bias in which there is an error in choosing the individuals 
or groups to take part in a scientific study). If the selection bias is not taken into 
account then certain conclusions drawn may be wrong. In our cohort the decision to 
start modafinil treatment in patients with MS was based on the presence of 
subjective fatigue. This means that fatigue was a feature for all modafinil-treated 
patients while this was only the case for some of the included patients in non-
modafinil group. Fatigue may has negative impact on disease severity in MS and 
may interfere with calculation of EDSS scores.  This can particularly affect any of the 
analysed outcomes when clinical measures are the outcomes for the study 
Although given in different doses, we considered modafinil as a single therapeutic 
class, a robust comparison between different doses would be challenging in a 
retrospective study like ours. Moreover our study was not designed to adjust for 
adverse events associated with modafinil treatment which may have had an impact 
on EDSS calculation. 
The main outcome measure in our study was difference in the mean of baseline 
EDSS and last recorded EDSS after three or more years of modafinil treatment in 
treated group and follow up period in non-treated group. The EDSS has recognised 
limitations however, it is the most widely used and internationally recognised 
disability assessment tool in MS, its use being ubiquitous in MS clinical trials and 
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observational studies. Limitations relevant to the study EDSS end points include 
reliance on ability to walk and an inability to capture well the myriad MS symptoms 
(cognition; fatigue; bowel, bladder, or sexual function; visual acuity; or health-related 
QoL).  
Conclusions 
In conclusion, we found evidence that administration of modafinil was associated 
with a reduction in disability progression in patients with relapsing-remitting MS and 
progressive MS.  
Advances in the understanding of the mechanism of the action of modafinil and 
histochemistry and neuroimaging studies provide increasing evidence that modafinil 
has neuroprotective properties in neurological diseases including MS. Further 
investigation is essential. 
Future work 
Although the result of this study supports the potential for modafinil to slow down the 
progression of disability in MS, the limitations of the study need to be taken into 
account, Prospective studies using surrogate markers of disease progression and of 
neuroprotection are needed to confirm this important and promising finding.  
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CHAPTER 3 MODULATION OF EXPERIMENTAL 
AUTOIMMUNE ENCEPHALOMYELITIS BY MODAFINIL 
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3.1     Introduction  
Multiple sclerosis (MS) is an inflammatory and demyelinating disease of the central 
nervous system (CNS) with no cure available so far. Experimental autoimmune 
encephalomyelitis (EAE) is a CD4+ T-cell-mediated inflammatory demyelinating 
disease of the CNS that is commonly used as an experimental model of MS. EAE 
can be induced in a number of species, including mice, rats, guinea pigs, rabbits 
and primates. It presents with pathological and clinical features very similar to those 
of MS, making it amenable for mechanistic and intervention studies (Baxter, 2007; 
Dittel, 2008; Gold et al., 2006). Therefore, EAE has been extensively used to 
investigate potential therapeutics for MS.  
Active immunisation with myelin antigen (active induction) and adoptive transfer of 
encephalitogenic T cells (passive induction) can both be used to induce EAE (Lando 
et al., 1980; Lassmann and Wisniewski, 1979). Of different types of myelin antigens, 
myelin basic protein (MBP), proteolipid protein (PLP) or myelin oligodendrocyte 
glycoprotein (MOG) are the most commonly used ones. Immunodominant 
encephalitogenic peptides can also be used for immunisation. Mice are widely used 
for EAE model and among different mice species suggested to be used as a model, 
C57BL/6 is commonly used. Active immunisation with MOG in C57BL/6 mice yields 
a chronic type of EAE, which is usually monophasic and followed by different 
degrees of recovery, which depend on specific immunisation protocols (Miller et al., 
2010). C57BL/6 mice were first shown to be susceptible to MOG-induced EAE by 
%HQ1XQ¶VJURXSDQGKDYHVLQFHEHHQZLGHO\XVHG(Ben-Nun et al., 1981; Derosbo 
et al., 1995), one of the advantages of this model being the availability of numerous 
genetically modified lines. 
In both MS and EAE, T cell activation and proliferation with subsequent migration 
through the blood brain barrier (BBB) are thought to lead to reactivation of myelin 
reactive T cells by perivascular antigen presenting cells in the CNS, production of 
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pro-inflammatory cytokines and reactive oxygen and nitrogen species, followed by 
demyelination and axonal damage (Friese et al., 2006; Gold et al., 2006; Miller et 
al., 2010).  Interventions that reduce or suppress one or more of these events 
should reduce both clinical and pathological symptoms and, thus, are candidates for 
pre-clinical and clinical evaluation. 
Three of the seven food and drug administration (FDA) approved drugs for MS 
(Natalizumab, Glatiramer acetate, and Mitoxantrone) were clinically developed as 
a direct result of initial discoveries made using an EAE model. Recently, fingolimod 
(FTY720) had approval by FDA and became the first FDA approved oral medication 
IRU WKH WUHDWPHQWRI06)LQJROLPRG¶s success has been associated with research 
conducted in EAE, which has shown that fingolimd protects against disease 
development and causes a rapid and sustained improvement in neurological deficits 
[reviewed in (Lim and Constantinescu, 2010)]. 
Several EAE trials have conducted to test new agents including statins (Greenwood 
et al., 2003; Stanislaus et al., 2001; Vollmer et al., 2004; Youssef et al., 2002), 
peroxisome proliferators-activated receptor (PPAR) agonists (Lovett-Racke et al., 
2004), laquinimod (Polman et al., 2005a; Yang et al., 2004), altered and native 
myelin peptides (Bielekova et al., 2000; Brocke et al., 1996) and antigen-specific 
DNA vaccination (Garren et al., 2001; Robinson et al., 2003). 
Modafinil is a wakefulness-promoting agent, increasingly being used for the 
treatment of fatigue and excessive sleepiness in neurological disorders including 
MS, psychiatric disorders, and for cognitive enhancement. Preclinical studies 
suggest a potential neuroprotective effect of modafinil (Pierard et al. 1995; Antonelli 
et al. 1998).  
Work on modafinil as possible neuroprotective agents in EAE, and therefore with 
potential in human MS, is very encouraging (Jenner et al. 2000; Xiao et al. 2004; 
van Vliet et al. 2006).  The present study was designed to examine the efficacy of 
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modafinil in EAE induced by MOG peptide in mice and to elucidate the possible 
neuroprotective potential of modafinil in EAE, which is a useful animal model of 
chronic MS.  
As part of this thesis, our aim was to perform a pilot experiment to determine 
whether modafinil, at doses that showed a therapeutic neuroprotective effect in vivo 
in other experimental systems, suppresses the clinical signs of EAE. This would 
represent a first, proof-of-concept, step, that would be followed in futures studies 
(not part of this thesis) by mechanistic studies to determine whether the suppression 
of EAE is at least in part through a neuroprotective effect. 
3.2     Methods and Animals 
3.2.1     Animals  
Nineteen 6-8 weeks old female mice (C57BL/6), purchased from Charles River, 
Cambridge-UK, were used in this study. Weight at the time of immunisation was 20-
25g. 
3.2.2     Peptide 
MOG35±55 peptide obtained from Cambridge research biochemical, emulsified in 
FRPSOHWH IUHXQG¶V DGMXYDQW &)$ 'LIFR 'HWURLW 0, FRQWDLQLQJ PJPO NLOOHG
Mycobacterium Tuberculosis (strain H37Ra; Difco)  was used for active 
immunisation. 
3.2.3     Induction of EAE 
Mice were acclimatised in individually ventilated cages. 3-4 mice were housed per 
cage under a 12 hour light/ dark cycle at 22°C ± 2°C and had free access to food 
and water for 1 week before the start of experiments. Mice were then randomly 
assigned to three groups, i.e., two treatment groups; group 1 (n=7) (low dose 
treatment group), group 2 (n=7) (high dose treatment group), and group 3 (n=5) 
(negative control group that were injected with vehicle only). On day 0 EAE was 
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induced using synthetic MOG35±55. Mice were injected subcutaneously at two sites in 
WKH EDFN ZLWK DQ HPXOVLRQ FRQWDLQLQJ  ȝJ RI 02*35±55 GLVVROYHG LQ  ȝ/ RI
phosphate-buffered saline (PBS), emulsified in CFA containing (4mg/ml killed 
Mycobacterium Tuberculosis H37 Ra). The animals then received an intraperitoneal 
injection of 200 ng of pertussis toxin (Sigma-$OGULFK LQȝ/RI3%67wo days 
later, mice received a second pertussis toxin injection. Mice were housed at 3/cage 
throughout the experiment. 
As mentioned above, this well-established model was selected as it is thought to 
appropriately reflect acute paralysis in MS, followed by incomplete neurological 
recovery.  
All animal protocols were approved by the Ethical Review Committee of the 
University of Nottingham. The study was performed in compliance with Home Office 
regulations under project licence (PPL) 40-3095 (Dr B Gran). Data were plotted as 
daily mean clinical score for all animals. Several parameters of disease were 
examined to evaluate the severity of EAE and the efficacy of modafinil therapy that 
include mean clinical score, peak clinical score, and histopathology.  
3.2.4     Treatment of mice 
Modafinil was dissolved in a warm 0.9% PBS, with 1.5% dimethylsulfoxide (DMSO). 
Two doses of modafinil; low (50mg/Kg) and high (100mg/Kg), were chosen. 
Modafinil was administered intraperitoneally in doses of 50mg/kg (low dose), and 
100mg/kg (high dose). The doses chosen were based on earlier studies in 
marmosets, rats and mice (Duteil et al., 1990; Engber et al., 1998; Jenner et al., 
2000). PBS-treated EAE mice were administration PBS only. As we look to the 
therapeutic effect of modafinil in EAE, and to give similarity between EAE scores 
and early disability in MS, the modafinil treatment started when the animals reached 
a clinical score of 1. Following that, treatment was given intraperitoneally, every day 
throughout the course of the study until mice were sacrificed at day 30 post-
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immunisation. To evaluate the treatment effects on inflammation and demyelination, 
the lumbar spinal cords of different treated EAE mice were subjected to 
histopathology assay.  
3.2.5     Clinical evaluation 
Because EAE is a progressive, ascending paralysis, daily monitoring for body 
weight and grading the clinical signs was needed. Blind to the treatments, the 
grading was done on a daily basis from day 0 (immunisation) to the day 30 post-
immunisation.  Mice were removed from the home cage and evaluated for tail tone, 
ambulation, limb weakness, and righting response. The clinical scoring scale was as 
follows; 0²healthy, 1²flaccid tail, 2²impaired righting reflex and/or impaired gait, 
3²partial hind-leg paralysis, 4²total hind-leg paralysis, 5²any sign of front-leg 
paralysis, and 6²moribund/ dead (O'Brien et al., 2010). Animals were sacrificed at 
the end of study period. The overall disease burden of each mouse was represented 
as the cumulative disease severity, which was the sum of the disability scores 
obtained daily over the course of the 30-day experiment. 
3.2.6     Immunohistopathological evaluation of neuroprotection potential of 
modafinil in EAE 
The first part of the present study (and part of this thesis) was designed to determine 
whether modafinil had beneficial effects on clinical severity of EAE in mice. The 
second part of this study (not part of this thesis) was designed to precisely 
GHWHUPLQHPRGDILQLO¶V XQGHUO\LQJPHFKDQLVPRIDFWLRQ LQ WKLVPRXVHPRGHO RI06
and assess its possible neuroprotective effect in this chronic demyelinating disease 
model. To examine the beneficial effect of modafinil and its potential neuroprotective 
and immunomodulatory effects  in chronic EAE induced by immunisation with MOG 
peptide in C57/Bl6 mice the effects of two distinct doses of modafinil administered 
daily i.p. after the mice developed score 1 of disease severity were evaluated and 
compared with vehicle-treated group. In the clinical evaluation of this experiment we 
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found that modafinil markedly suppressed neurological deficits associated with EAE 
compared with vehicle-treated mice.  The result revealed that modafinil significantly 
reduces the clinical score of severity of EAE. To look at the mechanism of action of 
modafinil and assess its possible neuroprotective effect in this chronic demyelinating 
disease model we collected spinal cord samples for histological evaluation (the 
spinal cord is the predominant site of pathology in this model), serum for future 
measurement of neurotransmitters and cytokines, spleen samples for immunological 
studies, and microdissected thalami for proteomics.  
Using immunohistopathology, we investigate whether modafinil alleviates the 
infiltration of macrophages/microglia and astrogliosis and whether it prevents 
demyelination in the spinal cord of EAE mice. This is done with microglia specific 
markers such as the F4/80 antibody or CD11c antibody. We will also count axonal 
density using axon-specific immunohistochemistry staining with neurofilament heavy 
chain (NF-H) antibodies. 
Altogether immunohistopathological investigations will shed light on effectiveness of 
modafinil in the treatment of MS and whether to be piloted in clinical trials. 
3.2.6.1     Histopathological Examination of EAE.  
At the end of the study (day 30), animals were anaesthetised with tri-bromo-ethanol 
(300 mg/kg) and then perfused through the left ventricle with cold PBS (4°C) for 3±5 
min followed by 4% paraformaldehyde for 10 min. The brain and spinal cord were 
resected and stored in 10% paraformaldehyde at 4°C. Serial 5-µm thick cross-
sections were prepared and were stained with haematoxylin and eosin to assess 
inflammation. In each group, at least 10 sections per mouse distributed over the 
whole length of the spinal cord are to be examined histologically and quantified. The 
sections were prepared for examination for inflammatory cell infiltrates under a 
microscope. Inflammation and demyelination will be scored as described (Michael, 
2005) using a semi-quantitative scale. Inflammation scores are:  scored 0 = no 
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inflammatory cells; 1 = a few scattered inflammatory cells; 2 = organisation of 
inflammatory infiltrates into perivascular cuffs; 3 = extensive perivascular cuffing 
with extension into adjacent subarachnoid space and CNS dense parenchyma; 4= 
extensive perivascular cuffing with increasing subarachnoid and parenchymal 
inflammation. Demyelination scores are: 0= no demyelination; 1= a few, scattered 
naked axon; 2= small groups of naked axons; 3= large groups of naked axons; 4= 
confluent foci of demyelination; 5= widespread demyelination.  
3.2.6.2     Determination of Various Cytokines/Chemokines in Serum. 
Peripheral blood was collected on day 30 from vehicle and modafinil treated EAE 
mice. Presence of various cytokines/chemokines will be examined in blood serum. 
To further examine the phenotype of inflammation, mononuclear cells will be 
isolated from the spinal cords of EAE mice and analysed by flow cytometry, and 
cells will be isolated from the spleen for analysis to assess effects on T cells in the 
periphery also examine the expression of these cytokines in CNS and peripheral T 
cells. Analyses of cytokine production in the periphery of the mice will provide insight 
on how modafinil can reduces Th1 and Th17 cytokines known to contribute to the 
development of EAE. Modafinil may suppress signal transducer and activator of 
transcription 3 (STAT3) and p65 nuclear factor kappa-light-chain-enhancer of 
DFWLYDWHG%FHOOV1)ț%SKRVSKRU\ODWLRQLQWhe spleen and the brain of EAE mice. 
These two transcription factors regulate a large array of inflammatory genes 
including cytokines suggesting a mechanism by which modafinil antagonises pro-
inflammatory cytokine production. 
3.2.6.3     Detection of modafinil-Induced Apoptosis in Primary T Cells.  
To determine modafinil-induced apoptosis in primary T cells, T cells from modafinil-
treated mice will be purified from the spleens using nylon wool column 
(Polysciences, Inc., Warrington, PA) followed by depletion of B cells and 
macrophages.  
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3.2.6.4     Statistical analysis of immunohistopathological data.  
Results will be presented as the mean _S.E.M. Statistical analysis for significant 
differences on clinical scores will be performed with the non-parametric Mann±
Whitney test for the clinical course of EAE and the histopathological parameters. 
Statistical analyses will be performed using Mann-Whitney U WHVW6WXGHQW¶Vt test for 
EAE, significant difference between control and experimental groups or two-factor 
ANOVA as appropriate, with a P value of _ .05 considered to be statistically 
significant. 
 3.2.7     Statistical Analysis 
Because the data were not normally distributed, statistical analysis was performed 
with non-parametric tests using GraphPad Prism version 6.00 for Windows, 
GraphPad Software, San Diego California USA, www.graphpad.com. Descriptive 
analysis included, mean and SEM. Differences between two groups were assessed 
with Wilcoxon±Mann±Whitney U-test. Differences between three groups were 
assessed with One-way ANOVA, non-parametric, Kruskal±Wallis test, followed by 
pair-wise Wilcoxon±Mann±Whitney U-tests. Data are expressed as mean values ± 
SEM. Results are reported as mean ± SEM; P values <0.05 were considered to be 
statistically significant. 
3.3     Results 
3.3.1     Modafinil ameliorated clinical severity of EAE mice 
All the mice have the first disease symptom (flaccid tail) at day 12 or 13 and this was 
considered a score 1 according to the clinical scoring scale (Figure 3.1). After 4-5 
days the effect of the treatment with modafinil appeared which was represented by 
difference in clinical scores between treatment groups and control group.  Mean± 
SEM of the control (PBS) group was 2.32±0.23, mean±SEM of the low dose- 
modafinil group was 1.82±0.14, and mean±SEM of the high dose-modafinil group 
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was 1.53±0.08 (Table 3.1). The maximal score±SEM (maximum severity of disease 
in individual mouse) of PBS, low-dose and high dose modafinil- treated EAE mice 
were 3.8± 0.122, 2.78± 0.285, and 2.28± 0.342 respectively. The cumulative 
 
Table 3.1 Mean ± SEM of the subject groups 
Group Number Mean ± SEM of 
daily clinical 
score 
Mean ± SEM of 
maximum 
severity score 
cumulative  
score ± SEM 
Control group/EAE 
only 
5 2.32±0.23  3.8± 0.122  43.7±6.06  
Low dose 
treatment group 
7 1.82±0.14 2.78± 0.285 32.71±3.73  
High dose 
treatment group  
7 1.53±0.08 2.28± 0.342 23.36±2.84 
 
 
Figure 3.1 Effect of modafinil treatment on clinical score of EAE associated 
disease activity 
EAE was induced in (n=19) female C57 BL/6 mice with MOG 35-55 and treatment with 
PBS and modafinil was started when the mice reached score I of the EAE as 
described under material and methods. The group (green) was treated with vehicle 
only. The group (blue) received low dose (50mg/kg) (1mg) modafinil and the group 
(gray) received high dose (100 mg/kg) (2mg) modafinil. Daily intraperitoneal 
injections were used in all groups until the end of the study (day 30). Animals were 
scored daily for clinical symptoms on a 0-6 scale. Mean clinical scores were 
determined for each group. One way ANOVA (Kruskal-Wallis test), Values represent 
the mean±SEM of both treated groups vs. PBS-treated group (***P= 0.009). 
PBS= phosphate- buffered saline; LDM= low dose modafinil-treated group; HDM= high dose modafinil-
treated group; MOG= Myelin Oligodendrocyte Glycoprotein. 
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score±SEM (cumulative disease severity) of PBS, low-dose and high dose 
modafinil- treated EAE mice were 43.7±6.06, 32.71±3.73, and 23.36±2.84 
respectively (Table 3.1). Kruskal-Wallis test found that the maximal severity and 
cumulative scores were significantly reduced in both modafinil-treated mice 
compared with PBS-treated group (p= 0.009 and 0.018 respectively).  
The difference in clinical scores between PBS group and both high-dose and low 
dose modafinil- treated EAE mice groups was statistical significance in favour of 
treated groups (p=0.008; p= 0.021 respectively). The effect of high dose modafinil in 
reducing the severity of the disease was greater than the low dose modafinil, the 
difference did not reach statistically significance (Figure 4.2). 
 
 
 
 
Figure 3.2 The maximum Severity of clinical course in three groups of EAE 
Mann Whitney U test, Values represent the mean±SEM. Green bar represents PBS-
treated group (control group); Blue represents Low dose (1mg) modafinil-treated 
mice; Gray represents high dose (2mg) modafinil-treated mice. 
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3.4     Discussion 
The neuroprotective actions of modafinil have been the focus of much attention. 
However, little is known about the effects of modafinil on immune inflammatory 
diseases such as EAE, an established model of MS. In attempt to explore the 
beneficial effect of modafinil on severity of EAE, and possible neuroprotective action 
of modafinil in this animal model of MS we conducted the present study. 
The results of present study show that modafinil can significantly improve the clinical 
score, typically found in EAE. We observed that modafinil administration initiated at 
the disease onset (score 1) is effective to reduce the severity of EAE in C57 BL/6 
mice when evaluated clinically.  
In this study, we focused on clinical results, but have collected spinal cord samples 
for histological evaluation, serum for future measurement of neurotransmitter and 
cytokines, spleen samples for immunological studies, and microdissected thalami for 
proteomics.  
Following the first few days of the treatment the improvement in the neurological 
deficits measured by clinical scores was observed in modafinil-treated mice as 
compared to PBS-treated EAE mice.  
The dose-response experiments carried out in the present study demonstrated that 
modafinil is effective at the two doses (50mg/kg and 100mg/kg). The high dose-
treated subject has significantly, experienced less disease severity while there was 
trend to decrease disease severity in low dose-treated mice.  
To best of our knowledge this is the first study that has tested modafinil for its effect 
on disease severity in EAE.  The underlying mechanism of this action is not obvious. 
However, modulating the neurotransmitters by modafinil and possible anti-
inflammatory effect as well as the potential neuroprotective properties of modafinil 
might explain this promising effect.  
 92 
The effect may be mediated by an effect of modafinil on mitochondria as shown 
before. The exact target for the action of modafinil in mitochondrion is not fully 
understood, however, cytochrome c has been suggested. Modafinil inhibits the 
cytochrome P450 enzymes particularly CYP2C9 (Robertson et al., 2000). Inhibition 
of cytochrome P450 enzymes reduces damage in arterial ischemia and reperfusion 
(Fleming et al., 2001; Granville et al., 2004) 0RGDILQLO¶V VXSSUHVVLRQ RI EUDLQ
cytochrome P450 could occur through a direct intracellular site of action to suppress 
CYP2C9 or through enhancement of serotonin release (Ferraro et al., 2005; 
Tanganelli et al., 1995). Future studies will use the samples generated in this project 
to measure CYP1A2 and CYP2C9 as well as serotonin.  
Modulating CNS neurotransmitters by modafinil could be another mode which can 
exert its preventive action on neuronal damage. Antonelli et al (1998) in a preclinical 
study have found that modafinil was able to prevent further reduction in gamma 
aminobutyric acid (GABA) release after initial reduction in the cells exposed to 
glutamate and modafinil may help cells recover their neurosecretory coupling 
mechanism after glutamate exposure.  
Modafinil also protects noradrenergic and serotonergic neurons against mechanical 
trauma induced by partial hemitransection as well as neostriatal neurons against 
ischemic lesions associated with local endothelin-1 microinjection (Ueki et al., 
1993a). These neurotransmitters will be measured in future studies. 
Treatment with modafinil has also been suggested to limit neurodegeneration 
associated with neurodegenerative disease and to prevent neuronal damage in 
models of PD (van Vliet et al., 2006). Recently, modafinil  was retrospectively, tested 
in patients with MS  (Bibani et al., 2012) this study has reported the beneficial of 
modafinil in reduction of diseases progression measured by EDSS in patients with 
MS. 
A characteristic hallmark of EAE, and of MS itself, is pathological demyelination, 
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which results in motor deficits. To determine whether the protection conferred by 
modafinil treatment in the subset of modafinil-treated mice was the result of a 
reduction in demyelination the result of the histological examination may answer this 
question.  
This experiment could be a start point for further study on modafinil in MS. We 
believe that modafinil may be a new treatment strategy for MS, perhaps with an 
action towards the neurodegenerative aspect of the disease.  
In conclusion, this study has reported a significant reduction in the clinical scores of 
the severity of the EAE in modafinil treated mice in comparison with the control 
group. Thus, it SURYLGHV DQ PRWLYDWLRQ IRU FOLQLFDO WULDOV IRU PRGDILQLO¶V WKHUDSHXWLF
potential for MS patients. We acknowledge that there are some limitations in our 
experiment such as, the study is a pilot study it has limited outcome measures, we 
looked only at clinical scores of the disease. Barring these limitations, we conclude 
that modafinil is beneficial in EAE and may has protective effects against EAE.  
Further work using different study outcome measures and different treatment 
starting points to determine both possible preventive and therapeutic effect of 
modafinil in EAE may confirm our finding. 
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CHAPTER 4 ASSOCIATION OF A DEFICIT OF AROUSAL 
WITH FATIGUE IN MULTIPLE SCLEROSIS: EFFECT OF 
MODAFINIL 
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4.1     Introduction 
This study is based on an in-depth, complete reanalysis of data collected by 
Graham Niepel, a PhD student and researcher in the Division of Clinical Neurology 
in collaboration with the Division of Psychopharmacology (Professor Bradshaw and 
Szabadi). The patient characteristics, demographics, and procedures can also be 
found in the dissertation of Graham Niepel, entitled Deep Gray Matter and fatigue in 
Multiple Sclerosis, 2012. The focus of the thesis chapter that is based on this data is 
to find whether the pupillographic sleepiness test and other autonomic nervous 
system tests can be used as surrogate measures of fatigue in MS. Our analysis 
(and published paper) is focused on the effects of modafinil and the association 
between alertness and fatigue, as these aspects may give clues to the 
neuroprotective properties of modafinil (please see also Chapter six, meta-analysis). 
The entirely rewritten paper (G Niepel, first author) is very different from the thesis 
chapter, eliminates a large number of data due to its different focus, and uses 
parametric statistics (in contrast to the thesis chapter that uses non-parametric 
statistics) 
Fatigue is a common symptom of MS irrespective of its clinical form (Bakshi, 2003; 
Krupp et al., 1988; MacAllister and Krupp, 2005).  Fatigue in MS is also unrelated to 
the degree of physical disability or to lesion load on conventional MRI  (Racke et al., 
2004).  Fatigue has been defined DV ³VXEMHFWLYH ODFN RI SK\VLFDO DQGRU PHQWDO
HQHUJ\ WKDW LVSHUFHLYHG WR LQWHUIHUHZLWKXVXDODQGGHVLUHGDFWLYLWLHV´ (Tartaglia et 
al., 2004). Multiple sclerosis (MS) patients rate fatigue as one of their worst 
symptoms, interfering with their quality of life (QoL) and leading to disability 
(Janardhan and Bakshi, 2002; Krupp et al., 1988; Krupp et al., 1989). A number of 
clinical scales have been developed for the measurement of fatigue in MS, such as 
the fatigue severity scale (FSS) (Krupp et al., 1989)  which is part of the Fatigue 
Assessment Instrument (FAI) (Schwartz et al., 1993),  the fatigue impact scale (FIS) 
 96 
(Fisk et al., 1994b),  the modified fatigue impact scale (MFIS) (Fisk and Doble, 
2002) and the neurological fatigue index (NFI-MS) (Mills et al., 2010).  Only a weak 
FRUUHODWLRQKDVEHHQIRXQGEHWZHHQGLIIHUHQWUDWLQJVFDOHVVXJJHVWLQJWKDW³IDWLJXH
is a multidimensional symptom and therefore the available tests measure and 
ZHLJKWGLIIHUHQWDVSHFWVRIIDWLJXH´(Flachenecker et al., 2003).  It has been reported 
that fatigue in MS may be associated with increased sleepiness. The relationship 
between fatigue and sleepiness is complex, and some patients may report tiredness 
RUIDWLJXHZKHQWKH\PHDQ³LQFUHDVHGQHHGIRUVOHHS´(Dement et al., 2003).  The 
WHUP³WLUHGQHVV´PD\EHXVHGDVHXSKHPLVPIRU³VOHHSLQHVV´7KHUHLVHYLGHQFHRI
sleep disturbance in MS (Attarian et al., 2004; Brass et al., 2010; Constantinescu et 
al., 2011b; Kaminska et al., 2011; Kaynak et al., 2006)  which has been implicated in 
the fatigue reported by patients (Kaminska et al., 2011). Disrupted night time sleep 
may lead to excessive daytime sleepiness (EDS). Indeed, a correlation has been 
demonstrated between the scores obtained on sleepiness and fatigue rating scales 
in MS patients with fatigue (Attarian et al., 2004). 
Like fatigue, depression commonly accompanies MS, with a prevalence of up to 
50%  (Figved et al., 2005). Another study found that 75% of the participants with MS 
have  complained of symptoms of depression, making it the second most common 
complaint after fatigue (Forbes et al., 2006). This study also found that depression 
and fatigue in the population with MS are interactive, but that one does not cause 
the other (Forbes et al., 2006).  
In general, a high rate of coexistence of fatigue and depressive disorder has been 
identified. Several cross-sectional studies have reported an association between 
fatigue and depression (Bakshi et al., 2000; Ford et al., 1998; Schwartz et al., 1996).  
It has been shown that more than 90% of patients with major depressive disorder 
(MDD) had severe fatigue despite taking antidepressant medications (Ferentinos et 
al., 2010).  
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Depression is a pathophysiological concept that is related to, but distinct from 
fatigue. It is often hard to distinguish between fatigue and depression because 
fatigue can be a symptom of depression and depression can be a consequence of 
fatigue (Aaronson et al., 1999; Kos et al., 2008). The relationship is further 
confounded because instruments that measure depression generally include 
questions about fatigue (Aaronson et al., 1999). 
Depression has been cited as a factor that causes secondary fatigue in people with 
MS (Kos et al., 2008). However, some researchers argue that depression does not 
cause fatigue in patients with MS (Egner et al., 2003; Forbes et al., 2006). 
Nevertheless, it is important to treat depression in patients with MS because 
reducing depression can lead to increased physical activity and overall 
improvements in health-related quality of life ((Bakshi, 2003). 
Fatigue in MDD patients can appear in three distinct categories: physical, cognitive 
and emotional symptoms and it can be difficult to differentiate between independent 
symptoms of fatigue from symptoms directly related to MDD (Arnold, 2008). 
As both depression and fatigue are often assumed to be related in MS, and given 
that both depression and MS fatigue likely have multifactorial aetiologies, and that 
both disorders have potentially chronic as well as episodic components, any 
relationship between the two is likely complex. Nevertheless, there are some 
explanations, which are not mutually exclusive. One is that, because fatigue is a 
symptom of depression, the association is due to a methodological confounder 
(Mohr et al., 1997). This suggests that fatigue items should be removed from 
depression measures when analysing outcomes. Another explanation is that 
depressed mood is associated with increases in self-reported severity fatigue. 
Furthermore, another possible explanation is that there is a common underlying MS 
disease mechanism responsible for both depressive mood and fatigue severity 
(Noseworthy et al., 2000).  
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MS exacerbation, which is caused by immune activation, is known to result in 
increases in depressive symptoms (Fassbender et al., 1998). Treatment for 
depression has been shown to reduce MS-related proinflammatory cytokines in MS 
(Mohr et al., 2001b). Thus, treatment for depression may reduce proinflammatory 
cytokines related to MS symptoms, thereby altering disease processes that may in 
part be responsible for fatigue.  In MS patients with both depression and fatigue, 
treatment of depression may be a useful adjunct treatment, may reduce the 
subjective severity of fatigue symptoms (Mohr et al., 2001a). 
As there is a close association between the level of arousal and autonomic activity 
(Samuels and Szabadi, 2008b),  it is of interest that MS patients may also show 
disturbance of autonomic functions (Elie Louboutin, 1995; Haensch and Jörg, 2006; 
McDougall and McLeod, 2003; Merkelbach et al., 2006; Sanya et al., 2005). 
Furthermore, (Flachenecker et al., 2003) found an association between fatigue in 
MS and sympathetic vasomotor dysfunction. 
Interestingly, autonomic dysfunction has also been reported in other conditions, 
such as chronic fatigue syndrome, characterized by pathological fatigue (Newton et 
al., 2007). 
Treatment of fatigue in MS is difficult (Zifko, 2004).  Recently, there has been an 
interest in the wakefulness-promoting drug modafinil (Ballon and Feife, 2006; 
Minzenberg and Carter, 2007) as a possible treatment for MS fatigue. A number of 
open label studies (Brioschi et al., 2009; Lange et al., 2009; Littleton et al., 2010; 
Nagels et al., 2007; Wilken et al., 2008; Zifko et al., 2002) and one placebo-
controlled trial (Rammohan et al., 2002) have found that modafinil was efficacious in 
relieving fatigue in MS patients; although this was not confirmed in two placebo-
controlled trials (Möller et al., 2011; Stankoff et al., 2005). 
Apart from fatigue, cognitive impairment is also a common clinical feature of MS 
(Bobholz and Rao, 2003; Rao, 2004). Interestingly, the subjective experience of 
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fatigue is often associated with both subjective cognitive difficulties and 
demonstrable cognitive impairment, and it has been reported that modafinil may be 
effective in relieving not only the fatigue but also the associated cognitive deficits in 
MS patients (Wilken et al., 2008). 
It is not clear in what way modafinil may alleviate fatigue in MS patients. It is well 
documented that modafinil increases the level of alertness (Hou et al., 2005; 
Minzenberg and Carter, 2007), and there is also evidence that the increase in 
alertness is accompanied by the activation of the sympathetic nervous system (Hou 
et al., 2005; Taneja et al., 2005). 
Therefore, it is possible that the beneficial effect of modafinil on fatigue in MS 
patients is due to the alleviation of some symptoms (sleepiness, sympathetic 
dysfunction) associated with fatigue rather than to the relief of fatigue per se. 
In the present study, in an attempt to explore the relationship between the 
antifatigue and alerting/sympathomimetic effects of modafinil, we examined whether 
there is any difference between MS patients with fatigue, MS patients without 
fatigue, and healthy controls on measures of alertness and autonomic function. We 
also examined the hypothesis that MS patients with fatigue may be more sensitive 
to the alerting and sympathetic activating effects of modafinil than MS patients 
without fatigue or healthy subjects. Therefore we compared the effects of a single 
dose (200 mg) of modafinil and placebo on measures of alertness and autonomic 
function in the three groups of subjects. 
4.2     Material and Methods 
4.2.1     Subjects 
Three groups of subjects (MS patients with fatigue, MS patient without fatigue, 
healthy controls), matched for age and sex, were studied (Table 4.1). 
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4.2.1.1     Patients 
Twenty-six patients with MS, as defined by the criteria of (McDonald et al., 2001), 
were recruited (Table 4.1). The group distribution by clinical type of the disease was:  
 
Table 4.1 Characteristics of the subjects. 
Subjects Number Age (year) 
(Mean±SD) 
FSS scores 
Male Female 
Group1* 
Fatigue Patients 
5 12 49.4±9.2 >4.1 
Group 2** 
Non-fatigue 
Patients 
4 5 41.8±13.1 <2.9 
Group 3 
Healthy Controls 
4 5 40.6±12.1 - 
*14 RRMS + 3 PMS.  
**8 RRMS +1 PMS 
RRMS= relapsing remitting MS; PMS= progressive MS 
 
21 relapsing remitting MS (RRMS), 3 secondary progressive MS (SPMS) and 2 
primary progressive MS (PPMS). There were 9 males and 17 females. All subjects 
were relapse and corticosteroid free for at least one month prior to commencement 
of the study as well as for the duration of the study. No patients suffered from any 
significant medical or psychiatric conditions that could confound the study. No 
patients had evidence of prior ocular manifestations of MS or impaired visual 
function, as assessed by the visual function questionnaire (VFQ25) (Noble et al., 
2006). 
As there can be an association between fatigue and depression (Goodwin, 1998), all 
patients were asked to complete the Beck Depression Inventory (BDI; (Beck et al., 
1996))  prior to inclusion in the study. All patients included had BDI scores <19 (a 
cut-off to indicate no or mild depression). All patients were divided into two groups 
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according to severity of fatigue, based on their scores obtained on the fatigue 
severity scale (FSS; (Krupp et al., 1989),WLVJHQHUDOO\DFFHSWHGWKDWDVFRUH 
TXDOLILHVIRU³IDWLJXH´ZKHUHDVDVFRUHRITXDOLILHVIRU³QRIDWLJXH´(Anderson et 
al., 2009; Bakshi et al., 2000).  In our sample 16 patients had FSS in excess of 5.0 
and thus fulfilled the critHULRQIRU³IDWLJXH´)*URXSSDWLHQWVKDG)66VFRUHV
OHVV WKDQ  DQG WKXV IXOILOOHG WKH FULWHULRQ IRU ³QR IDWLJXH´ 1) *URXS  2QH
patient had a borderline score between 4.1 and 4.9 and this patient was included in 
the fatigue group (Table 1). No patients with fatigue were receiving medication that 
could potentially affect their fatigue. Three patients in each group were receiving 
glatiramer acetate (GA) treatment and one patient in the NF group was receiving 
intramuscular beta-interferon. 
4.2.1.2     Healthy controls 
9 healthy control subjects were recruited to match with the patients for age and 
gender (Group 3). None of them had a history of neurological and/or psychiatric 
disease or other significant medical condition. 
Approval was obtained from the Nottingham Research Ethics Committee (Appendix 
1). All subjects gave informed consent.  
4.2.2     Drugs 
Single doses of modafinil (200 mg) and lactose placebo were administered in 
matching capsules. 
4.2.3     Design 
Each subject participated in an initial introductory session and two experimental 
sessions, two weeks apart. In the experimental session the subjects were allocated 
to treatment according to a double-blind balanced cross-over design. 
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4.2.4     Procedure 
In the introductory session the subjects completed the fatigue and depression 
questionnaires, and underwent a full neurological examination by an experienced 
clinician. 
The time-course of the experimental sessions was based on the single-dose 
pharmacokinetics of modafinil: peak plasma concentration is attained two hours 
after the ingestion of a dose (Robertson and Hellriegel, 2003). After a 30-minute 
acclimatisation period, the pre-treatment tests (sleepiness questionnaires, visual 
analogue scales for fatigue (VAS-F), pupillographic sleepiness test (PST), critical 
flicker fusion frequency (CFFF), choice reaction time (CRT), systolic and diastolic 
blood pressure, heart rate and sustained handgrip; for details, see below) were 
carried out. On completion of the pre-treatment tests, the subject ingested the 
capsule. Two hours later, the post-treatment tests (pre-treatment tests repeated and 
pupillometry) were carried out. 
4.2.5     Tests and apparatus 
4.2.5.1     Tests of alertness 
4.2.5.1.1     Self-rating of alertness 
For the subjective assessment of sleepiness two questionnaires Epworth Sleepiness 
Scale (ESS): (Johns, 1991);  Stanford Sleepiness Scale (SSS): (Hoddes et al., 
1973), together with a battery of VAS, were used. Subjects rated their subjective 
state of mood by using a computerized version of the VAS developed by (Norris, 
1971).  The ratings on the 16 scales were grouped under the headings of 
³DOHUWQHVV´ ³DQ[LHW\´ ³FRQWHQWHGQHVV´ EDVHG RQ D IDFWRU DQDO\VLV FDUULHG RXW E\
(Bond and Lader, 1974). 
 103 
4.2.5.1.2     Instrumental measurements of alertness 
4.2.5.1.2.1     Critical flicker fusion frequency (CFFF) 
The CFFF test, defined as the frequency at which a flickering light appears to be 
continuous (Smith and Misiak, 1976), conducted conventionally. CFFF is the level of 
individual sensitivity at the beginning and at the end of light flickering, caused by 
changes in the frequency of light flashes. CFFF is measured with the flicker test. 
Ascending and descending thresholds are distinguished in CFFF. The ascending 
(fusion) threshold is an indicator of human sensitivity to the perception of the end of 
light flickering. It is measured with the lowest frequency of the flashing light (Hz), at 
which the subject perceives a steady light instead of a flickering one. The 
descending (flicker) threshold is measured with the highest frequency of the flashing 
light when the flicker appears (Luczak and Sobolewski, 2005). The Leeds 
Psychomotor Tester (Psychopharma Ltd, Surrey, UK) was used to collect eight 
measurements of the threshold, four with increasing frequencies and four with 
decreasing frequencies. The mean of the eight measurements was taken as the 
value of CFFF for each testing session (Abduljawad et al., 1997). 
4.2.5.1.2.2     Pupillographic sleepiness test (PST) 
The sleepiness waves are monitored by means of a video camera with built-in 
infrared illumination. The person being tested wears a pair of protective spectacles 
which are transparent for infrared light only. The spectacles protect the eyes from 
any residual and visible light and only a dimmed red spot is visible for fixation. The 
pupil diameter is recorded up to 11 minutes. From this data the pupillary unrest 
index (PUI) is calculated. The PUI  is a quantitative value which describes the 
amount of the pupillary fluctuations in darkness as a measure of sleepiness (setup 
version 1.20: AMTech, Weinheim, Germany) (for details, see (Hou et al., 2005)). 
The PST quantitatively analyses pupil diameter fluctuations, which are regarded a 
physiological index of level of alertness (Lowenstein et al., 1963; Yoss et al., 1970). 
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The method yields two measures of pupillary fluctuations, the PUI (the distance 
travelled by the margin of the pupil over 1 min) and the total power of the pupil 
diameter fluctuations (obtained from a Fast Fourier Transformation (FFT)) (Lüdtke et 
al., 1998). 
4.2.5.1.3     Psychomotor tests 
4.2.5.1.3.1     Choice reaction time (CRT)  
For testing the CRT (Hindmarch, 1980) subjects were required to extinguish one of 
six equidistant red lights, illuminated at random, by pressing the associated 
response button as quickly as possible. Two components were recorded; 
Recognition Reaction Time (RRT) and Motor Reaction Time (MRT), which together 
yield the Total Reaction Time (TRT). RRT was the time it took for the subject to 
notice the light, the measurement being the time between stimulus onset and the 
subject lifting his/her finger from the start button. MRT included the majority of the 
movement component of this task and was the time between the subject having 
lifted his/her finger from the start button and touching the response button. The 
mean reaction times of 50 trials were recorded. 
4.2.5.2     Tests of autonomic function 
4.2.5.2.1     Cardiovascular measures 
Blood pressure and heart rate recordings were taken in the sitting position using an 
electroaneroid sphygmomanometer. A modified version of the method of (Ewing, 
1992) was used to record the pressor response to isometric handgrip. The subject 
was asked to maintain his/her handgrip at 20 % of his/her maximum voluntary 
contraction of a handgrip dynamometer for five minutes, and the blood pressure was 
recorded every minute. The difference between the diastolic blood pressure just 
before release of the handgrip and before starting was taken as the measure of 
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response. An increase in diastolic blood pressure of at least 16 mmHg was taken as 
a normal response. 
4.2.5.2.2     Pupil diameter 
Resting pupil diameter was obtained using a binocular infra-red video pupillometer 
with a calibrated internal light source (Procyon Limited, London, UK) in darkness 
and at three luminance levels (6, 91 and 360 cd m-2 ) (for details, see (Hou et al., 
2005)). 
4.2.6     Data analysis and statistics 
One-way analysis of variance, with group being the factor, was used to compare the 
performance of the three groups of subjects on the tests prior to the administration 
of any treatment. The differences between pre- and post-treatment scores on the 
individual tests were subjected to a two-way analysis of variance (treatment x 
group). A significance criterion of P < 0.05 was adopted. If a significant F ratio was 
obtained, multiple comparisons were carried out using the least significant difference 
test (significance criterion P < 0.05). In the case the pupil diameter data obtained 
post-treatment, a three-way ANOVA (luminance x treatment x group) was used. 
4.3     Results 
4.3.1     Measures of alertness 
4.3.1.1     Comparison of groups prior to treatment 
Figure 4.1 shows the scores obtained by the three groups of subjects on five 
measures of alertness (Epworth rating scale, Stanford rating scale, VAS rating of 
alertness, motor component of CRT, CFFF). On all these measures there was a 
significant effect (P < 0.05) of group as indicated by ANOVA (Epworth scores: F(2, 
32) = 4.6; Stanford scores: F(2, 32) = 7.9; VAS alertness scores: F(2, 32) = 3.4; 
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Figure 4.1 Measures of alertness: comparison of groups prior to treatment. 
Top row: scores of subjective ratings, bottom row: instrumental measurements. 
Columns correspond to the three groups: black Group 1, grey Group 2, and white 
Group 3; vertical bars are s.e.mean. ANOVA showed a significant effect of group, 
and individual comparisons indicated that Group 1 was significantly different from 
Group 3 (*P < 0.05) (see text for details). Higher scores on the Epworth and 
Stanford sleepiness scales and lower scores on VAS ratings, together with longer 
choice reaction times and lower thresholds of flicker fusion frequency are indicative 
of reduced level of alertness in Group 1 (MS patients with fatigue). In Group 1 there 
was a significant positive correlation between the FSS and the subjective ratings of 
daytime sleepiness on the Epworth rating scale (rho = 0.407, P = 0.039), and a 
significant negative correlation between the FSS scores and the subjective ratings of 
alertness with the VAS (rho = - 0.419, P = 0.033). 
 
CRT motor time: F(2, 32) = 5.0; CFFF: F(2, 32) = 3.5). Multiple comparisons (least 
significant difference test) indicated that the scores were significantly (P < 0.05) 
higher for the Epworth, Stanford and CRT motor time scores and lower for the VAS 
alertness and CFFF scores in Group 1 than by Group 3 (P < 0.05). There was no 
significant difference between the scores obtained in Groups 2 and 3 on any of the 
measures. The differences between Groups 1 and 3 on all five measures are 
indicative of reduced level of alertness in Group 1 compared to Group 3. 
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4.3.1.2     Effect of modafinil 
Figure 4.2 shows the pre/post-treatment differences on four measures of alertness 
(CFFF, CRT motor time, and two measures obtained from the PST: pupillary unrest 
index (PUI) and total power of pupillary fluctuations) following treatment (modafinil, 
placebo) in the three groups. For the PST measures one subject was excluded from 
Group 3 for technical reasons.  
 
 
MS-F= MS with fatigue; MS-NF= MS without fatigue; HC= Healthy controls 
Figure 4.2 Measures of alertness: effect of modafinil 
Columns indicate changes from pre-treatment following the administration of 
placebo (white) or modafinil 200 mg (black), in the three groups; vertical bars are 
s.e.mean. ANOVA showed that modafinil significantly raised the flicker fusion 
frequency threshold, shortened choice reaction time, and reduced the two indices 
(PUI and total power) of sleepiness on the Pupillographic sleepiness test, 
irrespective of group (see text for details). The effect of modafinil was consistent 
with its alerting action. 
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The results of the two-way ANOVA (treatment x group) were as follows: CFFF:; 
treatment F(1, 32) = 9.3 P < 0.05; no significant effect of group and no significant 
interaction CRT motor time: treatment F(1, 32) = 4.6 P < 0.05; group F(2, 32) = 5.6 
P < 0.05; no significant interaction; PUI: treatment F(1, 31) = 7.4 P <0.05; no 
significant effect of group and no interaction; FFT: treatment F(1, 31) = 4.5 P < 0.05; 
no significant effect of group and no interaction. Visual inspection of the graphs 
indicates that modafinil increased CFFF and reduced CRT motor time, PUI and FFT, 
consistent with its alerting effect. This effect of modafinil was apparent in all three 
groups of subjects. 
4.3.2     Autonomic measures 
4.3.2.1     Comparison of groups prior to treatment 
Figure 4.3 (left hand graph) shows the percentage of subjects who attained the 
threshold criterion (i.H DQ LQFUHDVH LQ GLDVWROLF EORRG SUHVVXUH RI   PP+J LQ
each of the three groups on the isometric handgrip test. Statistical comparison using 
the chi square test showed that the percentage of subjects reaching the criterion 
was significantly less (P < 0.05) in Group 1 than in either Group 2 or Group 3. There 
was no significant difference between the three groups on any other cardiovascular 
measure. 
4.3.2.2     Effect of modafinil 
4.3.2.2.1     Cardiovascular measures 
Figure 4.3 (right hand graphs) shows the effects of treatments on the pre/post-
treatment differences in systolic blood pressure, diastolic blood pressure and heart  
rate. Two-way analysis of variance showed that there was a significant effect of 
treatment for all three measures: systolic blood pressure F(2, 32) = 8.8 P < 0.05; 
diastolic blood pressure F(2, 32) = 15.2 P < 0.05; heart rate F(2, 32) = 5.3 P < 0.05). 
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Figure 4.3 Autonomic measures: comparison of group prior to treatment. 
Left: comparison of groups prior to treatment on the isometric handgrip test. 
Columns correspond to the percentage of subjects who attained an increase in 
diastolic blood pressure at or above the threshold (16 mmHg); black Group 1; grey 
Group 2, white Group 3. Brackets indicate statistical comparisons (c2 test) between 
the groups (* and #P < 0.05). A significantly smaller proportion of subjects reached 
the threshold criterion in Group 1 than in the other two groups, consistent with 
reduced sympathetic responsiveness in MS patients with fatigue. Right: effect of 
modafinil on systolic and diastolic blood pressure and heart rate. Columns indicate 
changes from pre-treatment following the administration of placebo (white) or 
modafinil 200 mg (black), in the three groups; vertical bars are s.e.mean. ANOVA 
showed that modafinil significantly increased systolic and diastolic blood pressure 
and heart rate, irrespective of group (see text for detail), consistent with its 
sympathomimetic effect. 
 
However, the effect of group was not significant (F < 1.0 NS for systolic blood 
pressure and heart rate, and F(3, 32) = 1.3 NS for diastolic blood pressure), and 
there was no significant treatment x group interaction in the case of any of the 
measures. The results indicate that the treatment effects were due to increases in 
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systolic and diastolic blood pressure, and heart rate by modafinil, and this effect was 
present irrespective of group. 
4.3.2.2.2     Pupil diameter 
Figure 4.4 shows the relationship between luminance intensity and pupil diameter 
following treatment in the three groups. Three-way ANOVA (light intensity x 
treatment x group) was used to analyse the data. There were significant main 
effects of light intensity (F(3, 96) = 407.5 P < 0.05) and treatment (F(1, 32) = 5.1 P < 
0.05), but not of group (F(2,32) = 1.7 NS). 
There was a significant interaction between light and treatment (F(3, 96) =3.1 P < 
0.05); the interactions between light and group (F < 1.0 NS), and treatment and 
group (F < 1.0 NS), and the three-way interaction (F < 1.0 NS) were not statistically 
significant. The analysis indicates that modafinil increased pupil diameter 
irrespective of group. 
 
Figure 4.4 Relationship between light intensity and Pupil diameter 
Relationship between light intensity (cd m_2) and pupil diameter (mm) 2 h after the 
ingestion of a single dose (200 mg) of modafinil (closed symbols) or placebo (open 
symbols), in the three groups. ANOVA revealed that there was a significant effect of 
treatment but not of group (see text for details). The treatment effect was due to 
pupil dilatation in response to modafinil, consistent with its sympathomimetic effect. 
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6XEMHFWV¶YHUEDOUHSRUWV 
At the end of each session, subjects were asked about their subjective experiences 
during that session. The debriefing was unstructured, and no leading questions were 
used. 
Both the subject and the experimenter were blind to the medication applied in the 
session. 
,Q JHQHUDO VXEMHFWV UHSRUWHG IHHOLQJ D ELW PRUH ³DFWLYH´ LQ VHVVLRQV LQYROYLQJ
modafinil, in agreement with the quantitative assessments of alertness by both 
subjective and objective tests (see figure 4.1). However, there was no obvious 
difference between the reports of patients and healthy controls. 
4.4     Discussion  
As reviewed in the Introduction, it has been reported that MS patients often suffer 
from disturbed night time sleep which can lead to EDS. Although EDS has been 
implicated in the symptom of fatigue in MS (Attarian et al., 2004; Kaminska et al., 
2011),  it is not clear whether the EDS is specifically associated with fatigue in MS or 
whether it also occurs in some MS patients who do not suffer from fatigue. 
Therefore we compared a number of subjective and objective measures of alertness 
between three groups of subjects: MS patients with fatigue, MS patients without 
fatigue and healthy controls. We found that MS patients with fatigue showed 
evidence of reduced level of alertness on a number of subjective (ESS, SSS, visual 
analogue ratings of alertness) and objective (motor component of CRT, CFFF) 
measures of alertness, in contrast to MS patients who did not suffer from fatigue and 
healthy controls. In fact, there was no significant difference between MS patients 
without fatigue and healthy control subjects on these measures. Our observation 
indicates that it is fatigue in MS rather than MS per se that is associated with a 
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reduced level of alertness in some MS patients. Indeed, we found a significant 
positive correlation between fatigue ratings on the FSS of patients in Group1 and 
their subjective ratings of daytime alertness on the ESS, and a significant negative 
correlation between the FSS scores and the measures of alertness obtained on the 
VAS. Fatigue (subjective lack of physical and/or mental energy) and sleepiness 
(increased need for sleep) are different entities (see Introduction). The relationship 
between fatigue and sleepiness is likely to be complex. Some patients may refer to 
fatigue when tKH\DUHRQO\VOHHS\VHH,QWURGXFWLRQVRPHSDWLHQWV¶IDWLJXHUDWLQJV
may be aggravated by the experience of sleepiness, and finally in some patients 
fatigue and sleepiness may co-exist without any interaction between them. 
Due to the close association between level of arousal and autonomic activity 
(Samuels and Szabadi, 2008b),  it was of interest to examine whether the MS 
patients with fatigue, who show evidence of reduced level of alertness, differ from 
the other two groups on measures of autonomic activity. While there was no 
difference between the three groups on baseline measures of autonomic function, a 
significant difference was identified on a measure of evoked sympathetic activity. 
We found that MS patients with fatigue showed a reduced diastolic pressor 
response on the isometric handgrip test, compared with the other two groups, 
consistent with reduced sympathetic activation (Ewing, 1992; Wallin, 1992). 
As reviewed in the Introduction, the wakefulness-promoting drug modafinil has been 
reported to be able to alleviate fatigue in MS patients. It is well documented that a 
single dose of modafinil increases laboratory measures of alertness and 
sympathetic activity in human subjects (Hou et al., 2005; Taneja et al., 2005), and 
the present results show that MS patients with fatigue have decrements on 
measures of both alertness and sympathetic activity. Therefore, we hypothesized 
that MS patients with fatigue might be more sensitive to the alerting and sympathetic 
activating effects of modafinil than MS patients without fatigue or healthy control 
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subjects. Modafinil displayed both alerting and sympathetic activating effects in the 
present study, however, the size of increase in alertness and sympathetic measures 
did not differ between the three groups. As MS patients with fatigue had a lower pre-
treatment baseline on both alertness and sympathetic measures, it is likely that 
PRGDILQLO H[HUWHGD ³FRUUHFWLQJ´HIIHFW RQ WKHVHPHDVXUHV DOOHYLDWLQJ WKH negative 
subjective experience of EDS in these patients. It would have been of interest to 
obtain some measure of the effect of a single dose of modafinil, which had marked 
effects on alertness, on subjectively experienced fatigue in patients in Group 1. 
However, this was not feasible for two reasons: firstly, the fatigue rating scales 
measure fatigue as a trait and not a state at a particular point in time and secondly 
any anti-fatigue effect of modafinil has been reported after the administration of 
more than one dose for several weeks (Littleton et al., 2010; Rammohan et al., 
2002; Zifko, 2004). As argued above, if the experience of excessive sleepiness is 
associated with the experience of fatigue in some patients, the alleviation of 
sleepiness is likely to lead to a reduction in subjectively rated fatigue. Therefore the 
therapeutic efficacy of modafinil in MS-related fatigue may be secondary to its 
efficacy in relieving EDS in these patients. This proposal seems to be supported by 
WKHUHVXOWVRIDFOLQLFDOVWXG\ZKLFKFRQFOXGHGWKDW³PRGDILQLl may be useful [for the 
treatment of MS-related fatigue] particularly when MS fatigue is associated with 
H[FHVVLYHVOHHSLQHVV´(Littleton et al., 2010). 
The pathological changes and physiological mechanisms underlying fatigue in MS 
are poorly understood (Comi et al., 2001b; Leocani et al., 2008). A number of 
mechanisms have been suggested, such as increased levels of cytokines, 
dysregulation of the hypothalamic pituitary- adrenal axis and axonal loss (for review, 
see (Braley and Chervin, 2010). 
Furthermore, the dysfunction of the basal ganglia has been proposed as the 
pathological basis of fatigue in MS (Téllez et al., 2008). A recent finding is of 
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particular interest since it may shed light on the development of EDS in MS. It has 
been found that the central noradrenergic nucleus, the locus coeruleus (LC), is 
damaged in MS (Polak et al., 2011), and it is well documented that this nucleus 
plays a pivotal role in the maintenance of arousal and sympathetic activity (Samuels 
and Szabadi, 2008b). Therefore the EDS in MS patients, and in particular in MS 
patients with fatigue, may be the reflection of reduced central noradrenergic activity 
resulting from LC damage. 
There has been considerable controversy surrounding the mode of action of 
modafinil. While modafinil, similarly to amphetamine, increases alertness and is an 
effective treatment of EDS in narcolepsy, in contrast to amphetamine, it has 
relatively little addictive potential (Szabadi and Samuels, 2008). Therefore, it was 
proposed that modafinil is likely to have a mode of action that is different from that of 
amphetamine (Ballon and Feife, 2006; Ferraro et al., 1997; Gerrard and Malcolm, 
2007; Minzenberg and Carter, 2007; Saper and Scammell, 2004).  It is well 
established that the main action of amphetamine is the release of dopamine from 
nerve terminals together with the inhibition of the re-uptake of dopamine into nerve 
endings (Szabadi and Samuels, 2008). Although a number of possible mechanisms 
have been implicated in the mode of action of modafinil (Ballon and Feife, 2006; 
Gerrard and Malcolm, 2007; Minzenberg and Carter, 2007), there is accumulating 
HYLGHQFHWKDWPRGDILQLO OLNHDPSKHWDPLQH LVD³GRSDPLQHUJLF´GUXJDFWLQJPDLQO\
by inhibiting the reuptake a dopamine into dopaminergic nerve terminals (Madras et 
al., 2006; Volkow et al., 2009; Wisor et al., 2001; Zolkowska et al., 2009). This 
action of modafinil is likely to be most pronounced in the dopaminergic arousal 
system (see Figure 4.5), leading to the wakefulness-promoting effect of modafinil, 
with relative sparing of the mesolimbic dopaminergic system, responsible for 
mediating the addictive property of dopaminergic drugs (Samuels et al., 2007). 
It has been reported that modafinil increases the release of histamine, a potent 
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wakefulness-promoting neurotransmitter in the hypothalamus (Ishizuka et al., 2003). 
Histamine is located in neurons in the tuberomamillary nucleus (TMN), a major 
wakefulness-promoting nucleus, in the hypothalamus. The TMN is under inhibitory 
GABAergic control from the ventrolateral preoptic nucleus (VLPO) of the anterior 
hypothalamus. 
The VLPO is a major sleep-promoting nucleus, whose activity is kept in check by an 
inhibitory output from the LC (Hou et al., 2007). Therefore the enhancement of the  
dopaminergic stimulation of the LC by modafinil would lead to an arousal-enhancing 
cascade: LC activation would lead to inhibition of the VLPO; this in turn would result 
in the release of the TMN from GABA-ergic inhibition, and finally the activation of the 
TMN, would lead to an alerting effect (Figure 3-5). The wakefulness-promoting 
orexinergic neurons of the lateral hypothalamic/perifornical area (LH/PF) are also 
likely to contribute to the alerting effect of modafinil. Via an excitatory projection to 
the LH/PF, dopaminergic neurons of the ventral tegmental area stimulate 
orexinergic activity (Szabadi and Samuels, 2008). 
Orexinergic neurons enhance wakefulness partly by a direct projection to the 
cerebral cortex, and partly by projections to other wakefulness-promoting nuclei, 
such as the LC and TMN (Samuels and Szabadi, 2008a) . The importance of the 
facilitation of TMN activity via the orexinergic neurons has been demonstrated 
experimentally: modafinil fails to enhance histamine release after destruction of the 
orexinergic neurons (Ishikuza et al., 2012; Ishizuka et al., 2010). As fatigue in MS is 
associated with a reduced level of alertness, and modafinil is a wakefulness-
promoting drug, the anti-fatigue effect of modafinil in MS may be related to the 
alleviation of EDS in these patients. It is an intriguing possibility that the reduced 
level of alertness in MS patients with fatigue may result from damage to 
the LC brought about by the disease process (Polak et al., 2011). 
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Figure 4.5 Schematic diagram of the dopaminergic arousal system showing 
the possible sites of action of modafinil. Source (Szabadi, 2006). 
The level of arousal at any one time reflects the balance between the activities of a 
QXPEHU RI VXEFRUWLFDO ³ZDNHIXOQHVV-SURPRWLQJ´ DQG ³VOHHS-SURPRWLQJ´ QXFOHL >IRU
details, see references 1 and 2]. Encircled letters in the figure indicate the arousal-
modulating nuclei: white e wakefulness-promoting, dark grey e sleep-promoting. 
Some of the major wakefulness-promoting nuclei, that project directly to the cerebral 
cortex, include the glutamatergic intralaminar nuclei of the thalamus (Th), the 
histaminergic tuberomamillary nucleus (TMN) and the orexinergic lateral and 
perifornical areas (LH/PF) of the hypothalamus, the cholinergic 
peduncolopontine/laterodorsal tegmental nuclei (PPT/LDT) and the noradrenergic 
locus coeruleus (LC) of the pons, and the three dopaminergic nuclei of the midbrain: 
ventral periaqueductal grey (VPAG), ventral tegmental area (VTA), pars compacta 
of the substantia nigra (SN). The major sleep-promoting nucleus is the GABAergic 
ventrolateral preoptic nucleus of the hypothalamus. Arrows correspond to 
projections from the nuclei: solid arrow e excitatory; broken arrow e inhibitory. 
Letters next to each arrow designate the neurotransmitter utilised by the projection: 
Glu e glutamate; ACh e acetylcholine; H e histamine; DA e dopamine; Ox e orexin; 
NA e noradrenaline. The three midbrain dopaminergic nuclei (highlighted in figure) 
promote wakefulness by projecting to the cerebral cortex and to other wakefulness-
promoting nuclei. The VPAG is active during wakefulness and quiescent during 
sleep, and projects directly to the cerebral cortex, the LH/PF and LC [3]. The VTA 
projects to the LC [4] and LHA/PF [5; 6]. 
The SN projects to the striatum (St) via the nigrostriatal pathway which sends 
collaterals to the Th [6]. Modafinil would exert its alerting effect by blocking the 
reuptake of dopamine, and thus making more neurotransmitter available for 
transmission, at the sites indicated by asterisks (*). Increased LC activation is likely 
to be important since the LC, apart from directly stimulating the cerebral cortex, also 
removes the inhibitory influence of the VLPO on the TMN, leading to increased 
histaminergic activation of the cortex [8]. References: 1. (Szabadi, 2006); 2. (Lin et 
al., 2011); 3. (Lu et al., 2006); 4. (Deutch et al., 1986); 5. (Yoshida et al., 2006); 6. 
(Bubser et al., 2005); 7. (Freeman et al., 2001); 8. (Hou et al., 2007).  
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As modafinil is a powerful activator of the LC (Hou et al., 2007; Minzenberg et al., 
2008)  via the dopaminergic system (see Figure 4.5), modafinil may exert its 
therapeutic effect on MS fatigue by correcting deficient LC activity. In conclusion, we 
have found that MS patients with fatigue have reduced levels of alertness and 
sympathetic activity, and suggest that modafinil may exert its anti-fatigue effect by 
correcting these deficiencies, probably via the activation of the noradrenergic LC. 
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CHAPTER 5 CEREBROSPINAL FLUID OLIGOCLONAL BAND 
AND MULTIPLE SCLEROSIS PROGRESSION: A 
RETROSPECTIVE STUDY 
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5.1     Introduction 
Antibody-mediated inflammation is believed to contribute to tissue injury in multiple 
sclerosis (MS). The majority of patients with MS have oligoclonal bands (OCB), 
corresponding to antibodies against a variety of antigens, in their CSF. Up to 95% of 
MS patients in Northern Europe have OCB in the cerebrospinal fluid (CSF), but this 
frequency varies depending on laboratory routines, study populations and was 
recently also related to latitude (Lechner-Scott et al., ; Link and Huang, 2006). The 
absence of OCB in CSF has been claimed to be associated with a better (Joseph et 
al., 2009), worse (Siritho and Freedman, 2009)  or equal  (Lourenco et al., 2012) 
clinical outcome compared to OCB positive MS. 
During the process of data collection for our retrospective study detailed in chapter 2 
aiming to explore the potential neuroprotective effect of modafinil in patient with MS, 
the Nottingham University Hospital. (NUH) MS database was reviewed. The NUH 
MS database is a hospital database of all MS patients attending the QMC MS Clinic, 
where patients are followed by three specialists in neurology at different intervals 
when visits are necessary. Therefore, we identified all patients in the QMC MS 
database, who had undergone a lumbar puncture as part of their diagnostic workup, 
and we included only patients who have had recorded OCB status. Other variables 
(age, gender, date of first disease onset, Onset type of MS, disease duration, last 
recorded EDSS scores and MSSS) were also recorded.  As disease progression 
was the primary outcome for our retrospective study and on the assumption that 
OCB status may has interfere with disease progression and has had affected the 
recorded EDSS scores of included patients in our cohort and could affect the 
outcome of the study we evaluated the role of OCB status on  disease progression.   
We took advantage of the statistical method (linear regression model) we used in 
analysing the data assessing the effect of modafinil on EDSS progression and we  
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applied same method evaluate the role of OCB status on disease progression in 
patients diagnosed with MS in our cohort.  
OCBs are IgG immunoglobulin secreted by plasma cells into the CSF and can be 
detected using IEF technique in combination with Western blotting. Intrathecally 
synthesised OCBs in CSF are the immunological characteristic of MS, found in over 
85-95% of the  patients (Idiman et al., 2009). IEF is regarded as the gold standard 
for detection of intrathecal synthesis of IgG (Beckett et al., 2010). The detection of 
CSF OCBs by IEF is not absolutely specific for MS as CSF OCBs can be detected 
in a variety of other inflammatory disorders of the CNS. Despite vast improvement in 
MRI techniques for diagnosis of MS, CSF examination for detection of OCBs 
remains a valuable measure especially, in the diagnosis of primary progressive MS 
(PPMS). The presence of OCBs is used in conjunction with clinical evidence to help 
VDWLVI\ WKH UHTXLUHPHQW IRU ³GLVVHPLQDWLRQ LQ VSDFH´RI WKHSUHYLRXV3RVHU FULWHULD
Currently, positive CSF for OCBs and 2 or more MRI lesions satisfies the revised 
diagnostic McDonald criteria, when MRI lesions alone do not suffice (Polman et al., 
2011). 
Different studies have reported different frequencies of OCBs in CSF of the MS 
patients between countries and even in the same country. There are reports that 
OCB are more likely to be detected in MS patients in the UK, USA and Scandinavia 
(95%, 90%, and 100% respectively) (Fortini et al., 2003; Kostulas et al., 1987; 
McLean et al., 1990) compared to patients in the Czech Republic and southern 
Europe (81%, and 83% respectively) (Bednarova et al., 2005; Sa et al., 2005). The 
occurrence of CSF OCB in Japan and some other Asian countries is less frequent 
(53%-77%) (Kikuchi et al., 2003; Nakashima et al., 2005). 
The role of OCB and its prognostic value in MS has been studied previously. There 
were conflicting results to support the use of OCBs as predictors of disease course 
or progression. Some of these studies have suggested that MS patients lacking CSF 
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OCBs are purported to have a milder course of disease and less disability (Sa et al., 
2005; Stendahl-Brodin and Link, 1980; Zeman et al., 1996). It has also been 
suggested that fewer OCB are attributed to lower numbers of active plaques and 
plasma cells in white matter and the meninges  (Farrell et al., 1986).  One study 
described a significant delay in disability progression during treatment with 
interferon-beta in the subgroup of MS patients with no CSF OCB detectable by IEF 
compared to the patients with detectable OCBs also have shown the absence of 
OCB which also was associated with lower numbers of baseline T2-weighted MRI 
lesions (Annunziata et al., 2006)  
In a relatively new case-control study a slightly better prognosis measured as the 
hazard ratio to reach EDSS milestones of 4 and 6, of OCB-negative patients 
compared with OCB- positive was reported (Joseph et al., 2009). 
On the other hand the prognostic significance of OCBs in MS has been disputed by 
several studies (Koch et al., 2007; Lourenco et al., 2012; Siritho and Freedman, 
2009). These studies have found that OCBs in the CSF were not associated with 
either worsening or stability of disability in patients with MS, and OCB negative 
patients did not have more benign form of MS. 
The association of OCB status with MS clinical course (relapsing-onset MS vs. 
progressive onset MS) has been assessed too. Some studies have suggested more 
OCB positivity with PPMS (Fukazawa et al., 1998; Imrell et al., 2006; Kikuchi et al., 
2003; Trojano et al., 1987). In contrast the above suggested association has not 
supported by other studies and even they found a reverse association, i.e. patients 
with relapsing-remitting MS (RRMS) being more likely to present with OCBs than 
those with PPMS (Ford et al., 2002; Siritho and Freedman, 2009).  
In the present study we aimed to: - assess the association of OCB status (the 
primary focus), with disease progression (measured by EDSS scores and MS 
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severity score (MSSS)) and OCB status with disease course (RRMS vs. PPMS), as 
well as effect of OCB status on time to definite diagnosis (secondary focuses).  
5.2     Methods 
5.2.1     Subjects and Setting  
Study subjects were obtained from a well-documented clinical cohort of MS patients 
held by NUH. Patients included in this study are those with clinically definite MS 
(CDMS) diagnosis according to the Poser and/or MacDonald criteria with the 
recorded results of CSF OCBs investigation provided by the hospital diagnostic 
database. Patients in this cohort are seen regularly and undergo extensive medical 
and neurological examination. The database includes general demographic data as 
well as MS specific information including records of first symptom, onset date, test 
results, type of MS, EDSS score, MSSS, and records of use of disease modifying 
treatments (DMT). 
5.2.2     Data used and main outcome measures 
Age, sex, onset age, date of OCBs results, initial type of MS, use of DMTs and last 
recorded EDSS were obtained. DMT use was modelled as a binary variable for use 
RIOHVVWKDQD\HDURURQH\HDUDQGPRUH/DVWUHFRUGHG('66VFRUHZDV
used to score the disability in patients.  In this study disease duration was defined as 
the time interval between the date of last obtained EDSS score and the date of the 
first manifestation of the disease. We also calculated the diagnostic delay by 
measuring the time gap between the diagnosis date and date of the onset of the 
initial symptoms. MSSS was calculated according to guidelines by Roxburgh et al 
(Roxburgh et al., 2005). EDSS score and MSSS were used as two main measures 
of disease progression and severity.   
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5.2.3     Study design 
On the basis of the positivity and negativity of OCBs in the CSF, the sample was 
divided into two groups (a patient is considered positive for CSF OCB if there are 
two or more bands in the CSF immunoglobulin region that are not present in the 
serum). We compared the proportion of positive and negative OCB results for 1980-
2010 time periods. The correlation of diagnostic delay and the results of OCBs was 
investigated by comparing the median delay time in two OCB groups. We also 
measured the effects of OCBs results on clinical outcomes. The independent effects 
of OCBs on EDSS score and MSSS were measured while controlling for potential 
confounders including sex, age, disease duration, MS initial type and treatment.  
 5.2.4     Statistical analyses 
Descriptive statistics were used to compare and summarise the data. Non-
parametric test (Mann Whitney U test) was used to compare ordinal independent 
variables such as EDSS, and Student t test to compare means of normally 
distributed independent variables. We used the logistic regression model to estimate 
the odds of having progressive clinical course at disease onset (PP vs. RR) while 
controlling for onset age and gender. The effects of OCB status on EDSS and 
MSSS were calculated using linear regression models with adjustment for potential 
confounding variables (age at onset, gender, use of DMTs and disease duration). 
Linear models were tested for underlying normality assumption. Statistical analysis 
was performed using STATA software (StataCorp. 2009. Stata Statistical Software: 
Release 11. College Station, TX: StataCorp LP). 
5.3     Results 
The final sample consisted of 434 (283 female and 151 male) CDMS patients. 348 
(80%) of cases were reported as OCB positive and 86 (20%) were OCB negative. 
The mean (SD) age of MS onset was 34 (10) years and mean (SD) disease duration 
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was 14.7 (9) years. 50% of patients were RR, 33% SP and 17% were PP (Table 
5.1).  
 
Table 5.1 Demographic and clinical characteristics of the patients. 
 
OCB  Negative 
n=86 
OCB Positive 
n=348 
Gender    
Female (%) 
 
53 (61%) 
 
230 (66%) 
Age (Mean(±SD)) 52.26 (±11.42) 47.83 (±11.10) 
Disease duration 
(Mean(±SD)) 
18.54 (±10.17) 13.81 (±8.53) 
Age at the first symptom 
(Mean(±SD)) 
33.69 (±10.14) 34.01 (±10.53) 
EDSS2 5.5(1-9) 6(0-8.5) 
Type 
RR (n=218) 
SP (n=142) 
PP (n=74) 
 
36 (16.5 %) 
32 (22.5 %) 
18 (24.3 %) 
 
182 (83.5 %) 
110 (77.5 %) 
56 (75.7%) 
'07Q  33 (20.5%) 128 (79.5 %) 
1Mean(±SD), 
2We used Median and Range due to ordinal nature of EDSS 
 
5.3.1     Association between OCB status and disease progression 
We compared the disability progression in the two OCB groups as measured by 
EDSS score and MSSS. As the comparative variables measured in different units, to 
determine the relationship between OCBs and EDSS scores or MSSS we looked at 
the beta coefficient (ȕ) for each of EDSS scores and MSSS. The OCB positive 
group had a higher median EDSS score (6 vs. 5.5), but after controlling for sex, age, 
disease duration, treatment and initial type of MS, we were unable to find any 
significant influence of OCB status on the EDSS score  (ȕ = 0.29, P=0.19, 95%CI=-
0.14 to 0.73). The model was repeated for MSSS score (excluding disease duration) 
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which yielded similar results and did not reach significance level (ȕ = 0.52, P=0.08, 
95%CI=-0.06 to 1.12) (Table 5.2). 
 
Table 5.2 Results of linear regression models analysis to calculate the effects of OCB 
on EDSS and MSSS. 
Dependent Variable Beta Coefficient (B) R2 P-value 
EDSS 0.29 0.24 0.19a 
MSSS 0.52 0.13 0.08b 
a adjusted for; age, sex, DMT, disease duration and initial MS type (RR vs. PP) 
b adjusted for; age, sex, DMT and initial MS type (RR vs. PP). 
 
5.3.2     OCB results over time 
In total approximately 20% of patients were OCB negative. A great proportion of the 
weight in the total percentage was due to higher percentage of negative patients in 
1980-1990 period. We investigated the proportion of positive and negative OCB 
results over the past three decade (1980-2010). In 1980 to 1990, of 48 recorded 
OCB results, 41% were reported negative while the percentage decreased to 14% in 
2001 to 2010 (Table 5.3). The statistical analysis using linear model revealed a 
significant trend of increasing OCB positivity by 11% over the study period (P= 
<0.001) in our patient cohort. 
 
Table 5.3 Prevalence of the OCB positive and OCB negative patients at the 
time of the diagnosis. 
OCB 1980-1990 1991-2000 2001-2010 total 
Negative 20 39 26 86 
41.67% 19.6% 14.21% 19.86% 
Positive 28 160 157 347 
58.33% 80.40% 85.79% 80.14% 
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5.3.3     Effects of OCB status on time to diagnosis and initial disease type  
OCB-negative patients had longer time to diagnosis than OCB-positive patients. We 
found that the median (interquartile range) diagnosis delay from the onset of disease 
was 4.5 (11) years in OCB negative and 2 (6) for OCB positive group (Mann-
Whitney U p=0.006). We tested the influence of OCB status on clinical course of the 
disease at its onset. After controlling for sex and age at the onset of the disease 
having PP or RR MS was independent of OCB status (OR=0.79 95%CI= 0.41 to 
1.53). 
5.4 Discussion 
In the present study, we could not find significant effects of OCBs status on disease 
progression as measured by EDSS score and MSSS, in both relapse-onset MS and 
PPMS patients. The direction of our findings was not changed much even after 
adjusting for the sex, age, disease duration treatment and initial type of MS. This 
result is consistent with previous studies, which have found that OCBs in the CSF 
were not associated with either worsening or stability of disability in patients with 
MS, and OCB negative patients do not have more benign form of MS (Koch et al., 
2007; Lourenco et al., 2012; Vilisaar et al., 2005). In contrast, some relatively small 
studies have found contrary results. A small case-control study reported that OCB-
negative patients had a slightly better prognosis, measured as the hazard ratio to 
reach EDSS milestones of 4 and 6, (Joseph et al., 2009). Zeman et al., in a study 
ZLWKDVPDOOVDPSOHIRXQGWKDW2&%QHJDWLYHSDWLHQWVKDGD³ORZHUSODTXHEXUGHQ´
on MRI and a lower median EDSS compared with OCB positive patients (Zeman et 
al., 1996). A study by Avasarala et al has also concluded that a low number or 
absence of OCBs in CSF at diagnosis predicts a better prognosis (Avasarala Jr, 
2001). There may be reasons for the difference results reported among the studies; 
different study designs with different study samples size may have contribution to 
the contradictory results. However, our results are in line with most of the relatively 
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new studies have used large sample size (Koch et al., 2007; Lourenco et al., 2012; 
Vilisaar et al., 2005). While the conflicting results were mainly highlighted from 
studies have had small study sample and some of them has conducted long time 
ago (Avasarala et al., 2001; Sa et al., 2005; Stendahl-Brodin and Link, 1980; Zeman 
et al., 1996). Our finding suggests that lack of OCBs in the CSF of suspected cases 
of MS does not decrease the possibility of the cases to be MS as suggested by 
some studies. 
In our cohort OCB negative result was associated with significant later diagnosis of 
MS. Although widespread availability of new MRI techniques has made a great 
improvement in the diagnosis of MS, MS is still considered a disease of exclusion 
which means often using other diagnosis modalities in case of any diagnosis 
uncertainty. As the result, LP is often offered to the patients whose diagnosis is not 
entirely certain which may introduce bias towards patients with more complicated 
diagnosis. We measured the proportion of our patients with MS testing negative for 
CSF OCBs to see whether any changes in the percentage of OCB status can be 
explain by fewer number of ambiguous suspected MS cases recruited for LP.  
Oligoclonal banding in the CSF not matched in the serum has high sensitivity for MS 
(Marchetti et al., 1999), however, its specificity for MS range between 62.5 to 82% 
(Marchetti et al., 1999; Siddiqui et al., 2002). There is evidence suggesting that OCB 
status in suspected cases of MS is potentially important to exclude differential 
diagnosis. Therefore, negativity of OCBs in the process of MS diagnosis while other 
diagnostic measures do not suffice for the diagnosis makes the alternative 
diagnoses always be in mind.  
Although the proportion of MS patients with negative OCB  in our cohort was greater 
(~ 20%) than the 5% reported in the UK in an earlier study (McLean et al., 1990), it 
adds to the established evidence that the incidence of OCB negative patients 
meeting the diagnostic criteria for MS is small. Findings from other studies from 
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different countries used different OCB detection techniques and these varied 
between studies and countries (see Introduction).  
 Although our result was greater (~ 20%) than the 5% reported in the UK in an 
earlier study (McLean et al., 1990), it adds to the established evidence that the 
incidence of OCB negative patients meeting the diagnostic criteria for MS is small. 
Findings from other studies from different countries used different OCB detection 
techniques and these varied between studies and countries (see Introduction).  
Our study showed that the OCB positive and OCB negative groups show no 
differences in the clinical course (relapse-onset MS and PPMS). In contrast, some 
studies have  suggested the association of OCB positivity with PPMS (Fukazawa et 
al., 1998; Imrell et al., 2006; Kikuchi et al., 2003), Contrary to these studies, and in 
line with our finding other studies have not found this association, and even they 
found that the OCB positive  patients have  developed more likely a relapsing form 
of disease (Pirttilä and Nurmikko, 1995; Siritho and Freedman, 2009).  
In our study the frequency of negativity of OCBs decreased over time. We found a 
significant trend for positive CSF OCBs overtime. The prevalence of OCB positive 
was 58.3% in MS patients were diagnosed between 1980 and 1990. This was raised 
to 83.8% during 2000 to 2010. It is difficult to explain the exact reasons for this 
change over 30 years, but, some potential confounding issues such as indication for 
performing a lumbar puncture and the methods used for OCB detection may 
account for this change. 
5.5 Conclusion 
In conclusion, we report that positivity or negativity of OCBs in the CSF is not 
associated with worsening of disability in patients with MS. The absence of OCBs; 
although not associated with a slower disease progression, is associated with a 
slightly increased time to reach the diagnosis of MS. The prevalence of the OCB 
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negative in our MS cohort was approximately 20% which is in line with previously 
reported studies. We have not reported a significant trend of PPMS patients to have 
more positive OCBs than the RRMS patients as suggested in some of the previous 
studies. 
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CHAPTER 6 A META-ANALYSIS OF fMRI STUDIES ON 
FATIGUE IN MULTIPLE SCLEROSIS 
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6.1     Introduction 
In the previous chapters, the concept of fatigue in multiple sclerosis (MS) and the 
evidence that the wakefulness-promoting drug modafinil may relieve MS fatigue is 
reviewed. Since the cerebral mechanisms of fatigue in MS are still poorly 
understood the functional effects of modafinil may be better understood in the 
context of cerebral functional reorganisation in people with MS who experience 
fatigue. 
The aim of this chapter is to offer an functional MRI (fMRI) insight into cerebral 
function associated with fatigue in MS patients, using a novel method of meta-
analysis applied to current available published data. This is, to our knowledge, the 
first meta-analysis study of fatigue. 
Another element of novelty is the use of a new locally developed method for meta-
analysis of fMRI data, which incorporates recently published advances in meta-
analysis of fMRI. 
A brief overview of MRI and fatigue in MS is presented first. 
6.1.1     Structural MRI and Fatigue in Multiple Sclerosis 
)DWLJXHVHHDOVRLQWURGXFWLRQWRWKLVWKHVLVGHILQHGDV³ODFNRI energy and sense of 
WLUHGQHVV QRW UHODWHG WR PXVFOH ZHDNQHVV´ VKRXOG EH GLIIHUHQWLDWHG IURP VLPSOH
muscle fatigability alone; however some degree of overlap may exist and it is likely 
that both aspects are important in MS patients. Fatigability means a susceptibility to 
fatigue.  
Structural MRI studies have provided, so far, only inconclusive and somewhat 
conflicting results. Initial MRI studies did not find any correlation between the degree 
of subjective fatigue, as measured by clinical scales, lesion load (van der Werf et al., 
1998), frequency of enhancing lesions (Mainero et al., 1999) or brain atrophy 
(Bakshi et al., 1999; Van der Walt et al., 2010). However, other studies reported 
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fatigue to correlate with white and grey matter volume loss (Tedeschi et al., 2007), 
confirming the association between a subjective awareness of fatigue and 
progressive brain atrophy as reported by an eight-year follow up study of relapsing-
remitting MS (RRMS) patients with mild clinical disability (Marrie et al., 2005). 
Together, the conventional MRI data suggest that subjective fatigue may be 
associated with gray matter (GM) atrophy. This would support a link between fatigue 
and dysfunction of deep grey matter nuclei (Colombo et al., 2000; Inglese, 2006; 
Niepel et al., 2006). 
Magnetisation transfer and diffusion tensor MRI studies found no difference between 
MS patients with and without fatigue in the normal- appearing brain tissue 
involvement, as well as in the severity of GM damage. An association between 
fatigue and neuronoaxonal pathology in MS was supported by the demonstration of 
abnormal T1 relaxation times in the thalamus of MS patients with fatigue (Niepel et 
al., 2006) . 
Therefore, the question whether fatigue in MS is due to a damage of GM or to a 
disconnection of specific white matter (WM) pathways secondary to the presence of 
T2 lesions, or to a combination of the two, is still open. This invites fMRI studies 
addressing the issue.  
 6.1.2     fMRI and fatigue in Multiple Sclerosis 
fMRI techniques take advantage of the relationship between brain activity and small 
changes in MRI signal using the blood oxygen level-dependent (BOLD) effect 
(Logothetis et al., 2001). Upon initiating a task, the neurons in the brain regions 
involved in that task have an increased metabolic demand. Subsequently, the 
cerebral blood increases in the local blood capillaries within approximately one 
millimetre of the neural activity. The increased blood oxygen produces an increase 
in the MRI signal (BOLD) which is typically only a few percent of the baseline signal, 
which can make it difficult to detect from background noise (Fox et al., 2011). 
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In MS patients with fatigue, fMRI studies have consistently shown an abnormal 
recruitment of several cortical and subcortical networks, supporting a central origin 
of fatigue in MS (Fox et al., 2011). Those studies showed widespread cortical 
activation, including that of non-motor cortical areas, during simple motor tasks in all 
types of MS (Filippi et al., 2002a; Reddy et al., 2000a; Reddy et al., 2000b; Rocca et 
al., 2002a; Rocca et al., 2002b). An increase in cortical activation has been 
considered as an adaptive response to weakness due to dysfunction in motor 
pathways. Also, MS-related fatigue may result from an impairment in cortico-
subcortical -thalamus and basal ganglia- interactions involved in motor planning and 
execution (Filippi et al., 2002a). Some fMRI studies have demonstrated a 
relationship between cortical activation and fatigue severity (Filippi et al., 2002a). 
Fatigue severity score (FSS)  correlated inversely with right hand finger flexion-
extension motor activation in several motor-associated regions: greater fatigue was 
associated with less relative activation in these regions (Filippi et al., 2002a). 
Subsequent studies indicate that non-motor functions of the basal ganglia may be 
involved in fatigue, where greater activation over time in MS patients was observed 
over repeated sessions of a processing speed task (DeLuca et al., 2008). 
Performance of a cognitively fatiguing mental task measured with Paced Auditory 
Serial Addition Test (PASAT) between motor fMRI scans led to an increase in 
activation to a paced finger task in primarily non-motor areas of MS patients, but a 
decrease in controls (DeLuca et al., 2008). This observation implies that fatigue may 
increase the level of neuronal organisation required to perform a particular task 
(Tartaglia et al., 2008). Furthermore, newly-recruited tissue may not habituate or 
respond in the same way as older ingrained circuitry in the presence of fatigue. All 
these data suggest that fatigue in MS is associated with reaching the limit of 
neuronal compensation (Fox et al., 2011).  
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In line with these fMRI findings, reduced glucose metabolism in cortical motor and 
basal ganglia regions in MS patients has been reported using positron emission 
tomography (PET) (Roelcke et al., 1997). This reduction in cerebral glucose 
metabolism correlated with the severity of fatigue. The authors suggested that 
central fatigue in MS is associated with dysfunction of the frontal cortical and basal 
ganglia connections, most likely resulting from demyelination in the frontal WM. 
Clearly, further exploration using fMRI in the area of fatigue in MS is needed. A 
meta-analysis of current studies using fMRI as a measure of changes associated 
with fatigue in MS has not been done until now. Such an approach can offer a global 
perspective of the functional modifications in those patients, and serve as a basis for 
further study aiming to follow those changes prospectively. 
To this date there are no consistent fMRI studies on modafinil effects in MS. As a 
basis for further study on this matter, a meta-analysis of fMRI data after modafinil 
administration may be interesting in outlining its effects in a brain without reported 
macroscopic lesions. These include healthy people, and possibly also drug addicts 
or patients with narcolepsy.  
Finally, meta-analysis of differences between fMRI activations in patients with 
chronic fatigue syndrome (CFS) and healthy people is performed. Being aware of 
the complexity and heterogeneity of mechanisms underlying fatigue in different 
conditions, a meta-analysis of studies involving central nervous system (CNS) 
patients can offer a different insight in fatigue conditions, thus suggesting a specific 
and adapted approach for future fMRI studies in MS patients with fatigue. 
6.2     Methods  
6.2.1     Local activation likelihood estimate (LocalALE) 
The activation likelihood estimate (ALE) is a quantitative meta-analysis method that 
was developed concurrently but independently by Turkeltaub et al. (2002) and Chein 
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et al. (2002) and probably the most commonly used algorithm for coordinate-based 
meta-analyses (CBMA)  so far.  An alternative approach to CBMA is kernel density 
analysis (KDA) (Wager and Smith, 2003). Both algorithms (KDA and ALE) are 
based on the idea of describing those locations in the brain where the coordinates 
reported for a particular paradigm or comparison show an above-chance 
convergence. The available meta-analysis algorithms employ a false discovery rate 
(FDR) control (Benjamini and Hochberg, 1995; Genovese et al., 2002) (it is a 
statistical method used in multiple hypothesis testing to correct for multiple 
comparisons) or family wise error rate (FWER) control (it is the probability of making 
one or more false discoveries when performing multiple hypothesis tests in 
statistics) of the number of voxels falsely declared significant. The results of meta-
analysis of fMRI studies are clusters of foci where multiple studies have reported in 
the same spatial region, indicting functional relevance. The clusters then indicate 
which brain areas are involved in the specific task. One of the major issues with 
previously reported CBMA of fMRI studies is type 1 statistical error. This results 
directly from controlling the type 1 error on a voxel-wise basis, rather than on a 
cluster-wise basis; clusters forming the results of the CBMA, while voxels only form 
parts of clusters. 
 To address this issue Tench and his colleagues have developed a new method of 
CBMA called Local activation likelihood estimate (LocalALE). The LocalALE method 
is strongly based on previous methods and it is consider an evolutionary step, rather 
than a new method. It is a numerical method that finds where studies report in the 
same anatomical region. The specific novelty of this method is in the clustering and 
the false cluster discovery rate (FCDR) type 1 error control. FCDR LVGH¿QHGDVWKH
expected proportion of falsely rejected clusters among those rejected. The FCDR 
FRUUHFWLRQJXDUDQWHHVWKDW LQWKHVHWRIFOXVWHUVGHHPHGVLJQL¿FDQWIRUDWHVWRI Į 
0.05, there are on average no more than 5% of clusters that are false positives. 
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FCDR is particularly interpretable and relevant to the results of CBMA, controlling 
the type 1 error by limiting the proportion of clusters that are expected under the null 
hypothesis. Without FCDR there is considerable risk of false positives with the 
competing methods. By using this method the false clusters can be better controlled 
than the widely used ALE method by performing numerical experiments and if there 
are significant results, they are less likely to be false positives than the competing 
methods.  
The clustering algorithm employed in LocalALE is also more advanced than that 
used in other CBMA algorithms. LocalALE uses the density of studies reporting 
activations to detect clusters, while a cluster in the competing methods is simply 
formed by significant voxels that are connected. As a result LocalALE provides a 
more complete report of the specific GM structures involved in the task; structures 
that may be merged into just one cluster by the other methods.  
In our study the LocalALE was used to perform meta-analysis. LocalALE is part of 
NeuROI can be found on:  
http://www.nottingham.ac.uk/scs/divisions/clinicalneurology/software/neuroi.aspx). 
The reported activations (foci) from each of the studies are combined to create the 
ALE (Eickhoff et al., 2009); the ALE relates to the probability that there is at least 
one study reporting an activation at a particular location in the GM. To test which 
parts of the ALE are statistically significant, a randomisation procedure is performed. 
The ALE is declared significant when multiple studies report activations in similar 
locations, resulting in clustering of the reported foci. The centroids of each cluster of 
significant foci are reported, along with Talairach region (Talairach and Tournoux, 
1988). These reports indicate areas where multiple studies have reported fMRI 
activations more often than expected by random chance. 
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6.2.2     Study inclusion 
A search for fMRI studies of fatigue in MS, CFS and modafinil was performed using 
standard literature databases (Science Direct, Web of Knowledge, and PubMed); 
NH\ZRUGV ³I05,´ $1' ³IDWLJXH´ $1' ³PXOWLSOH VFOHURVLV´ RU ³FKURQLF IDtigue 
V\QGURPH´RU ³PRGDILQLO´7KH UHIHUHQFHVRI WKHVHDUWLFOHVZHUH WKHQDVVHVVHG IRU
additional studies which could be considered for inclusion, along with the references 
from review articles of fatigue in MS or CFS. Abstracts were reviewed to select 
studies involving motor or cognitive fatiguing stimuli. In addition, only studies that 
reported whole-brain group analysis as coordinates in Talairach (Talairach and 
Tournoux, 1988) or Montreal Neurological Institute (MNI) reference space (Collins et 
al., 1994) were considered. Additional filtering of the data excluded single-subject 
reports from further analysis, along with those reporting only a restricted field of 
view. The filtering process retained 7 articles in MS patients (totalling 135 MS 
patients), 7 on modafinil, and 5 articles in CFS, which were carried forward to the 
analysis. 
6.2.3    Data extraction 
7KH GDWD H[WUDFWHG IURP HDFK DUWLFOH LQFOXGHG WKH DXWKRUV¶ QDPHV GDWH RI
publication, study population, sample size, mean age, sex ratio, type of fatiguing 
tasks or stimuli, presence of motor task in the experiment, pre-study reported 
fatigue, brain activation coordinates and their associated standardised space 
(Talairach or MNI). Here, we only included foci of activation (except studies with 
modafinil) because all articles reported activation foci, while the majority of studies 
did not comment on the presence or absence of deactivation foci. As the encoding 
of motor tasks takes place primarily in the contralateral hemisphere to the 
stimulation site the coordinates from left-sided body stimulation were reflected into 
the opposite hemisphere and analysed along with the coordinates from right-sided 
body stimulation to maintain homogeneity across all studies as previously carried 
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out by Lanz et al (2011).  Differences in the standardised coordinate space were 
addressed by converting all reported coordinates to Talairach. 
6.3     Results 
6.3.1     Multiple sclerosis patients with fatigue 
The analysis included 4 studies with 59 patients (Table 6.1). All but one experiment  
analysed in this section included patients with subjective fatigue undergoing motor 
tasks. 
 
Table 6.1 Studies providing data on activations in MS patients with fatigue. 
Experiment Task-induced 
fatigue 
(Cognitive / 
Motor) 
Motor task 
included (Y/N) 
Subjective 
fatigue reported 
(Y/N) 
Subjects 
(Specogna et 
al., 2012) 
- Y Y 12 
(Filippi et al., 
2002a) 
- Y Y 15 
(Rocca et al., 
2007) 
- Y Y 12 
(Steens et al., 
2012) 
M Y N 20 
 
 
 
Figure 6.1 ALE maps for the independent activation likelihood analysis in MS 
patients with fatigue undergoing motor tasks-significant clusters.ALE maps 
for the independent activation likelihood analysis in MS patients with fatigue 
undergoing motor tasks - significant clusters. 
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The analysis revealed 2 significant clusters in the left thalamus and left parietal lobe 
brodmann area (BA40) for a false cluster discovery rate (FCDR) with level 0.05 
(Figure 6.1). Adjusting for FCDR at level 7%, another cluster located in ventral 
anterior cingulate (BA24) was obtained. 
6.3.2     Multiple sclerosis patients without reported subjective fatigue 
The analysis included 3 studies with 36 patients (Table 6.2). All experiments 
analysed in this section included patients without subjective fatigue undergoing the 
same motor tasks and experimental procedures as MS patients with fatigue (Table 
6.1). None of the patients analysed had reported fatigue and the task did not have a 
fatiguing component. 
Initial analysis using FCDR with level 0.06 elicited 5 clusters, including the following 
structures on the Talairach map: ipsi- and contralateral inferior Parietal Lobules (BA 
40), ipsilateral inferior frontal gyrus (BA 44), contralateral medial frontal gyrus (MFG) 
(BA6), postcentral gyrus (BA40), transverse temporal gyrus. (BA41), and anterior 
and posterior cerebellar lobes. 
 
Table 6.2 Studies providing data on activations in MS patients without fatigue. 
Experiment Task-induced 
fatigue 
(Cognitive / 
Motor) 
Motor task 
included (Y/N) 
Subjective 
fatigue reported 
(Y/N) 
Subjects 
(Specogna et 
al., 2012) 
- Y N 12 
(Filippi et al., 
2002a) 
- Y N 14 
(Rocca et al., 
2007) 
- Y N 10 
 
$IXUWKHUDQDO\VLVDWĮ IXUWKHUDGGHGWKHSRVWHULRUFLQJXODWHJ\UXV%$DQG
the dentate nucleus (Figure 6.2).  
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Figure 6.2 ALE maps for the independent activation likelihood analysis in MS 
patients without fatigue undergoing motor tasks-significant clusters (FCDR 
level 0.06). 
 
 6.3.3     Multiple sclerosis patients with fatigue vs. MS patients without fatigue 
The analysis included data from 3 experiments with 75 patients (Table 6.3), which 
reported activations being different for MS patients with fatigue vs. patients without 
fatigue. A unique cluster of activations was obtained (FCDR 7%) in the ipsilateral 
lentiform nucleus (Putamen) (Figure 6.3). No further loci were obtained for a more 
permissive FDCR. 
Table 6.3 Studies providing data on activations in MS patients with fatigue vs. 
patients without fatigue. 
Experiment Task-induced 
fatigue 
(Cognitive / 
Motor) 
Motor task 
included (Y/N) 
Subjects 
 
With fatigue Without fatigue 
(Specogna et 
al., 2012) 
M Y 12 12  
(Filippi et al., 
2002a) 
- Y 15 14 
(Rocca et al., 
2007) 
- Y 12 10 
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6.3.4     Healthy controls under same tasks as MS patients with fatigue 
This group included 3 studies with 47 healthy controls undergoing same tasks as 
MS patients (Table 6.4). There was no significant common activation cluster arising 
from the analysis. 
 
 
 
Figure 6.3 ALE maps for the independent activation likelihood analysis in MS 
patients with fatigue vs. without fatigue undergoing motor tasks-significant 
clusters (FCDR level 0.07). 
 
  
Table 6.4 Studies providing data on activation in healthy control. 
Experiment Task-induced 
fatigue 
(Cognitive / 
Motor) 
Motor task 
included (Y/N) 
Subjective 
fatigue reported 
(Y/N) 
Subjects 
(Specogna et 
al., 2012) 
- Y - 12 
(Filippi et al., 
2002a) 
- Y - 15 
(Steens et al., 
2012) 
M Y - 20 
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6.3.5     Brain activations in MS patients (with or without fatigue) vs. healthy 
controls 
This analysis included activations in MS patients with reported subjective fatigue, 
without reported subjective fatigue but under fatiguing tasks, and without reported 
fatigue undergoing non-fatiguing tasks; versus healthy controls (Table 6.5). The 
structures reported as foci for significant activations in MS patients were MFG (BA 
6) (FCDR level 5%) and cingulate gyrus (BA 31) (FCDR level 8%) (Figure 6.4). 
 
Table 6.5 Studies providing data on activations in MS patients (with 
fatigue/without fatigue) vs. healthy controls. 
Study (author, 
year) 
Type of 
experiment-
induced fatigue 
(Cognitive=C; 
Motor = M) 
Motor task 
included in the 
experiment 
(Y/N) 
Pre-study 
subjective 
fatigue (Y/N) 
No subjects 
(patients) 
With 
fatigue 
Without 
Fatigue 
(Huolman et 
al., 2011) 
C Y Y 15   - 
(Filippi et al., 
2002a) 
- Y Y 15 14 
(DeLuca et al., 
2008) 
C Y N 15 - 
(Tartaglia et 
al., 2008) 
C Y Y 10 - 
(Steens et al., 
2012) 
M Y N 20 - 
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Figure 6.4 ALE maps for independent activation likelihood analysis in MS 
patients with fatigue vs. without fatigue undergoing motor tasks-significant 
clusters. 
 
6.3.6    Comparing ALE in multiple sclerosis patients and healthy controls 
Next data sets previously analysed (MS patients with fatigue; MS patients without 
fatigue; Healthy controls) were compared. The following comparisons: MS with 
fatigue vs. healthy controls, MS without fatigue vs. healthy controls, did not elicit any 
significant activation in favour of any group. However, when comparing MS patients 
with fatigue with MS patients without fatigue, a significant activation cluster was 
found in the contralateral precentral gyrus (BA4). While the reverse comparison 
elicited a significant cluster located in contralateral anterior cerebellar lobe for MS 
patients without fatigue.  
6.3.7     Activation clusters related to modafinil exposure in people without 
conventional MRI-detectable brain morphological lesions (healthy; drug 
addicts; narcoleptic patients) 
The analysis of modafinil activations included experiments extracted from 7 
publications, including 186 subjects (145 healthy persons and 41 cocaine or 
methamphetamine addicts and narcoleptic subjects). Of those, 4 studies reported no 
significant differences in activations between patients and controls; however, they 
were included in analysis (Table 6.6). 
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There were no significant activations arising from analysis of data on patients, on 
healthy controls under modafinil, or the comparisons of the two. 
When all the data were included in the analysis, activations were found in the left 
inferior parietal lobule (BA 40), left and right insula (BA13 and 47), anterior 
cerebellar lobe, claustrum and the right inferior frontal gyrus (BA47) (FCDR level 
8%) (Figure 6.5) and (Figure 6.6). 
 
Figure 6.6 Studies providing data on activations in subjects under modafinil 
(healthy; drug addicts; narcoleptic patients). 
Experiment Number of participants Dose of 
modafinil 
Type of the 
Task 
 
Deactivati
on 
reported 
Y/N 
Health
y 
contro
l 
Others 
Numb
er 
Type 
(Goudriaan 
et al., 
2012) 
16 13  Cocaine 
dependant 
200mg/single 
dose 
Visual - 
(Rasetti et 
al., 2010) 
38   100 mg/7 days cognitive Y 
(Minzenber
g et al., 
2008) 
21   200mg - Y 
(Ghahrema
ni et al., 
2011) 
19 16  Methamphet
amine-
dependant 
200mg/Single 
dose 
  
(Joo et al., 
2008) 
21 -  400mg/2 Single 
dose 2 week 
apart 
auditory + 
visual 
 
(Minzenber
g et al., 
2011) 
18 -  200mg/Single 
dose 
Visual 
sensorimotor 
Y 
(Ellis et al., 
1999) 
12 12 narcolepsy 400mg/ Single 
dose  
Visual+Audito
ry 
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Figure 6.5 ALE maps for the independent activation likelihood analysis in 
subjects under modafinil (healthy; drug addicts; narcoleptic patients) -all 
clusters. 
 
 
Figure 6.6 ALE for the independent activation likelihood in subjects under 
modafinil (healthy; drug addicts; narcoleptic patients) -significant clusters of 
activations. 
 
We looked for modafinil-related deactivations and retrieved data from 3 experiments 
(3 publications, 77 subjects). The analysis revealed a trend for 2 regions belonging 
to the same structure: left anterior cingulate (BA 24 and 32). However, this did not 
reach significance. 
6.3.8     Activation or deactivation clusters in people with chronic fatigue 
syndrome vs. healthy controls 
For a more comprehensive overview of the multiple facets of fatigue, analysis was 
extended to include a pathological entity characterised by fatigue; CFS. Five 
experiments, including 60 subjects and deactivations from 2 experiments including 
29 subjects, were analysed (Table 6.7). No significant activation or deactivation 
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resulted after analysis both between CFS patients and healthy controls at baseline 
or after fatiguing tasks. 
Table 6.7 Studies providing data on activations or deactivations clusters in 
people with CFS vs. healthy controls. 
Experiment Type of 
stimuli, 
Visual=V/ 
Auditory= A 
Task-induced 
fatigue 
Cognitive(C)/ 
Motor (M) 
Deactivation 
reported (Y/N) 
Subjects 
Healthy 
controls 
CFS 
(Caseras et 
al., 2008) 
- C Y 13 12 
(Tanaka et al., 
2006) 
V+A C N 7 6 
(Caseras et 
al., 2006) 
M C Y 12 17 
(Cook et al., 
2007) 
- C N 11 9 
(de Lange et 
al., 2004) 
- M+C N 16 16 
 
6.4     Discussion 
Fatigue related to MS is an unsolved matter. It is not known whether it is mainly due 
to damage of GM, a disconnection of specific WM pathways, or to a combination of 
the two. Moreover, the significance of cortical reorganisation in MS patients with 
subjective or provoked fatigue is unclear and difficult to interpret. It may represent 
either a mechanism of compensatory activation or a sign of neural inefficiency. Also, 
LW LV QRW FOHDU LI WKH EUDLQ IXQFWLRQDO FKDQJHV DUH D µPDUNHU¶ RI IDWLJXH LQ 06 IRU
example in the cortico- strio-thalamo-cortical loop or a causal mechanism with 
impact on recovery and performance. 
In this study we used a meta-analysis approach to fatigue and MS-related fatigue. In 
addition, data from fMRI studies using modafinil were analysed, to assess whether 
they provide indirect information about MS fatigue, and to search for hints on 
PRGDILQLO¶VVLWHVRIDFWLRQ LQWKHEUDLQWRH[SODLQ WKHUROHRIPRGDILQLODVDSRVVLEOH
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neuroprotective treatment for MS. To this end, studies using fMRI as measure for 
brain activity in relation to fatiguing tasks or in patients with reported having fatigue 
were carefully selected. A novel method for data analysis, designed to improve 
accuracy, was used. This analysis offers a multi-angle view which might elicit 
structures that may be important nodes for fatigue circuitry. 
fMRI studies in MS usually show widespread functional reorganisation during motor, 
sensory, and cognitive tasks in different phenotypes and stages of the disease 
(Filippi et al., 2002a). However, it is not clear if this enrolment of additional brain 
circuits, which are usually inhibited in healthy subjects when performing the same 
task represents functional reorganisation or adaptive mechanisms underlying neural 
disorganisation or disinhibition. The multiple activations obtained in MS non-fatigued 
patients are partially overlapping with some of the clusters in fatigued patients, 
suggesting that caution must be exercised in interpreting fMRI data in the latter 
group as being related to fatigue.  
There was no common pattern of activation in healthy controls; which might be 
expected taking into account the different study designs. Interestingly, from direct 
ALEs comparisons, while MS patients with fatigue had stronger cortical activations 
in BA4, non-fatigued MS patients showed cerebellar clusters of activation. We 
cannot interpret the above mentioned difference between groups (fatigued vs. non-
fatigued MS) as being related to the presence or absence of fatigue; they may be 
explained by difference between patient populations. Comparisons using larger 
patient groups are needed to study potential difference in activations patterns 
between two groups. 
However, deactivations were not reported constantly in those studies, and MS 
patients are known to be deficient in maintaining initial activations throughout the 
motor tasks in comparison to healthy controls. Therefore, a complete picture of 
 148 
functional changes during motor tasks in MS patients with or without fatigue and 
healthy controls should include an analysis of brain deactivations as well. 
The difference between results in MS patients vs. controls and CFS vs. controls (the 
latter showing no activation) might suggest that the concept of fatigue cannot be 
generalised between such different conditions. We might eventually state that a 
proper study tackling the matter of fatigue in MS should maybe use a behavioural 
model for fatigue in a brain with multi-tiered structural damage. 
6.4.1     Brain activation in MS with fatigue, without fatigue or undergoing 
fatiguing tasks vs. healthy controls 
The structures reported as loci for significant activations in MS patients with fatigue 
or undergoing fatiguing tasks were MFG (BA 6) and cingulate gyrus (BA 31). The 
increased activations in MS patients vs. healthy controls are not an unexpected 
finding, since most fMRI studies in MS reported this as a characteristic feature of 
MS-related functional central reorganisation. It was hypothesized that activation in 
task-relevant areas may reflect compensation, whereas activation in task-irrelevant 
areas may be linked to inefficiency to overcome increased task demands (Morgen et 
al., 2007). Current data suggest that fatigue is related to dysfunction in the cortical 
organization of task performance, but it is not clear whether this association is 
causal (Filippi et al., 2002a). Fatigue in MS might be related to the impaired cortico-
subcortical interaction, responsible for motor planning and execution (Filippi et al., 
2002a). 
The experiments resulting in the reported activations were relatively homogenous in 
regard to the type of fatigue: in 3 of 5 of them cognitive fatigue was induced, 
whereas in all but one subjective fatigue was present. The motor task was part of all 
experiments irrespective of design, adding an element of homogeneity. 
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The MFG is a region associated with high-level executive functions and decision-
related processes (Fitzgerald et al., 2010), while BA13 is found on dorsal posterior 
cingulate cortex (DPCC) which is involved in higher order sensory and sensory-
motor integration (Pearson et al., 2011). DPCC shows high connectivity to 
frontoparietal networks involved in cognitive control and has intense communication 
with attentional systems during periods without a focused task (Leech et al., 2012). 
The DPCC activation resulting from our analysis arose from the experiment of 
Tartaglia et al (Tartaglia et al., 2008), in which mental fatigue was induced in MS 
patients with reported fatigue performing a motor task. Although the DPCC 
activation might prove increased compensatory networking in the face of demanding 
tasks, a decreased capacity to optimize recruitment of the motor network with 
practice (inefficiency), cannot be excluded and may contribute to MS fatigue. 
We have considered that fatigue perceived during motor fatiguing tasks in MS 
patients may be share a common ground with subjective reported fatigue. Recently 
it was shown that correlates between perceived fatigue during maximal task and 
muscle activity were found for hand muscles, despite the lack of correlation with 
parameters associated with the integrity of the corticospinal tract (Steens et al., 
2012). This is of particular importance since all studies included in this meta-
analysis used hand motor tasks either as fatigue inducing task or activation task in 
subjects with reported fatigue.  
6.4.2     MS patients with fatigue: role of thalamo-striate loop 
In MS patients with reported fatigue at the start of the study, the contralateral 
thalamus (pulvinar) is the region resulting from our analysis as the most consistently 
activated. However, some other areas showed significant activations under less 
conservative parameters: medial and precentral gyri in the frontal lobes (BA 4); 
postcentral gyrus (parietal lobe, BA3); ventral cingulate gyrus (BA 24) and ipsilateral 
lentiform nucleus (Putamen).  
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Interestingly, both thalamus and parietal cortex atrophy have been associated with 
fatigue in RRMS (Calabrese et al., 2010). Moreover, the posterior parietal cortex 
was shown to be one of the best predictors of the MFIS cognitive domain, 
suggesting the major role of the posterior attentional system in determining cognitive 
fatigue in RRMS (Calabrese et al., 2010). 
The thalamus is an important relay station of the complex re-entrant circuitry that 
links the motor and the prefrontal cortices to the basal ganglia and which is part of 
the feedback loops of the limbic system able to modulate the cortical motor output 
(Chaudhuri and Behan, 2000). Several functional imaging studies suggested that 
fatigue in MS could result from altered connection between cortical and sub-cortical 
areas involved in motor planning (DeLuca et al., 2008; Filippi et al., 2002b). 
0RUHRYHULWZDVVXJJHVWHGWKDWµLQWHUUXSWLRQRIWKHassociated loop of striatocortical 
fibres or a net change in the thalamic activity suppressing cortical activation via the 
striato-thalamo-cortical loop will predispose to the symptoms of FHQWUDO IDWLJXH¶ 
(Chaudhuri and Behan, 2000). A reduction in the dopaminergic drive to the pallido±
thalamo±cortical loop might suppress frontal activation (a loss of motivational 
influence of the striato±thalamic input to the frontal lobe - prefrontal, orbitofrontal 
and cingulate regions) (Chaudhuri and Behan, 2004). This may result from the 
anatomical loss of structures of both WM and GM. 
Of note, the subjects analysed in this group did not undergo cognitive tasks. This 
may explain some difference with concomitant activations seen in fMRI studies 
using this type of task (DeLuca et al., 2008). Nevertheless, activations in frontal 
areas, cingulate gyrus and, most importantly, thalamus, suggest a common network 
in connection with fatigue in MS, independently of the trigger used to elicit it, with the 
thalamus as  key bidirectional relay centre. 
Activation of the ipsilateral lentiform nucleus (putamen) is the element differentiating 
patients with reported fatigue from those without. Basal ganglia are involved in the 
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higher order, cognitive aspects of motor control and these neurons also influence 
many other functions through their extensive connections with the association cortex 
and limbic structures. The association of central fatigue with basal ganglia diseases, 
whether structural, metabolic or chemical has been suggested (Chaudhuri and 
Behan, 2000). Therefore, our data support the concept of central fatigue associated 
to the dysfunction of the cortico- strio-thalamo-cortical loop. 
Based on the results of this study and the functional studies in the literature, central 
fatigue in MS might involve a multi-tiered brain functional disorganisation. Therefore, 
a drug that could act at more than one level in this complex dysfunction may offer 
the rationale for a functional interference with the key nodes involved in central 
fatigue mechanisms in MS. Modafinil may represent an ideal candidate for this 
purpose. 
6.4.3     Modafinil-related activations and deactivations: possible implications 
for fatigue in Multiple Sclerosis 
The analysis showed multiple brain activations under modafinil in a group of healthy 
controls and patients with narcolepsy or drug-addicts. Although the heterogeneity of 
subjects and experimental designs of studies included in the analysis might be a 
point of criticism, a common feature of the analysed group is the lack of known brain 
morphological lesions. Although the molecular effects of modafinil may be 
nonspecific, it is accepted that modafinil potentiates both dopamine (DA) and 
norepinepherine (NE) transmission through the inhibition of their transporter 
enzymes (Minzenberg et al., 2008; Volkow et al., 2009). Therefore, it is likely that 
the neurophysiologic effects of modafinil on the brain structures such as prefrontal 
cortex and anterior cingulated, both of which are rich in catecholaminergic 
projections, during tasks involving executive cognition are most likely driven by DA, 
NE or both.  
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5HFHQW DQLPDO VWXGLHV VXJJHVW WKDW 1( HQKDQFHV µVLJQDOV
 WKURXJK SRVWV\QDSWLF
DGUHQRFHSWRUVRQSUHIURQWDOFRUWH[GHQGULWLFVSLQHVZKHUHDV'$GHFUHDVHVµQRLVH

through modest levels of D1 receptor stimulation (Brennan and Arnsten, 2008). 
Drugs that modulate DA and NE system and enhance catecholamine transmission 
have been shown to increase efficiency of information processing in prefrontal 
circuits as consistently shown through functional neuroimaging studies (Apud et al., 
2007; Cools and Robbins, 2004). 
Importantly, recent data suggest that modafinil might act efficiently only in subjects 
having a certain degree of disregulation in the targeted circuitry (see also 
introduction chapter of the thesis). This is consistent with findings from a wider 
range of cognitive functioning. Modafinil can improve response inhibition only in 
alcohol-dependent patients that show poor initial response inhibition while making it 
worse in healthy controls (Schmaal et al., 2012), and was found to be effective only 
in healthy individuals and patients with schizophrenia and methamphetamine 
dependence who show poor baseline performance on working memory (Kalechstein 
et al., 2010; Spence et al., 2005), cognitive control and visual attention tasks (Finke 
et al., 2010; Hunter et al., 2006). This is in line with an inverted U-shaped 
relationship between catecholamine neurotransmitter levels and cognitive 
performance (Levy, 2009) implying  that there is an optimum for catecholamine 
neurotransmitter levels to efficiently execute cognitive tasks  (Schmaal et al., 2012). 
The degree of fatigue in MS is related at least in part to cognitive parameters 
(Andreasen et al., 2010). MS patients wLWK PRUH SURQRXQFHG µFRJQLWLYH IDWLJXH¶
might be a potential group of responders for modafinil, and further studies might 
tackle on this issue.  
In our analysis, thalamus was significantly activated in MS patients with fatigue. 
Thalamus activation as identified by fMRI may represent either excitatory or 
inhibitory neural activity. In alcohol-dependent subjects with poor initial response 
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inhibition, modafinil positive effects were associated with thalamic activation and 
decreased thalamo-cotical output. These and other data suggest that modafinil 
exerts its effect directly on the thalamus, resulting in subsequent changes in 
functional connections of the thalamus with other brain regions (Joo et al., 2008; 
Minzenberg and Carter, 2007). The thalamus is a key node for dopamine in the 
brain (Govindaiah et al., 2010; Sanchez-Gonzalez et al., 2005). This might be 
relevant for fatigue in MS and deserves further study. 
Concluding, although the mechanisms by which modafinil may impact fatigue in MS 
are still unclear, an interference with the thalamo-cortical loop is possible. Modafinil 
might have multi-level actions which could translate in improvement in fatigue 
(especially fatigue having a cognitive component), and this deserve further study 
with appropriate experimental design 
6.5     Conclusions 
In summary, our analysis suggests the following: 
- Thalamus and striate are central and relevant nodes for the pathogenesis of 
fatigue in MS. 
- fMRI studies in MS-related fatigue should take into account not only the extreme 
variability of MS brains, but also the common functional pattern of activation of a 
sick brain, which always shows increased activations and recruitment in response to 
damage; it is the time and phase sequence of those activations, as well the failure to 
appropriately deactivate when the task is formed which might be relevant to the 
occurrence of fatigue; 
- The present meta-analysis study suggests the interference of modafinil with the 
thalamo-cortical loop is possible.  
- Further study with more complex experimental paradigms is needed in order to 
shed light on MS-related fatigue.  
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CHAPTER 7 GENERAL SUMMARY AND CONCLUSIONS 
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7.1     General summary  
The main objective of this thesis was to gain greater insight into the potential 
neuroprotective effects of modafinil in multiple sclerosis (MS). In order to study this, 
we examined the effects of modafinil on several different outcomes including the 
expanded disability status scale (EDSS), fatigue and the autonomic nervous system 
(ANS) in humans and clinical scores of severity of the disease and pathological 
findings, in experimental autoimmune encephalomyelitis (EAE).  
The meta-analysis study presented in chapter six used a new locally developed 
functional MRI (fMRI) meta-analysis method. This study may provide a better view 
into the central mechanism of the fatigue in general and in MS in particular. 
Evidence from previous studies suggests the beneficial role of modafinil in MS 
fatigue. Since the cerebral mechanisms of fatigue in MS are still not clear, the 
functional effects of modafinil may be better understood in the context of cerebral 
functional reorganization in people with MS who experience fatigue. Therefore, the 
study addressed what areas could be activated by modafinil treatment and if 
whether these areas and areas affected by MS fatigue overlap. 
Also, as a future work we have designed a protocol for a randomised, assessor-
blind, non-treatment controlled, parallel group design exploratory trial (see appendix 
10 for detail).  
We also included a study of the relation between oligoclonal band (OCB) positivity 
and disease progression in MS. Although somewhat separated from the main focus 
of this thesis, the study relates to the evolution of disability in MS, which is the focus 
of a significant part of the thesis, and although not related to modafinil, it has 
relevance to the progression of MS.  Moreover, I collected the data on OCB status 
and EDSS progression of patients as part of the retrospective assessment of MS 
patients in the database that was used for evaluation of modafinil effects, and thus I 
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thought it may be appropriate to incorporate this information as part of a separate, if 
not tightly related, information. 
MS is a challenging disease to treat. Traditional immunosuppressants such as 
cyclophosphamide and azathioprine have been used in MS for some time, showing 
a variable degree of benefit (La Mantia et al., 2007; Yudkin et al., 1991). However, 
the risk of serious side effects, and the emergence of new immunomodulatory 
drugs, has limited their use. 
Disease modyfing therapies (DMT) have been proved to reduce the frequency and 
severity of relapses in MS, as consequences, minimise disability and reduce 
disability progression without significant immunosuppressive effects. However, they 
may partially confer neuroprotection. The promising new drugs currently in 
development  such as monoclonal antibodies, and oral agents for relapsing and 
progressive forms of the disease (see chapter one). Neuroprotective agents that 
impact directly on neuronal well-being would be desirable, particularly since axonal 
loss and neuronal injury have been shown to be the histological correlates of 
neurological disability. Part from introductory chapter was specified for review of 
EAE. EAE is the most commonly used experimental model for MS. Many of the 
drugs that are in current or imminent use in MS have been developed, tested or 
validated on the basis of EAE studies. Therefore, in an attempt to test the possible 
neuroprotective effect of modafinil in MS reflected by EAE we conducted a study 
and detailed this in this thesis (see chapter four). 
The novelty of this thesis was that previously modafinil has been investigated 
exclusively as an anti-fatigue treatment for MS, but its potential for neuroprotection, 
as shown in other, non-MS studies, had not been investigated. 
In the initial study in this thesis we evaluated retrospectively the effects of 
continuous three or more years treatment with modafinil in MS patients compared 
with a matched group of MS patients who have no exposure to modafinil. We found 
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that the MS patients who had no exposure to modafinil experienced significantly 
greater increases in EDSS compared to patients with MS who received modafinil for 
three and more years without interruption. This was seen in both relapsing-remitting 
and progressive types of MS. Although retrospective, to the best of our knowledge 
this is the first study that examines the potential neuroprotective effect of modafinil in 
MS reflected by measurement of EDSS scores. These findings were in line with 
previous studies in animal models that have revealed that modafinil can be a 
neuroprotective agent for neurodegerative disorders (Jenner et al., 2000; van Vliet 
et al., 2006; Xiao et al., 2004).  
.In the second experimental study, we wanted to validate the results of the 
retrospective study in the experimental model of MS, EAE. The effect of modafinil on 
the severity of disease in EAE has not been previously assessed. The results of this 
experiment suggested a significant effect of modafinil in reducing the clinical severity 
of EAE. This was more obvious in animals treated with the higher dose (100mg/kg) 
of modafinil compared with low dose (50mg/kg) and compared to negative control 
group. Histopathology including staining for axons, myelin, inflammatory infiltrates, 
and proteomics are underway, and will represent the subject of future investigation 
but are not part of this thesis. Nevertheless, as modafinil was administered after the 
mice developed clinical signs and the modafinil treated mice generally failed to 
progress, it can be argued that the effect was at least in part, neuroprotective. 
The study detailed in chapter 4 was aiming to begin to understand which 
mechanisms of action of modafinil may expalian its neuroprotective effect. We 
explored the relationship between the antifatigue and alerting/sympathomimetic 
effects of modafinil. With some re-evaluation of previously collected data and 
reanalysing the data, we examined whether there is any difference between MS 
patients with fatigue, MS patients without fatigue, and healthy controls on measures 
of alertness and autonomic function. We also examined the hypothesis that MS 
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patients with fatigue may be more sensitive to the alerting and sympathetic 
activating effects of modafinil than MS patients without fatigue or healthy subjects. 
Although its mechanism is yet to be clarified, evidence supports an interaction with 
the arousal network. In this study a number of subjective and objective measures of 
alertness measures were utilised to explore more objectively the role of modafinil. It 
was demonstrated that in MS patients with fatigue, there was a significant 
improvement with modafinil, as compared to placebo. This supports a role of 
modafinil in MS-related fatigue management potentially through its effect on the 
arousal network. 
The reason the OCB study is included in the thesis is discussed above. Previous 
studies suggested that OCB negative MS carried a relatively more favourable long 
term prognosis, with milder disability (Moulin et al., 1983; Roxburgh et al., 2005; Tan 
et al., 1997; Zeman et al., 1996). However, these studies were conducted on 
relatively small patient cohorts. In chapter five, we evaluated the prevalence of 
OCBs negative CSF in our MS population and the impact on disease progression 
reflected by EDSS and MS severity score (MSSS) measures.  The findings suggest 
that OCBs has no impact on disease progression in MS patients and the negative 
OCB patients do not experience more benign disease.  
The primary aim of the meta-analysis study presented in chapter 6 was to obtain an 
insight into cerebral functional phenomena associated with fatigue in MS patients, 
using a novel method of meta-analysis developed by our group (Dr Christopher 
Tench),  applied to current available published data. The published data on 
modafinil using fMRI have also been analysed in this study aiming to observe if 
modafinil activity might provide indirect information about MS fatigue, and look for 
clues on the sites of action of modafinil in the brain, to see if these specific sites can 
add further evidence regarding its suggested neuroprotection in MS patients. The 
results of this meta-analysis revealed that the thalamus was significantly activated in 
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MS patients with fatigue. Although the mechanisms by which modafinil may impact 
on fatigue in MS are still unclear, the results could suggest that an interference with 
the thalamo-cortical loop is a possible mechanism. Evidence from our study has 
suggested that modafinil might have multi-level actions in the brain, especially it may 
interfere with thalamo-cortical loop which could translate into improvement in 
disability progression in MS and in turn may reflect its potential neuroprotective 
effect. This promising finding calls for further study with appropriate experimental 
design. 
7.2     Conclusion 
The objectives of these studies were relatively broad and for that the thesis may be 
subject to criticism as being unfocused. However, these studies (except perhaps 
one, see below) are all linked through their aim of directly or indirectly shedding light 
on as yet unelucidated aspects of modafinil and fatigue in MS. Our retrospective 
study of modafinil in MS suggests a reduction in EDSS progression and is 
consistent with evidence of possible neuroprotective action demonstrated in other 
neurodegenerative conditions. However, the retrospective study did not allow deep 
insights into the mechanism of the neuroprotective action. We hypothesized that 
clues to these mechanisms would be provided by a better knowledge of the 
wakefulness promoting and anti-fatigue mechanisms of modafinil. However, these 
are themselves far from being clarified. In view of this, we re-analysed data 
generated from a study looking primarily at whether the pupillographic sleepiness 
test and pupillary unrest index could be used as a surrogate measure of fatigue in 
MS, and looked at the relationship between fatigue and arousal in MS and the effect 
of modafinil.  The arousal pathways and neurotransmitters involved are better 
known, and therefore we can learn about neurotransmitter and circuit targets that 
modafinil can act on, and build plausible models about the potential sites for 
neuroprotective actions in MS. 
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Along these lines, we took advantage of a novel meta-analysis method developed 
in-house to investigate sites involved in MS-related fatigue, and fatigue in chronic 
fatigue syndrome (CFS), to obtain further information on plausible sites, circuits and 
neurotransmitters involved in the modafinil neuroprotective effects.   
In addition, we showed a positive (likely at least in part neuroprotective) effect of 
modafinil on EAE. The role of these studies was to provide preliminary results on 
whether modafinil can modulate EAE. The mechanisms are to be elucidated in 
future studies. These studies will benefit from results in this thesis, as we will try to 
determine whether results on neuroprotection are mediated by the same 
neurotransmitters and circuits as results on arousal/wakefulness and against 
fatigue.  For example, it has been shown that modafinil wakefulness effects are 
abrogated in Dopamine receptor 1 (DR1) knockout mice, and we will in future 
assess the neuroprotective effects on EAE in DR1 knockout mice or in the presence 
of a DR1 antagonist. We have demonstrated a cortico-striato-thalamo-cortical circuit 
to be involved in fatigue (and, likely, the effects of modafinil) through the fMRI meta-
analysis, and have obtained (and will obtain in further experiments) microdissected 
samples from these regions in EAE mice treated or not treated with modafinil, and 
subject them to proteomic analysis to obtain hints regarding the mechanisms of 
action. 
The one exception referred to above is the OCB study which is somewhat different 
from the others and is not related to modafinil. We included this study because the 
retrospective EDSS data were collected during the retrospective modafinil study, 
and OCB positivity has been reported to be a factor that determines the disease 
course. Therefore, we selected to include this study, being another aspect relevant 
to MS progression, which may be important to future studies of neuroprotective 
trials. For example, a proportion of patients with positive OCB with PPMS have a 
better response to B cell depleting therapies.  
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7.3     Limitations and Strengths of the studies 
7.3.1     Limitation of the studies 
Although the studies included in this thesis were carefully prepared, I am still aware 
of their limitations and shortcomings. 
We have discussed the limitation of retrospective studies in chapter 2. 
Although the sample size in our study was relatively large, retrospective studies may 
need larger sample sizes for appropriate outcomes.  It has become increasingly 
important both in the clinical setting and in therapeutic trials to measure disability 
levels repeatedly in order to assess progression of disability. Measuring EDSS has 
some limitations, which are well documented. Importantly, it is biased towards 
locomotor function, is insensitive to change at certain levels and has only moderate 
inter- and intra-UDWHU UHOLDELOLW\$Q LQFUHDVHRISRLQW LI WKHEDVHOLQH('66LV
DQGLQFUHDVHRISRLQWLIWKHEDVHOLQH('66LVDUHWKHPRVWFRPPRQO\XVHG
measures in assessing disability progression. 
In the third study the sample size was pre-established. We encountered difficulties 
in finding MS patients without fatigue, as well as patients with fatigue untreated with 
anti-fatigue drugs or other drugs that can influence fatigue, and therefore, although 
WKH UHVXOWV DUH ³FOHDQ´ LQ WKDW WKH\ UHSUHVHQW WKe effects of modafinil without 
confounding factors, they may not be representative of a large number of MS 
patients.  
Limitations regarding our meta-analysis study are that the results may be hampered 
by heterogeneity, which can be explained by the multiple differences between 
studies with regard to the study design, analytic procedures of fatigue measurement, 
and confounding factors and adjustment for confounders.  
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7.3.2     Strengths of the studies 
The studies that have been presented in this thesis; the potential neuroprotective 
effects of modafinil in MS; the antifatigue and alerting effects of modafinil, the effect 
of modafinil on severity progression in EAE, the role of OCBs in the CSF of MS 
patients on clinical aspects of the disease and finally, the brain areas affected by 
fatigue in general and in particular MS-related fatigue  also the brain areas activate 
by modafinil treatment in vary of pathological and non-pathological conditions, taken 
as a whole, they are addressing significant issues. These studies have a number of 
novel findings which will have improved the quality of the information. These include 
the finding of possible neuroprotection effects of modafinil in MS and animal model 
of MS. Previous studies have assessed the role of modafinil as an antifatigue agent 
in MS. Our findings have suggested that MS patients with fatigue have an arousal 
deficit and that modafinil can improve it. 
To the best of our knowledge the meta-analysis study presented in chapter six is the 
first meta-analytical approach on the fMRI in fatigue. Moreover, this is one of the first 
studies to apply the locally developed new method for meta-analysis of fMRI data, 
which incorporates recently published advances in meta-analysis of fMRI and new 
elements in terms of concept and statistical processing, which is another element 
with novelty of this study.   
7.4     Clinical implementation and importance of the findings 
Our retrospective study in MS, complemented by the preliminary results in EAE, 
suggests a neuroprotective effect of modafinil in inflammatory demyelination. An 
ideal neuroprotective compound will need to be potent, have a long-lasting effect 
and should be devoid of uncontrollable side-effects or risk of major toxicity 
(Drukarch and Van Muiswinkel 2001). Modafinil in part matches this profile as its 
use is considered safe without tolerance effects based on daily use in narcolepsy 
patients (Bastuji and Jouvet 1988). Moreover, generally modafinil elicits no 
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uncontrollable side-effects in humans (Robertson and Hellriegel 2003), although 
there have been issues related to hypertension, myocardial infarction and severe 
rashes. Taken together, the positive actions of modafinil on disease progression in 
MS and EAE are indicating that clinical application for its neuroprotection is 
possible. Therefore, testing for clinical efficacy of its therapeutic and neuroprotective 
actions in MS would be a logical and relatively easy second step as modafinil is 
already a marketed drug. 
Our studies have also identified regions affected by fatigue in MS, and have 
H[SORUHGZKHWKHUWKHVHUHJLRQVDUHWDUJHWVIRUPRGDILQLO¶VSKDUPDFRORJLFDODFWLRQV
These studies will help elucidate whether the wake-promoting/antifatigue and 
neuroprotective actions of modafinil act on the same pathways and neurotransmitter 
systems, which may enhance knowledge of both fatigue and pharmacological 
neuroprotection for future therapies in MS. 
7.5     Difficulties in clinical implication of modafinil 
Despite the positive findings regarding modafinil, and its neuroprotective potential in 
the experimental animal model, the prospect of its clinical application in the near 
future is uncertain. The reason for this is that clinical neuroprotection is much more 
difficult to establish. The discrepancy between experimental outcomes and clinical 
use may be a result of the shortcomings of EAE to completely reproduce the 
complex clinical MS pathogenesis.  However, the results of the retrospective study 
are encouraging and justify a prospective study (see below). 
However, despite the above described hurdles in clinical application of 
neuroprotective treatment in general and modafinil in particular, neuroprotection is 
still the best perspective in the treatment of MS patients.  
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7.6     Recommendations for future research 
A large randomized controlled study will be necessary to further evaluate these 
results and conclusion of these studies on potential neuroprotective effects of 
modafinil in MS.  Additional development of study design and application of clinical, 
laboratory and imaging techniques may also be appropriate. Furthermore, more 
NQRZOHGJHDERXWPRGDILQLO¶VPHFKDQLVPVRIDFWLRQZRXOGEHQHILWLWVDSSOLFDWLRQ. We 
designed a protocol for this kind of study (Appendix 10). The study is a randomised, 
assessor-blind, non-treatment controlled, parallel group design exploratory phase II 
trial. This design means that it is possible to test and examine the hypothesis that 
modafinil reduces disability progression in progressive MS forms. One of the 
advantages of this protocol is the relatively long study period. There has been no 
previous prospective study of modafinil for EDSS progression as a primary outcome 
measure. I have contributed to the design of this study, which is being funded by the 
J P Moulton Foundation and TEVA UK. Due to regulatory delays caused by the 
takeover of Cephalon, the manufacturer of modafinil, by TEVA, the study is not part 
of my thesis, but will answer important questions for future research into the 
mechanisms of action and efficacy of modafinil in MS. 
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Appendix 1 Ethics approval  
The study described in chapter three was performed on healthy volunteers and 
patients following the approval of the Nottingham Research Ethics Committee. 
Reference numbers NS100201 and NS090102. This study also approved by the 
Medicine Control Agency. Reference number: MF 8000/12346.  
 
Appendix 2 McDonald criteria for diagnosis of multiple sclerosis (2001). 
Source (McDonald et al., 2001). 
Clinical Presentation Additional Data Needed 
* 2 or more attacks 
(relapses) 
* 2 or more objective 
clinical lesions 
None; clinical evidence will suffice (additional evidence 
desirable but must be consistent with MS) 
* 2 or more attacks 
* 1 objective clinical 
lesion 
Dissemination in space, demonstrated by: 
* MRI 
* or a positive CSF and 2 or more MRI lesions consistent 
with MS 
* or further clinical attack involving different site 
* 1 attack 
* 2 or more objective 
clinical lesions 
Dissemination in time, demonstrated by: 
* MRI 
* or second clinical attack 
* 1 attack 
* 1 objective clinical 
lesion 
(monosymptomatic 
presentation) 
Dissemination in space demonstrated by: 
* MRI 
* or positive CSF and 2 or more MRI lesions consistent 
with MS 
and 
Dissemination in time demonstrated by: 
* MRI 
* or second clinical attack 
Insidious neurological 
progression 
suggestive of MS 
(primary progressive 
MS) 
One year of disease progression (retrospectively or 
prospectively determined) and  
Two of the following:    a. Positive brain MRI (nine T2 
lesions or four or more T2 lesions with positive VEP)    b. 
Positive spinal cord MRI (two focal T2 lesions)    c. 
Positive CSF 
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Appendix 3 Expanded disability status scale (EDSS). Source (Kurtzke, 1983) 
score Description 
1.0 No disability, minimal signs in one FS 
1.5 No disability, minimal signs in more than one FS 
2.0 Minimal disability in one FS 
2.5 Mild disability in one FS or minimal disability in two FS 
3.0 Moderate disability in one FS, or mild disability in three or four FS. No impairment to 
walking 
3.5 Moderate disability in one FS and more than minimal disability in several others. No 
impairment to walking 
4.0 Significant disability but self-sufficient and up and about some 12 hours a day. Able 
to walk without aid or rest for 500m 
4.5 Significant disability but up and about much of the day, able to work a full day, may 
otherwise have some limitation of full activity or require minimal assistance. Able to 
walk without aid or rest for 300m 
5.0 Disability severe enough to impair full daily activities and ability to work a full day 
without special provisions. Able to walk without aid or rest for 200m 
5.5 Disability severe enough to preclude full daily activities. Able to walk without aid or 
rest for 100m 
6.0 Requires a walking aid - cane, crutch, etc - to walk about 100m with or without 
resting 
6.5 Requires two walking aids - pair of canes, crutches, etc - to walk about 20m without 
resting 
7.0 Unable to walk beyond approximately 5m even with aid. Essentially restricted to 
wheelchair; though wheels self in standard wheelchair and transfers alone. Up and 
about in wheelchair some 12 hours a day 
7.5 Unable to take more than a few steps. Restricted to wheelchair and may need aid in 
transferring. Can wheel self but cannot carry on in standard wheelchair for a full day 
and may require a motorised wheelchair 
8.0 Essentially restricted to bed or chair or pushed in wheelchair. May be out of bed 
itself much of the day. Retains many self-care functions. Generally has effective use 
of arms 
8.5 Essentially restricted to bed much of day. Has some effective use of arms retains 
some self-care functions 
9.0 Confined to bed. Can still communicate and eat 
9.5 Confined to bed and totally dependent. Unable to communicate effectively or 
eat/swallow 
10.0 Death due to MS 
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Appendix 4 The 2005 revisions to the McDonald diagnostic criteria for multiple 
sclerosis (Polman et al., 2005). 
Clinical Presentation Additional Data Needed for MS Diagnosis 
Two or more attacksa; objective clinical 
evidence of two or more lesions 
Noneb 
Two or more attacksa; objective clinical 
evidence of one lesion 
Dissemination in space, demonstrated by: 
 Ɣ05,c or 
 Ɣ7ZRRUPRUH05,-detected lesions consistent 
with MS plus positive CSFd or 
 Ɣ$ZDLWIXUWKHUFOLQLFDODWWDFNa implicating a 
different site 
One attacka; objective clinical evidence of 
two or more lesions 
Dissemination in time, demonstrated by: 
 Ɣ05,e or 
 Ɣ6HFRQGFOLQLFDODWWDFNa 
One attacka; objective clinical evidence of 
one lesion (monosymptomatic 
presentation; clinically isolated syndrome) 
Dissemination in space, demonstrated by: 
 Ɣ05,c or 
 Ɣ7ZRRUPRUH05,-detected lesions consistent 
with MS plus positive CSFd and 
Dissemination in time, demonstrated by: 
 Ɣ05,e or 
 Ɣ6HFRQGFOLQLFDODWWDFNa 
 Insidious neurological progression 
suggestive of MS 
Insidious neurological progression 
suggestive of MS 
One year of disease progression (retrospectively 
or prospectively determined) and 
Two of the following: 
 a. Positive brain MRI (nine T2 lesions or four or 
more T2 lesions with positive VEP)f  
 b. Positive spinal cord MRI (two focal T2 
lesions) 
One year of disease progression (retrospectively 
or prospectively determined) and 
 
If criteria indicated are fulfilled and there is no better explanation for the clinical 
presentation, the diagnosis is MS; if suspicious, but the criteria are not completely 
PHWWKHGLDJQRVLVLV³SRVVLEOH06´LIDQRWKHUGLDJQRVLVDULVHVGXULQJWKHHYDOXDWLRQ
WKDWEHWWHUH[SODLQVWKHHQWLUHFOLQLFDOSUHVHQWDWLRQWKHQWKHGLDJQRVLVLV³QRW06´ 
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a         An attack is defined as an episode of neurological disturbance for which 
causative lesions are likely to be inflammatory and demyelinating in nature. There 
should be subjective report (backed up by objective findings) or objective 
observation that the event lasts for at least 24 hours (McDonald et al., 2001). 
B No additional tests are required; however, if tests (MRI, CSF) are undertaken 
and are negative, extreme caution needs to be taken before making a diagnosis of 
MS. Alternative diagnoses must be considered. There must be no better explanation 
for the clinical picture and some objective evidence to support a diagnosis of MS. 
C MRI demonstration of space dissemination must fulfil the criteria derived 
from Barkhof and colleagues (Barkhof et al., 1997; Tintoré et al., 2000). 
d Positive CSF determined by oligoclonal bands detected by established 
methods (isoelectric focusing) different from any such bands in serum, or by an 
increased IgG index (Andersson et al., 1994; Freedman Ms and et al., 2005; Link 
and Tibbling, 1997). 
e MRI demonstration of time dissemination must fulfil the criteria in appendix 5. 
f Abnormal VEP of the type seen in MS  
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Appendix 5 Magnetic resonance imaging criteria to demonstrate 
dissemination of lesions in time (Polman et al., 2005). 
Original McDonald Criterion 2005 Revisions 
1. If a first scan occurs 3 months or more after the onset 
of the clinical event, the presence of a gadolinium-
enhancing lesion is sufficient to demonstrate 
dissemination in time, provided that it is not at the site 
implicated in the original clinical event. If there is no 
enhancing lesion at this time, a follow-up scan is required. 
The timing of this follow-up scan is not crucial, but 3 
months is recommended. A new T2- or gadolinium-
enhancing lesion at this time then fulfils the criterion for 
dissemination in time. 
2. If the first scan is performed less than 3 months after 
the onset of the clinical event, a second scan done 3 
months or longer after the clinical event showing a new 
gadolinium-enhancing lesion provides sufficient evidence 
for dissemination in time. However, if no enhancing lesion 
is seen at this second scan, a further scan not less than 3 
months after the first scan that shows a new T2 lesion or 
an enhancing lesion will suffice. 
1. There are two ways to show 
dissemination in time using 
imaging:  
a. Detection of gadolinium 
enhancement at least 3 months 
after the onset of the initial 
clinical event, if not at the site 
corresponding to the initial 
event. 
 
b. Detection of a new T2 lesion 
if it appears at any time 
compared with a reference 
scan done at least 30 days 
after the onset of the initial 
clinical event. 
 
Appendix 6 Magnetic resonance imaging criteria to demonstrate brain 
abnormality and demonstration of dissemination in space (Polman et al., 2005) 
Original McDonald Criteria 2005 Revisions 
Three of the following:  
1. At least one gadolinium-
enhancing lesion or nine T2 
hyperintense lesions if there 
is no gadolinium-enhancing 
lesion 
2. At least one infratentorial 
lesion 
3. At least one juxtacortical 
lesion 
4. At least three 
periventricular lesions 
Three of the following:  
1. At least one gadolinium-enhancing lesion or nine T2 
hyperintense lesions if there is no gadolinium enhancing 
lesion 
2. At least one infratentorial lesion 
3. At least one juxtacortical lesion 
4. At least three periventricular lesions 
NOTE: One spinal cord lesion 
can substitute for one brain 
lesion/ 
NOTE: A spinal cord lesion can be considered equivalent to 
a brain infratentorial lesion: an enhancing spinal cord lesion 
is considered to be equivalent to an enhancing brain lesion, 
and individual spinal cord lesions can contribute together 
with individual brain lesions to reach the required number of 
T2 lesions 
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Appendix 7 Diagnosis of multiple sclerosis in disease with progression from 
onset (Polman et al., 2005).  
Original McDonald Criteria 2005 Revisions 
1. Positive CSF and 
 
2. Dissemination in space by MRI 
evidence of nine or more T2 brain 
lesions or 
 Two or more cord lesions or 
 Four to eight brain lesions and one 
cord lesion or 
 Positive VEP with four to eight MRI 
lesions or 
 Positive VEP with less than four 
brain lesions plus one cord lesion 
and 
3. Dissemination in time by MRI or 
Continued progression for 1 year 
1. One year of disease progression 
(retrospectively or prospectively determined) 
2. Plus two of the following: 
 
 
 
 
 
 a. Positive brain MRI (nine T2 lesions or four 
or more T2 lesions with positive VEP) 
 b. Positive spinal cord MRI (two focal T2 
lesions) 
 
 c. Positive CSFa (isoelectric focusing 
evidence of oligoclonal IgG bands or 
increased IgG index, or both). 
 
a MRI demonstration of space dissemination must fulfil the criteria derived from 
Barkhof and colleagues and Tintoré and co-workers as presented in appendix 5. 
CSF = cerebrospinal fluid; MRI = magnetic resonance imaging; VEP = visual-
evoked potential. 
 
 
 
 
 
 
 
 
 
 214 
Appendix 8 Revised McDonald diagnostic criteria (2010) (Polman et al., 2011). 
Clinical 
Presentation 
Additional Data Needed 
* 2 or more 
attacks 
(relapses) 
* 2 or more 
objective clinical 
lesions 
None; clinical evidence will suffice (additional evidence desirable 
but must be consistent with MS) 
* 2 or more 
attacks 
* 1 objective 
clinical lesion 
Dissemination in space, demonstrated by: 
* MRI 
* or a positive CSF and 2 or more MRI lesions consistent with MS 
* or further clinical attack involving different site. 
New criteria: Dissemination in Space (DIS) can be demonstrated 
by the presence of 1 or more T2 lesions in at least 2 of 4 of the 
following areas of the CNS: Periventricular, Juxtacortical, 
Infratentorial, or Spinal Cord. 
* 1 attack 
* 2 or more 
objective clinical 
lesions 
Dissemination in time (DIT), demonstrated by: 
* MRI 
* or second clinical attack 
New criteria: No longer a need to have separate MRIs run; 
Dissemination in time, demonstrated by: Simultaneous presence 
of asymptomatic gadolinium-enhancing  
and nonenhancing lesions at any time; or A new T2 and/or 
gadolinium-enhancing lesion(s) on follow-up MRI, irrespective of 
its timing with reference to a baseline scan; or Await a second 
clinical attack. [This allows for quicker diagnosis without 
sacrificing specificity, while improving sensitivity.] 
* 1 attack 
* 1 objective 
clinical lesion 
(clinically 
isolated 
syndrome) 
New criteria: Dissemination in space and time, demonstrated by:  
For DIS: 1 or more T2 lesion in at least 2 of 4 MS-typical regions 
of the CNS (periventricular, juxtacortical, infratentorial, or spinal 
cord); or Await a second clinical attack implicating a different 
CNS site; and For DIT: Simultaneous presence of asymptomatic 
gadolinium-enhancing and nonenhancing lesions at any time; or 
A new T2 and/or gadolinium-enhancing lesion(s) on follow-up 
MRI, irrespective of its timing with reference to a baseline scan; 
or Await a second clinical attack. 
Insidious 
neurological 
progression 
suggestive of 
MS 
(primary 
progressive MS) 
New criteria: One year of disease progression (retrospectively or 
prospectively determined) and  
two or three of the following:  
1. Evidence for DIS in the brain based on 1 or more T2 lesions in 
the MS-characteristic (periventricular, juxtacortical, or 
infratentorial) regions 
2. Evidence for DIS in the spinal cord based on 2 or more T2 
lesions in the cord 
3. Positive CSF (isoelectric focusing evidence of oligoclonal 
bands and/or elevated IgG index) 
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Appendix 9 Brodmann areas in the brain of human being 
Areas 3, 1 & 2 - Primary Somatosensory Cortex  
Area 4 - Primary Motor Cortex 
Area 5 - Somatosensory Association Cortex 
Area 6 - Premotor cortex and Supplementary Motor Cortex  
Area 7 - Somatosensory Association Cortex 
Area 8 - Includes Frontal eye fields 
Area 9 - Dorsolateral prefrontal cortex 
Area 10 - Anterior prefrontal cortex (most rostral part of superior and middle frontal 
gyri) 
Area 11 - Orbitofrontal area (orbital and rectus gyri, plus part of the rostral part of the 
superior frontal gyrus) 
Area 12 - Orbitofrontal area (used to be part of BA11, refers to the area between the 
superior frontal gyrus and the inferior rostral sulcus) 
Area 13 and Area 14 - Insular cortex 
Area 15 - Anterior Temporal Lobe 
Area 17 - Primary visual cortex (V1) 
Area 18 - Secondary visual cortex (V2) 
Area 19 - Associative visual cortex (V3, V4, V5) 
Area 20 - Inferior temporal gyrus 
Area 21 - Middle temporal gyrus 
Area 22 - Superior temporal gyrus, of which the caudal part is usually considered to 
contain the Wernicke's area 
Area 23 - Ventral Posterior cingulate cortex 
Area 24 - Ventral Anterior cingulate cortex. 
Area 25 - Subgenual cortex (part of the Ventromedial prefrontal cortex) 
Area 26 - Ectosplenial portion of the retrosplenial region of the cerebral cortex 
Area 27 - Piriform cortex 
Area 28 - Posterior Entorhinal Cortex 
Area 29 - Retrosplenial cingulate cortex 
Area 30 - Part of cingulate cortex 
 216 
Area 31 - Dorsal Posterior cingulate cortex 
Area 32 - Dorsal anterior cingulate cortex 
Area 33 - Part of anterior cingulate cortex 
Area 34 - Anterior Entorhinal Cortex (on the Parahippocampal gyrus) 
Area 35 - Perirhinal cortex (on the Parahippocampal gyrus) 
Area 36 - Parahippocampal cortex (on the Parahippocampal gyrus) 
Area 37 - Fusiform gyrus 
Area 38 - Temporopolar area (most rostral part of the superior and middle temporal 
gyri) 
Area 39 - Angular gyrus, considered by some to be part of Wernicke's area 
Area 40 - Supramarginal gyrus considered by some to be part of Wernicke's area 
Areas 41 & 42 - Primary and Auditory Association Cortex 
Area 43 - Primary gustatory cortex 
Area 44 - pars opercularis, part of Broca's area 
Area 45 - pars triangularis Broca's area 
Area 46 - Dorsolateral prefrontal cortex 
Area 47 - Inferior prefontal gyrus 
Area 48 - Retrosubicular area (a small part of the medial surface of the temporal 
lobe) 
Area 49 - Parasubiculum area in a rodent 
Area 52 - Parainsular area (at the junction of the temporal lobe and the insula). 
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Appendix 10 Protocol of a phase II randomised, assessor-blind, non-treatment 
controlled, parallel group design exploratory trial to explore the neuroprotecti 
-ve potential of modafinil in multiple sclerosis.  
 
STUDY/ TRIAL SYNOPSIS 
Title Exploring the Neuroprotective Effects of Modafinil in MS 
Acronym MS-MODENA 
Short title MS-Modafinil Effectiveness as Neuroprotective Agent 
Chief Investigator Prof Cris S Constantinescu 
Objectives To test the effects of modafinil on clinical and radiological 
measures of disease progression and on locus coeruleus 
activation in patients with progressive multiple sclerosis 
Trial Configuration Randomised, parallel group, assessor blind 
Setting Tertiary care University Hospital 
Sample size estimate A reduction in atrophy rate by 50% will require an approximate 
sample size of 60 SPMS and PPMS patients (Di Stefano et al 
Neurology 2010) 
Number of participants 60 
Eligibility criteria Clinically definite multiple sclerosis; primary or secondary 
progressive form. Male or female subjects; 18-70 years of age 
inclusive; EDSS 4.0-6.5. Females who are of childbearing 
potential only if taking effective contraception measures 
Description of interventions Modafinil 200 mg daily orally for 24 months  
Duration of study Overall 36 months; 24 months per participant  
Randomisation and 
blinding 
Subjects will be randomized to receive either active drug 
(modafinil) or no treatment at a ratio of 2:1. Pharmacy will be 
aware of the treatments of the subjects. Randomization will be 
performed by statistician using an internet program 
Outcome measures Normalised brain atrophy rates; Percent of patients with 
sustained (two consecutive measurements 6 months apart) 
GLVDELOLW\SURJUHVVLRQRIVWHSIRU('66RUIRU
('663URWRQ056PHDVXUHPHQWRI1$$&KDQJHLQ
MSIS29 score; MuSIQoL, MSFC, Rivermead mobility index; 
Change in FSS, ESS, NFI-MS; Change in Eye Blink Rate. 
Statistical methods Paired t-test of Mann Whitney test depending on data 
distribution 
 
 
